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The liver is the largest solid organ in the body and is frequently the site of injury.  
During disease, liver injury is usually compensated for by exceptionally efficient 
regeneration which occurs both from differentiated epithelia and also from an 
undifferentiated cell population with stem cell like qualities known as hepatic progenitor 
cells (HPCs).  HPCs are particularly active during massive or chronic liver injury and 
therefore are an attractive target for much needed novel therapies to enhance 
regeneration in patients for whom the only current effective therapy is liver 
transplantation. 
Stem cells in other organs systems are believed to reside in a specialised 
microenvironment  or niche which supports their maintenance and function.  To 
investigate the hypothesis that HPCs are supported by a functional niche and are capable 
of regenerating hepatocytes, we commenced by establishing a number of murine in vivo 
models.  Having shown a stereotypical niche, consisting of macrophages, myofibroblasts 
and laminin exists in both animal models and human disease, we investigated the active 
recruitment of extrahepatic cells into this niche and showed that macrophages are 
actively recruited from the bone marrow during liver injury.  Macrophages were shown 
to influence HPC behaviour during injury.  Furthermore using macrophages as a cellular 
therapy, induced HPC activation with corresponding changes to liver structure and 
function.  Investigation of signalling pathways revealed and confirmed a TWEAK 
dependent activation of HPCs following macrophage transfer. 
Having demonstrated the potential for macrophage therapy via HPC activation, we 
aimed to study the ability of HPCs to regenerate the hepatic parenchyma.  To do so we 
developed and characterised a novel model of hepatocellular injury and HPC activation.  
Using the genetic labeling of hepatocytes in this model we were able to show rapid and 
large scale repopulation of hepatocytes from a precursor source with HPCs being the 
critical precursor source of hepatocellular regeneration.  In addition this process is again 
dependent on TWEAK signalling, without which HPC mediated regeneration fails 
resulting in mortality.  Therefore HPCs are an attractive biological target for regenerative 
medicine, and both TWEAK signalling and autologous macrophage infusion offer 
genuine potential to manipulate these cells as future therapies.   
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Chapter 1: Introduction 
 
1.1 The need for new therapies for Liver Disease 
 
Chronic liver disease represents one of the major health burdens worldwide.  In the 
UK it is the 5
th
 most common cause of death.  Liver fibrosis currently kills more men 
than Parkinson‟s disease and more women than cervical cancer, and these numbers are 
increasing.  Over the last decade rates of cirrhosis in Scotland have more than doubled 
(Leon and McCambridge, 2006).  Liver disease continues to rise in the UK as a whole at 
approximately 5% per year on year to 2008.  Furthermore it is the only major cause of 
death still increasing year-on-year (Baker et al., 2008).  Liver transplant is the only life-
prolonging treatment in liver failure, and yet while organ donation rates are static, 
waiting list numbers and mortality continues to increase (Carpentier et al., 2009).  
Therefore there is an urgent need for alternative therapies for liver disease (Figure 1.1).   
 
Liver failure results from inadequate function of the liver and excess scar formation.  
A major clinical need exists for therapy to improve liver function when the liver‟s 
regenerative capacity is overwhelmed.  This is required for both acute massive liver 
injury, and more commonly with minor but sustained damage during chronic liver 
disease.  During both these situations a second regenerative compartment composed of 
liver stem cells and progenitor cells is activated to regenerate the liver.  In order to 
address our current shortfalls in therapy there is a great interest in characterising the 
stem cell mediated regenerative capacity of the liver to uncover ways in which these 
processes may be manipulated therapeutically.  There is also strong evidence pointing 
towards the liver stem cells and their progeny, in the formation of hepatocellular 
carcinoma (HCC).  Therefore an understanding of the process controlling hepatic stem 
cell function may offer the opportunity of maximising liver function while preventing 
the formation of HCC.  Stem cells also provide a potential precursor source of cells for 
extracorporeal liver support devices (Carpentier et al., 2009).   
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Figure 1.1 The requirement for alternative therapies for liver disease  
(A) Of the major causes of mortality in the UK liver disease is to continually increase over time 
(adapted from Baker et al., 2008).  (B) Rates of cirrhosis and mortality in the UK and Europe in 
men aged 45-65 (adapted from Leon and McCambridge, 2006).  (C) Statistics for 1995 to 2005 
from the European transplant registry, (adapted from Carpentier et al., 2009).   
 
1.2 Liver architecture and function  
 
The liver is the largest internal organ in the body.  Functionally it is divided into the 
right and left lobes.  The right is larger and contains the caudate and quadrate lobes.  
Each lobe is then further divided subdivided into a total of eight segments each receiving 
its own portal pedicle containing branches of the portal vein, hepatic artery, hepatic vein 
and biliary tree.   
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The blood supply to the liver constitutes approximately 25% of cardiac output and is 
provided predominantly (75%) via the hepatic portal vein which drains most of the 
gastrointestinal tract and spleen.  The other 25% of hepatic vascular supply is provided 
by arterialised blood from the hepatic artery.  Blood from these vessels is distributed to 
the segments and passes into the sinusoids via the portal tracts (Figure 1.2).  After 
passing along the sinusoid blood leaves the liver by entering branches of the portal vein 
before passing to the inferior vena cava.  Lymph is formed predominantly in the 
perisinusoidal space and in collected in lymphatic vessels present in the portal tracts.   
 








The hepatic sinusoids lack a basement membrane and are loosely surrounded by a 
specialised fenestrated endothelium along with phagocytic, monocyte derived, Kupffer 
cells.  The sinusoids are separated from the plates of hepatocytes by the space of Dissé 
which contains a matrix of basement membrane constituents and stellate cells.  Stellate 
cells in the normal liver store retinoids in their resting state and contain the intermediate 
filament desmin and glial fibrillary acidic protein (GFAP).  When activated they become 
the contractile cells, called myofibroblasts, which are characterised by their expression 
of α-smooth muscle actin (αSMA).  Following activation myofibroblasts play a major 
role in controlling sinusoidal blood flow and the deposition of extra-cellular matrix 
(Friedman, 2008).   
 
The functional unit of the liver is the acinus, which consists of parenchyma supplied 
by portal tracts containing portal vein radicals, hepatic arterioles, and bile ductules.  The 
hepatocytes in this vicinity are well supplied with oxygenated blood and are generally 
the most resistant to damage.  In contrast the hepatocytes nearer the central terminal 
hepatic venule branch of the hepatic vein are less well oxygenated and are more 
susceptible to damage.  These periportal and perivenular zones are referred to as zones 1 
and 3 respectively with a central area of intermediate hepatocytes lying in an area 
referred to as zone 2.  Specific enzymatic and metabolic activities, i.e. carbohydrate 
metabolism, ammonia detoxification, bile formation/transport/secretion and drug 
biotransformation, are confined to the perivenular zone 3 or periportal zone 1 (Gebhardt, 
1992).  Intriguingly, inversion of the blood flow direction changes the enzymatic 
gradients reverses much of the liver metabolism zonation, implying an influence exerted 
by the oxygen and circulating molecules on this phenomenon (Kinugasa and Thurman, 
1986).  For the bloodstream independent gradients, cell-cell and cell-extracellular matrix 
interactions have been suggested as crucial determinants of liver zonation together with 




The biliary system comprises the collection of ducts extend from the bile canaliculi 
formed between hepatocytes, to the ampulla of Vater which opens into the duodenum.  
Bile is produced principally by hepatocytes and is initially excreted into a fine network 
of channels formed between the cell membranes of hepatocytes known as bile canaliculi.  
These canaliculi then join to form thin bile ductules near the portal tract.  The smallest 
bile ductules which join the bile canaliculi to the specialised cholangiocyte lined tree of 
the biliary system are known as the canal of Hering (Figure 1.2B). 
 
1.3 Liver regeneration in the context of tissue regeneration and stem 
cells 
 
The liver is a site of frequent injury. The liver‟s anatomical position, together with its 
role in the metabolism and excretion of toxins, make it particularly susceptible to toxic 
injury.  In addition, a variety of infectious and autoimmune diseases frequently result in 
liver injury.  It is likely that frequent injury from these varied factors, have imposed 
upon the liver its remarkable regenerative capacity.   
 
Like most organs of the body, the liver has the potential to regenerate following 
cellular loss or injury.  Mammals, for example, can survive surgical removal of up to 
75% of the total liver mass.  Here within 1 week after liver resection, the total number of 
liver cells is restored (Michalopoulos and DeFrances, 1997).  Indeed this ability to 
maintain a constant size, following injury, transplantation of a size mismatched organ or 
even induced hypertrophy (Forbes et al., 2000), is one of the liver‟s defining 
characteristics.  This potential to grow or even shrink clearly demonstrates the liver‟s 
delicate balances of cellular regeneration and loss.   
 
Regeneration, while differing substantially between organs, retains many common 
features across the body as a whole.  While some tissues constantly shed large numbers 
of cells and are therefore in a constant state of highly active regeneration (e.g. intestine, 
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skin or testis), others remain relatively quiescent throughout adult life (e.g. brain).  With 
its relatively low rate of turnover, the liver lies somewhere between these two extremes.  
Within the uninjured mammalian liver approximately 0.5% of hepatocytes are in cell 
cycle at any one time in keeping with an average life span of adult hepatocytes of 200-
300 days (Duncan et al., 2009).  None-the-less, as is clear from the massive regeneration 
occurring following liver resection, the liver is capable of regeneration as impressive as 
any other organ when required. 
 
Tissue regeneration in most organs is thought to be principally from tissue stem cells.  
The concept of a stem cell implies that this cell possesses the potential for longevity in 
an unchanged state whilst continuing to producing a fresh source of progeny capable of 
differentiating into multiple cell types.  In other words, the key characteristics a cell 
must possess in order to be called a stem cell are multipotentiality combined with 
ongoing self renewal.  These two fundamental characteristics give rise to the key feature 
of a stem cell which is long term tissue reconstitution.  In practice these attributes are 
tested via a number of means.  Serial transplantation is able to test the self renewal of a 
stem cell in addition to multipotentiality.  Clonal assays utilise the assessment of a single 
cell to form colonies which can then be tested for multipotentiality.  This provides an 
improved assessment of the multipotentiality than transplantation of mixed cell 
populations.  Lineage tracing is used to demonstrate product precursor relationships 
between freshly generated cells of one phenotype from those of another and essentially 
provides a test of multipotentiality but also using well selected markers may demonstrate 
longevity within a tissue (Barker et al., 2007).  While the best and most obvious 
example of a stem cell remains as the fertilised egg, recent work has identified cells with 
stem cell characteristics in adult organs including the bone marrow (BM) and intestine 
(Taoudi et al., 2008; Barker et al., 2007; Rock et al., 2009; Barker et al.; Wagers, 2005).   
 
The extent to which liver regeneration relies on stem cells remains hotly debated.  The 
reasons for interest in this field are clear, particularly from a clinical perspective.  
Chronic liver disease is common and has severe clinical consequences that arise from 
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loss of functional hepatocytes together with excess scar formation.  Currently therapies 
are insufficient to treat these disorders effectively.  There is therefore a great interest in 
characterising the regenerative capacity of the liver in order to manipulate this process 
therapeutically.   
 
1.31 Hepatocyte mediated regeneration 
 
Acute liver injury, for example the removal of a number of liver segments by partial 
hepatectomy (PH), results in rapid and effective regeneration with hepatocytes 
undergoing mitosis leading to subsequent restoration of liver mass and function by 
compensatory hypertrophy within two cycles of hepatocyte division (Fausto et al., 
2006).  Naturally the question has been raised as to whether hepatocytes themselves 
function as stem cells.  Early work using retroviral mediated incorporation of beta-
galactosidase (Bralet et al., 1994) showed clonal patches of hepatocytes following 
regeneration scattered throughout the liver and argued strongly against a zonal source of 
liver regeneration in these models.  More recent landmark transplantation studies in 
fumarylacetoacetate hydrolase knockout (FAH 
-/-
) and urokinase plasminogen activator 
(uPA) transgenic mice have demonstrated that hepatocytes possess a virtually unlimited 
proliferative potential.  They are capable of a least 69 cell divisions and can restore 
normal architecture and impaired function in the injured liver (Overturf et al., 1997; 
Rhim et al., 1994).  Furthermore, Grompe and coworkers have shown in the FAH
-/-
 
mouse that adult hepatocytes expand clonally (Overturf et al., 1999) and may be serially 
transplanted (Overturf et al., 1997).  By the use of wild type hepatocytes in an 
environment of otherwise metabolically defective hepatocytes, these models do however 
rely on a strong selection advantage against native hepatocytes.  Additionally in 
alternative model of hepatocyte transplantation wild type hepatocytes appear to show 
multipotentiality when transplanted into the livers of Dipeptidyl Peptidase IV (DPPIV) 
knockout rats followed by PH and retrorsine treatment.  DPPIV is an exopeptidase 
expressed on the bile canalicular surface of hepatocytes in addition to diffuse 
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cytoplasmic expression by bile duct epithelia.  Using this model transplanted DPPIV
+
 
cells reconstitute bile ducts following bile duct ligation (BDL; Michalopoulos et al., 
2005).  The authors of this work have previously described the hepatocyte population 
used for this infusion to be a mixed population, therefore definitive multipotentiality at 
the level of single cells has not been confirmed (Michalopoulos et al., 2001).  None-the-
less, this study raises the possibility that hepatocytes may, in specific circumstances, 
display multipotentiality.  Under certain conditions therefore, hepatocytes may show 
many of the characteristics of stem cells.  However the many models demonstrating self 
renewal share a continual selection pressure for transplanted hepatocytes versus 
indigenous parenchyma in the context of persistent liver injury.  Whether human 
hepatocytes are capable of acting as true stem cells remains unclear.   
 
As implied above, hepatocytes posses the ability to remain quiescent for extended 
periods and yet re-enter cell cycle rapidly if required.  This feature is bestowed upon 
them by their propensity to remain in the G0 stage of the cell cycle.  The G0 phase is a 
period in the cell cycle where cells exist in a quiescent state.  G0 phase may be viewed as 
an extended G1 phase where the cell is neither dividing nor preparing to divide (Loyer et 
al., 1996).  Unlike many cells in the G0 phase hepatocytes may survive for long periods 
in this state, in which they may remain until stimulated to re-enter the cell cycle.  This 
quiescent state is in contrast to cellular senescence, which is a state that may be induced 
by tissue injury or degradation which could make a cell's progeny non-viable.  
Senescence then, unlike quiescence, is often a biochemical alternative to the self-
destruction of such a damaged cell by apoptosis and implies a failure to respond to 
normal mitotic stimuli.  Senescence is an important feature of hepatocytes during liver 
pathology, occurring frequently during chronic injury (Marshall et al., 2005; Paradis et 
al., 2001; Wiemann et al., 2002).  When hepatocyte senescence occurs, regeneration 
does not fail, implying that there is an alternative source of hepatocyte regeneration.  
The reasons for, and mechanisms of, hepatocytic senescence remain poorly understood, 
however they appear to involve telomerase shortening (Wege et al., 2007) and p53, p21 
and p16 activation (Ozturk et al., 2009; Shay et al., 1991; Teoh et al., 2010) along with 
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β-galactosidase expression which is used as a marker of senescence (Paradis et al., 
2001).   
1.32 Hepatic progenitor cells and liver regeneration 
 
While the liver‟s ability to utilise hepatocytes for regeneration is well described, it is 
clear that regeneration may occur even when proliferation of hepatocytes is prevented 
and hepatocytes may be generated from precursor cells other than hepatocytes (Bird et 
al., 2008).  These precursors may in time be demonstrated to reliably fulfill the 
characteristics of true stem cells, however whilst this remains to be demonstrated 
reliably I will refer to these precursors as Hepatic Progenitor Cells (HPCs); for clarity 
this population is identical to oval cells, which is frequently used pseudonym for this 
population in rodent models.   
  
The concept that regeneration may occur both from differentiated parenchyma and 
from precursors in the liver is perhaps not surprising.  Intuitively, hepatocytes are 
themselves derived from a primitive precursor during development.  Additionally 
regeneration in all other organs occurs from undifferentiated precursors.  Much of what 
is understood regarding adult HPCs shares strong similarities with what is known of the 
hepatic stem cells which are active during development.  HPCs in adults are described as 
facultative as they only participate in hepatocyte replacement when regeneration by 
mature hepatocytes is overwhelmed or impaired (Figure 1.3).  This population can be 
demonstrated by preventing hepatocellular proliferation using agents such as AAF or 
retrorsine, which are activated into toxic metabolites by mature hepatocytes.  When 
applied, in the context of simultaneous liver injury, these agents result in the expansion 
of HPCs from portal areas.   
 
The first description of HPCs as candidate hepatic stem-like cells was made in 1937 
(Kinosita, 1937) with the subsequent naming of oval cells in rodents following a report 
by Farber in 1956 (Farber, 1956).  Whilst described in a variety of models and diseases, 
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these cells are thought to possess the characteristics of a transit amplifying population or 
progenitor cells, and are characteristically not seen in the uninjured mammalian 
parenchyma.  These cells were described morphologically as „small ovoid cells with 
scant lightly basophilic cytoplasm and pale blue-staining nuclei‟.   
 
Investigation of HPCs has made remarkable progress since seminal work by 
Thorgeirsson and coworkers who used rats treated with AAF followed by PH (AAF/PH) 
and showed HPC proliferation beginning in the periportal region (Evarts et al., 1987; 
Evarts et al., 1989).  At later time points in these models, label retaining basophilic 
hepatocytes were seen in the mid parenchyma suggesting, but not definitely proving, a 
precursor/product relationship.  Detailed analysis of cells during regeneration has shown 
cells with a number of intermediate phenotypes between HPCs and fully differentiated 
hepatocytes (De Vos and Desmet, 1992; Mandache et al., 2002; Alison et al., 1996), and 
has shown that HPCs migrate into regenerative nodules (Vig et al., 2006).  Tracing 
tritiated thymidine transfer from HPCs to parenchymal cells in combination with 
differentiation markers demonstrates bipotentiality of HPCs, showing them capable of 
forming either hepatocytes or cholangiocytes (Evarts et al., 1989; Holic et al., 2000).  
More recent work using HPCs, either as primary cell culture or as cell lines has shown 
their bipotentiality during in vitro culture (Conigliaro et al., 2008; Lazaro et al., 1998; 
Lorenzini et al., 2010; Okabe et al., 2009; Rountree et al., 2007).  Indeed, even in their 
undifferentiated form, HPCs themselves may express mature hepatocyte or biliary duct 
markers such as CK18 or CK19 (Table 1.1).  In addition these cells are also capable of 
engrafting following transplantation and expanding in the recipient liver (Faris and 
Hixson, 1989; Wang et al., 2003a; Yasui et al., 1997).  Therefore HPCs, in rodents at 
least, appear to possess the characteristics of progenitor cells in addition to possessing a 
variety of markers implying stem cell function (e.g. c-kit, CD34, flt3 and CD133).  
Further studies analogous to those in the BM or intestine demonstrating long term tissue 
repopulation will require suitable lineage tracing or transplantation models (Barker et 




Figure 1.3 The two tiers of adult hepatocellular regeneration  
 
Regeneration of the mammalian liver may occur from two sources.  If hepatocytes are able to 
divide then they do so quickly and efficiently to fully restore the parenchyma without the 
expansion of HPCs (left hand panels).  If hepatocyte injury occurs in the context of impaired 
hepatocyte proliferation (right hand panels) then stem cells located in the terminal biliary tree are 
activated leading to the generation of HPCs which spread into the liver parenchyma and are able 

























Meticulous studies in rodents and humans are consistent with an origin of HPCs from 
the terminal ducts of the biliary tree known as the canals of Hering (Theise et al., 1999; 
Saxena et al., 1999; Paku et al., 2001; De Alwis et al., 2009; Fellous et al., 2009).  
Following activation they expand, forming ductular structures extending between the 
biliary tree and hepatocytes (Paku et al., 2001).  This anatomical position, at the 
interface between the parenchyma and the portal tract mesenchyme, is also the site of 




A crucial tool for the investigation of HPC biology has been their description in a 
variety of animal models.  The most common rodent HPC activation model to date 
utilises the mitogenic stimulus of PH in combination with inhibitors, such as 2-N-
acetylaminofluorene (AAF) or retrorsine, which are activated by hepatocyte 
cytochromes P-450s and subsequently inhibit the proliferation of these mature 
hepatocytes.  These inhibitors can alternatively be combined with other forms of hepatic 
injury e.g. carbon tetrachloride (CCl4) or allyl alcohol.  These models are principally 
employed in rats.  For many reasons, including their smaller size, reduced cost, breeding 
characteristics, and particularly their increasing genetic manipulation, mouse models 
have many advantages over those in other species, including the rat.  For these reasons 
focus will be given to the two most frequently utilised murine models, the Choline 
Deficient Ethionine supplemented (CDE) diet and the 3,5-diethoxycarbonlyl-1,4-
dihydrocollidine supplemented (DDC) diet (See Chapter 3).  Whilst these models have 
provided important breakthroughs in our understandings of HPCs they remain with some 
significant disadvantages.  In particular, neither operates via a characterised mechanism 
and both induce significant toxicity with only relatively modest HPC activation in 




Table 1.1 Markers of adult HPCs in humans and rodents 
Hepatic progenitor cell marker References
Adult biliary marker
Cytokeratin 19 (CK19) Bisgaard et al. 1993
PanCK Kofman et al. 2005
CK7 Paku et al. 2005
CK14 Bisgaard et al. 1993
γ-Glutamyl transpeptidase (γGT) Cameron et al. 1978
Glutathione-S-transferase P (GST-P) Tee et al. 1992
Muscle pyruvate kinase (MPK) Akhurst et al. 2005 
OV-6 (recognises CK14 and CK19) Bisgaard et al. 1993
OV1 Sanchez et al. 2004 
A6 Engelhardt et al. 1993
OC.2 and OC.3 Hixson and Allison 1985 
Connexin 43 Zhang and Thorgeirsson 1994 
CX3Cl1 Yovchev et al. 2007 
CD24 Yovchev et al. 2007 
MUC1 Yovchev et al. 2007 
Deleted in malignant brain tumour 1 (DMBT1) Bisgaard et al. 2002 
Adult hepatocyte markers 
Albumin Tian et al. 1997 
CK8 Libbrecht et al. 2000b 
CK18 Libbrecht et al. 2000b 
α1-Antitrypsin Gauldie et al. 1980 
Hepatocyte nuclear factor 4 (HNF4) Nagy et al. 1994 
HBD.1 Faris et al. 1991 
c-Met Hu et al. 1993 
Fetal hepatocyte markers 
Delta-like protein (Dlk 1) Yovchev et al. 2007 
Epitheliam Cell Adhesion Molecule (EpCAM) de Beor et al. 1999 
α-Fetoprotein (αFP) Evarts et al. 1987 
Aldolase A and C Lamas et al. 1987 
c-Met Hu et al. 1993 
Cadherin 22 Yovchev et al. 2007 
CD24 Yovchev et al. 2007 
CD44 Kon et al. 2006 
Others including adult haematopoietic markers 
c-kit Fujio et al. 1994 
Alanine aminopeptidase (CD13) Kakinuma et al. 2009 
CXCR4 Zheng et al. 2006 
CD34 Omori et al. 1997 
TROP 2 Okabe et al. 2009 
Sca-1 Petersen et al. 2003  
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The CDE diet 
 
The CDE diet is, to date, the most frequently studied murine model of HPC activation.  
It was originally developed in rats following the opportunistic observation this 
combination resulted in HPC expansion (Shinozuka et al., 1978; Yaswen et al., 1984).  
Initially, the carcinogen ethionine was used as a rat model of Hepatocellular Carcinoma 
(HCC) development.  Ethionine is the S-ethyl analogue of the essential amino acid 
methionine and is believed to act principally by inhibiting the SAM (S-adenosyl-L 
methionine) synthetase enzymes.  Consistent with this is the reversal of most of 
ethionine‟s biochemical and morphological effects by the administration of methionine 
or adenine (Alix, 1982). Ethionine is, therefore, believed to block one or more of the 
essential functions of methionine in cells.  However, the precise mechanism by which 
this combination stimulates HPC activation remains far from clear.  When choline 
deficiency was added to ethionine treatment pronounced HPC proliferation was noted.  
This model was developed as choline is both a methionine precursor and ethionine, as an 
antagonist of methionine, is also an inhibitor of choline biosynthesis via the 
transsulfuration pathway (Figure 1.4A).  Interestingly, neither choline deficiency alone 
nor administration of ethionine results in HPC activation.  Choline deficiency in humans 
was in the past, a not infrequent consequence of total parenteral nutrition and resulted in 
liver injury and steatosis (Buchman et al., 2001).  When applied to mice the CDE diet 
induces HPC activation analogous to that seen in the CDE diet in rats.  However in mice 
the HPCs infiltrate the injured parenchyma as thinner columns of cells often in single 
file, as opposed to the ductular morphology seen in rats (Akhurst et al., 2001; Tee et al., 
1996).  In mice the expansion of HPCs has been described to be progressive over 
approximately 2 weeks followed by a continuous but stable HPC activation (Figure 
1.4B).  In addition to inducing a maintained HPC activation the CDE diet also results in 
HCC in mice when given continuously  over six to twelve months in a chronic injury 





Figure 1.4 HPC activation in the CDE diet model  
(A) The transsulfuration pathway in eukaryotes enables the creation of the amino acid cysteine 
from the essential amino acid methionine.  Ethionine blocks the conversion of methionine to 
homocystiene.  (B) Published data examining A6
+
 HPCs following CDE diet in a murine model 
of HPC expansion.  Data is presented as mean±SEM (adapted from Akhurst et al., 2001) 
 
The DDC diet 
 
The DDC diet is an alternative model of HPC activation in the mouse (Preisegger et 
al., 1999).  Unlike the CDE diet it results in persistent proliferation of primitive ductules 
with poorly defined lumens.  These ductules accumulate in the periportal regions and 
while the cells of the ductules maintain many of the cellular markers of the HPCs in the 
CDE diet they are clearly morphologically distinct (Jelnes et al., 2007).  Once again, the 
mechanism of action resulting in HPC activation in this model is not known.  What is 
clear is that, as with the CDE diet, hepatocellular injury is seen both by raised serum 
transaminases, and architecturally.  In the recent past the DDC diet has been used in 
many published HPC studies.  Crucially HPCs extracted from DDC induced mice have 
been shown to be capable of hepatocyte repopulation in a transplantation model (Wang 
et al., 2003a). 
 




In humans, HPC activation is believed to take the form of a ductular reaction.  This is 
morphologically and immunohistochemically analogous to the rodent HPC response.  
The clinical relevance of the HPC reaction is implied by its frequency in the full 
spectrum of human liver diseases including fulminant hepatic failure, chronic viral 
hepatitis, alcoholic disease and non alcoholic fatty liver disease, immune 
cholangiopathies, and hereditary liver disorders (Falkowski et al., 2003; Roskams, 2003; 
Roskams et al., 1991; Roskams et al., 2003a; Roskams et al., 2003b).  During acute liver 
injury HPC regeneration may be seen occurring synchronously with a degree of 
hepatocyte replication.  The presence of HPC activation during chronic liver disease 
appears, however, to be a feature of eventual exhaustion of hepatocyte proliferation by 
senescence over many years or decades (Wiemann et al., 2002).  Characteristically the 
magnitude of HPC activation corresponds to the severity of liver fibrosis and 
inflammation (Libbrecht et al., 2000; Lowes et al., 1999; Roskams et al., 2003a) as is 
also observed in rodents (Pritchard and Nagy, 2010).  In addition the more aggressive a 
hepatocellular injury in humans, the higher the proportion of observed HPCs that 
resemble intermediate hepatocytes.  This implies that an escalating hepatocyte 
deficiency promotes a greater degree of differentiation down the progenitor cell–
hepatocyte axis (Roskams et al., 2003b).  A particular disease condition in which 
dramatic HPC activation and expansion is fibrosing cholestatic hepatitis, an aggressive 
and usually fatal form of viral hepatitis (Dixon and Crawford, 2007).   
 
Aside from histological and immunohistochemical demonstration of HPCs in a wide 
range of human diseases, other observations from human livers supports the role of HPC 
mediated regeneration.  Sequential biopsies, taken from patients with liver disease, have 
shown HPC proliferation and suggests their differentiation by observing a progressive 
increase in intermediate hepatocytes in association with their progressive extension into 
the liver lobule over time (Demetris et al., 1996; Falkowski et al., 2003; Roskams et al., 
1991).  These observations are in keeping with clonal analysis performed using 
mitochondrial mutations in both normal and injured liver which suggests that the portal 
tract, is likely to be a crucial origin of clonal hepatocytes in the adult human (Lin et al., 
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2010; Fellous et al., 2009).  Rodent HPCs are similarly described to arise from the Canal 
of Hering.  Finally proliferating cells, analogous to those in animal models, have been 
isolated from foetal and adult human liver and are capable of hepatocyte-like 
differentiation (Herrera et al., 2006; Porretti et al., 2010; Schmelzer et al., 2007).   
 
HPC markers and their relevance 
 
In order to aid the accurate and consistent identification of HPC in the wide variety of 
models and species they have been described an increasingly large number of cell 
markers have been ascribed to this population.  By their nature, HPCs are 
heterogeneous, consisting of a spectrum of cells ranging from an immature phenotype to 
mature cholangiocytes and intermediate hepatocytes.  Although markers for the most 
immature progenitor cells have not been identified, there are currently a variety of 
established markers for constituents of the HPC compartment (Table 1.1).  Many HPC 
markers are also expressed by mature cholangiocytes or hepatocytes.  No universal HPC 
marker, specific to this compartment, has been identified to date, with most of the 
frequently used HPC markers also identifying mature cholangiocytes.  This cross 
reactivity between mature and immature cell populations is likely to be a feature of the 
progressive differentiation of HPCs during which they vary their marker expression.  
Currently there is a genuine requirement for a thorough understanding of the stepwise 
marker expression in HPCs, akin to that described for the haematopoietic stem cell 
development (Bird et al., 2008).  A small number of these markers have been used to 
enrich HPCs which, as a population, have shown transplantability and hepatocellular 
reconstitution from either foetal (Dlk
+ 
- Oertel et al., 2008 or EpCAM
+ 
- Schmelzer et 
al., 2007), CD13
+
 (Kakinuma et al., 2009) or adult donors (cKit
+
 - Wang et al., 2003a).   
 
Early HPC markers described to date include c-kit, Sca-1, NCAM, SgIGSF and 
multidrug resistance transporters which denote a Side Population (SP) phenotype.  The 
SP phenotype was originally described in the haematopoietic system and relates to the 
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ability to efflux the dye Hoechst 33342.  It appears to identify cells with immature 
characteristics particularly in hepatic embryogenesis (Tsuchiya et al., 2005) and 
carcinogenesis (Chiba et al., 2006).  Another feature of immature cells is the absence of 
cytokeratin 7 (CK7) expression. CK7 is expressed as HPCs acquire a mature phenotype 
(Paku et al., 2005).  Alphafetoprotein (FP) is an HPC marker which is expressed also 
during hepatic embryogenesis and carcinogenesis.  It appears to be present in 
intermediate ducts (Theise et al., 1999) with prolonged expression for over 3 weeks 
following partial hepatectomy (PH) with retrorsine treatment (Gordon et al., 2000) and 
is also expressed by more differentiated hepatocyte like cells (Evarts et al., 1989).  FP 
is however difficult to detect histologically in murine HPC models (Jelnes et al., 2007).  
CD133, also known as prominin-1, is recognised as a marker for other stem cell 
populations (Shmelkov et al., 2005).  In the adult liver it appears to be marker of biliary 
cells consistent with HPCs in the Canal of Hering (Shmelkov et al., 2008).  Furthermore 
adult liver derived CD133
+
 cells have recently shown bipotentiality in clonogenic assays 
(Porretti et al., 2010 ; Suzuki et al., 2008). 
 
The cytokeratins and panCK 
The most frequently used markers for HPCs across all species and models of HPC 
activation utilise specific cytokeratins by HPCs (Santoni-Rugiu et al., 2005).  
Cytokeratins (CKs) form the intermediate filaments between the nucleus and the cell 
membrane of epithelial cells and, due to their many forms, a cell's CK expression may 
be used as a signature its epithelial tissue origin.  Briefly CKs are usually found in pairs 
comprising one basic or neutral type I CK (CK1-9) and one acidic type II cytokeratin 
(CK10-20).  Many CKs are used for HPC identification with other specific HPC 
identifying antibodies (e.g. OV6 and A6) known to recongnise epitopes within specific 
CKs (Table 1.1).  A polyclonal antibody to panCK recognises multiple cytokeratin 
epitopes and has been described to show near identical recognition pattern to the HPC 
marker A6 in mice, and additionally has the significant advantage of its effective use in 
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formalin fixed tissues (Kofman et al., 2005).  This commercially available antibody has 
become one of the most frequently used HPC markers in the field.  For historical reasons 
the work presented here uses PanCK as the default HPC marker.  Where appropriate, 
cross reference to other HPC markers particularly Dlk1 and EpCAM will be made. 
 
Dlk1  
The now accepted cell surface marker of hepatoblasts in the developing liver Dlk1 has 
more recently been described in adult HPCs (Jensen et al., 2004; Oikawa et al., 2009; 
Tanimizu et al., 2003).  While Dlk1 (also known as Pref1) is readily recognised in a 
variety of rat HPC models it has also been shown in low levels in murine models (Jelnes 
et al., 2007).  Functionally it is known to interact with the Notch receptor on the cell 
surface (Bray, 2006).  It is therefore of use also as a potential target for cell sorting of 
the HPC population (Tanimizu et al., 2004).  Furthermore its interaction with the Notch 
signalling pathway places it with the potential to influence cell fate choice (see Notch 
section Chapter 1) 
 
EpCAM 
A widely accepted marker of HPCs which has recently gained increasing credence is 
the cell surface antigen EpCAM (Epithelial cell adhesion molecule) or CD326.  EpCAM 
is a Type 1 transmembrane glycoprotein and is expressed on the basolateral membrane 
of cells by the majority of epithelial tissues.  Functional EpCAM is a Ca
2+
-independent 
cell-cell adhesion molecule and is known to be intricately linked with the Cadherin-
Catenin pathway and hence the Wnt pathway (see Wnt section Chapter 1).   
A key advantage to the use of EpCAM as an HPC marker is that it is not expressed by 
many differentiated epithelia including adult squamous epithelium and crucially 
hepatocytes (de Boer et al., 1999).  EpCAM expression has been reported to be a 
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possible marker of early malignancy, with expression being increased in tumour cells 
and almost all carcinomas, with de novo expression being seen in dysplastic squamous 
epithelium. 
 
The evidence for EpCAM as a marker of HPCs is many fold.  Following an early 
description of ductular reaction being EpCAM
+
 (de Boer et al., 1999) it has emerged as 
a marker with perhaps the strongest evidence for containing primordial HPCs.  Firstly 
adult mouse EpCAM
+ 
cells are bipotential with colonies forming both hepatocytes and 
cholangiocytes (Okabe et al., 2009).  Furthermore adult rat EpCAM
+
 HPCs are 
transplantable and can differentiate into hepatocytes in vivo.  The EpCAM
+
 HPC 
population also exists in human liver constituting approximately 2% of the hepatocyte 
depleted fraction from normal adults but increasing to over 10% in adults with chronic 
liver disease (Porretti et al., 2010).  Additionally, human derived EpCAM
+
 cells are 
bipotential and transplantable forming hepatocytes in a NOD/SCID mouse transplant 
model (Schmelzer et al., 2007).  EpCAM is also recognised not only as a marker of a 
cholangiocarcinoma and a subset of HCC (de Boer et al., 1999), but additionally 
provides prognostic information in HCC (Yamashita et al., 2008).  Interesting the 
EpCAM
+
 population within HCCs contains a transplantable cancer stem cell (Yamashita 
et al., 2009) adding further weight to its use as an HPC marker. 
 
More recently alternative approaches such as profiling HPC like cells during 
development (Ochsner et al., 2007) or immunising rabbits with cells isolated from adult 
HPC models (Dorrell et al., 2008) have been used to generate other novel HPC markers.  
While monoclonal antibodies which appear to recognise specific populations both of 
HPCs and their associated cells have been produced, their utility remains to be shown.  
In the future, these antibodies or their target molecules may permit more specific 
recognition of primitive HPCs or even hepatic stem cells as well as the various stages 
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during differentiation.  A thorough description of the stage of HPC differentiation from 
stem cell to fully differentiated hepatocyte will greatly benefit our understanding of 
hepatic regeneration.   
 
Despite the apparently stereotyped HPC response seen across a wide range of human 
diseases there is heterogeneity both between species and injury models (Jelnes et al., 
2007).  For example, the expression of FP which is characteristically seen in rat HPC 
models, is rare in the human ductular reaction and difficult to detect in many murine 
HPC models.  Differing characteristics are seen between models, for example the 
expression of DMBT1 is seen following hepatocellular injury but is not seen during 
human cholestatic liver disease or following BDL in rodents (Bisgaard et al., 2002).  
Consistent with the atypical HPC response observed in the BDL model, dexamethasone 
does not affect ductule formation following BDL in rats but inhibits HPC activation 
following AAF/PH (Nagy et al., 1998).   
 
Other potential hepatocyte precursor populations 
Lineage tracing experiments in the mouse have provided some information regarding 
alternative potential origins of hepatocytes during liver regeneration.  Using a 
constitutively active Foxl1-Cre mouse, a small number of labelled hepatocytes (0.5% 
max) were seen following biliary injury in this lineage tracing system.  Interestingly 
while this occurs in an injury model the proportion of hepatocytes derived from Foxl1
+
 
precursors during development and physiological liver homeostasis is extremely low 
suggesting that while Foxl1
+
 cells may have the potential to become hepatocytes, but in 
reality even during injury their propensity to support liver function is very low indeed 
(Sackett et al., 2009).   
 
Another constitutively active lineage tracing system, this time under the control of a 
GFAP promoter has also been used to track precursors of hepatocytes (Yang et al., 
2008).  In this model larger numbers of labelled hepatocytes are seen following exposure 
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to a dietary injury model.  However, once again the low level of labelled hepatocytes 
prior to dietary initiation calls into question how relevant GFAP
+
 precursor are during 
development and adult homeostasis.  Furthermore it is apparent that while GFAP is 
classically a marker of hepatic stellate cells, it is also a marker of HPCs and 
cholangiocytes (Yang et al., 2008).  Therefore, the role of hepatic stellate cells in the 
formation of hepatocytes remains in doubt.  It seems more plausible that these findings 
represent the differentiation of HPCs into hepatocytes as HPCs have been described to 
express GFAP, at least transiently.  Whether all HPCs express GFAP and at what point 
in their differentiation this occurs is a question that requires further investigation.  This 
in my opinion makes the assumption that hepatic stellate cells are HPCs, unreliable and 
currently unfounded.   
 
Mechanisms of HPC activation 
 
The mechanisms controlling the HPC response remain under intensive investigation.  
Many of the signals that control liver regeneration from hepatocytes themselves are also 
involved in HPC mediated regeneration.  None-the-less minor injury to a normal liver 
results in no evidence of activation of the HPC compartment and yet causes effective 
hepatocyte proliferation.  Therefore significant additional factors appear to be crucial in 
determining whether or not HPC activation occurs.  The most common contexts in 
which the HPC reaction is observed is when the hepatocyte‟s cell cycle is blocked either 
by toxins or replicative senescence.  Nevertheless these two modes of liver regeneration 
are not entirely mutually exclusive.  HPC and hepatocyte replication can be observed 
simultaneously in some injury models (Rosenberg et al., 2000; Wang et al., 2003a).  
This may simply be a function of the location, duration and/or magnitude of these 
specific signals in response to injury or the failure of sufficient regeneration.  However 
other factors such as the cellular environment are likely to be highly relevant in 
generating the HPC response.  Certainly the wide range of candidate signals, with many 
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showing only modest effects, suggests that there is a significant signal redundancy in 
HPC control.   
 
Observational studies show a correlation between the severity of liver disease and the 
magnitude of the HPC response (Libbrecht et al., 2000; Lowes et al., 1999).  A central 
role of inflammatory cytokines has been suggested in rodents also (Knight, Matthews et 
al.  2005).  These observations are consistent with the dramatic inhibition of HPC 
responses noted upon treatment with anti-inflammatory agents (Davies, Knight et al.  
2006; Nagy et al., 1998).  In terms of specific signals, many have been studied directly 
during HPC activation in vitro and in vivo (for overview see Table 1.2).  Many of these 
signals are also seen during PH; however they are often different in either intensity or 
duration of signal. 
 
TNF superfamily 
Members of the pro-inflammatory TNF superfamily include TNF, and TWEAK 
(TNF-like weak inducer of apoptosis) both of which appear to play pivotal roles in HPC 
activation.  TWEAK is upregulated during hepatic injury both in rodents and a variety of 
human diseases and mediates pro-proliferative effects directly on HPCs via its 
monogamous Fn14 receptor (Jakubowski et al., 2005; Winkles, 2008; Tirnitz-Parker et 
al., 2010; Burkly et al., 2007).  TWEAK is sufficient, although not necessary, to induce 
a modest HPC response, whilst its inhibition results in an attenuated murine HPC 
response to both the DDC and CDE diets (Jakubowski et al., 2005; Tirnitz-Parker et al., 
2010)).  This therefore positions TWEAK as arguably the most important paracrine 
signal inducing the hepatic HPC response.  Interestingly in a more detailed examination 
over time using Fn14 knockout mice treated with the CDE diet, a delayed, rather than 
prolonged loss of HPC expansion was observed.  This feature suggests a degree of 
redundancy in the control of HPC behaviour with compensation by other pathways of 
activation.   
Chapter 1-Introduction 
 42 
Table 1.2 Functional studies in HPC activation 
Artificial manipulation of target signal is shown by arrows,  indicates upregulation and  
indicates inhibition of signalling.  References are cited for each study.  For HPC models M and 
R denote murine and rat studies respectively.   
TABLE 2
Signal Oval Cell Model Effect on OCs Reference
 M=mouse, R=rat
TNF
 In vivo 50% CDE diet (M)  expansion (Knight et al. 2000)
 In vitro LE6 cells IV (R)  proliferation (Kirillova et al. 1999)
 In vitro LE6 cells IV (R)  mitogenesis (Brooling et al. 2005)
TWEAK
 In vivo Uninjured (M)  expansion (Jakubowski et al. 2005)
 In vivo Uninjured adults (M)  expansion  
 In vivo DDC diet (M)  expansion  
 In vitro NRC line (R)  mitogenesis  
LTα
 In vivo CDE diet (M)  expansion (Knight and Yeoh 2005)
LTβ
 In vivo CDE diet (M)  expansion (Akhurst et al. 2005)
STAT3
 In vivo None (M)  expansion (Subrata et al. 2005)
 In vivo CDE diet (M)  expansion,  migration (Subrata et al. 2005)
IL6
 In vivo 50% CDE diet (M)  proliferation (Knight et al. 2000)
 In vitro PIL2/PIL4 lines (M)  proliferation (Matthews et al. 2004)
 In vivo CDE diet (M)  expansion, proliferation (Subrata et al. 2005)
 In vivo AAF/PH (R)  expansion (Nagy et al. 1998)
OSM
 In vitro PIL2/PIL4 lines (M)  growth (Matthews et al. 2005)
 In vitro Primary OCs (M) No effect on growth (Matthews et al. 2005)
IFN
 In vivo Uninjured (M) OC like expansion (Toyonaga et al. 1994)
 In vitro LE6 cells (R)  mitogenesis (Brooling et al. 2005)
 In vitro LE2 cells (R) Possible  mitogenesis (Brooling et al. 2005)
 In vivo CDE diet (M)  expansion (Akhurst et al. 2005)
 In vivo 2/3 PH (M)  expansion (Brooling et al. 2005)
 IFN
 In vitro PIL2/PIL4 lines (M)  proliferation (Lim et al. 2006)
 In vivo CDE diet (M)  expansion, proliferation  
HGF
 In vivo AAF (R)  proliferation (Nagy et al. 1996)
 In vivo AAF/PH (R)  early expansion (Hasuike et al. 2005)
 In vivo AAF/PH (R)  expansion (Oe et al. 2005)
EGF
 In vivo AAF (R)  proliferation (Nagy et al. 1996)
 In vitro MOC lines (M)  proliferation  (Isfort et al. 1997)
TGFβ
 In vivo DDC diet (M)  expansion (Preisegger et al. 1999)
 In vitro LE2/LE6 cells (R)  proliferation (Nguyen et al. 2007)
SCF
 In vivo AAF/PH (R)  expansion (Matsusaka et al. 1999)
Sympathetic nervous system
 In vivo 50% CDE diet (M)  expansion (CK) (Oben et al. 2003)
Parasympathetic nervous system
 In vivo Galactosamine (R)  expansion (OV6) (Cassiman et al. 2002)
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The source of TWEAK in these models remains an important question.  In other 
situations TWEAK is produced predominantly by monocytes particularly following 
IFN stimulation (Nakayama et al., 2000) and is initially expressed as a membrane 
bound molecule which can also be released in a soluble form.  TWEAK activates NFB 
(Tirnitz-Parker et al., 2010) which is described as pro-proliferative to HPCs (Kirillova et 
al., 1999).  TWEAK may also play a role in the proliferation of other mesenchymal 
progenitors (Girgenrath et al., 2006) including promoting angiogenesis (Jakubowski et 
al., 2002) and contributes to hepatic embryogenesis and carcinogenesis (Kawakita et al., 
2005).  Examination of the source of TWEAK within the liver during the CDE diet 
suggests that macrophages and NK cells may be principal sources although other 
sources including myofibroblasts remain possible (Tirnitz-Parker et al., 2010). 
 
TNF production is increased during chronic human liver disease (Tilg et al., 1992).  
It too is described as being predominantly produced by macrophages, but also by other 
cells types including lymphocytes and fibroblasts (Locksley et al., 2001).  Hepatic 
TNF is upregulated during the rodent HPC response (Akhurst et al., 2005; Knight et 
al., 2000).  The cellular activity of TNF is mediated via the TNF R1 and TNF R2 
receptors.  Administration of TNF to HPC lines in vitro results in proliferation 
(Kirillova et al., 1999).  Furthermore TNF R1 knockout mice show a markedly impaired 
HPC response (Knight et al., 2000).  To date no study, including that with 
TNF/Lymphotoxin  (LT) knockout mice (Knight and Yeoh, 2005), has shown an 
absolute requirement for TNF for HPC activation.  However is appears that TNF is 
required for an optimal HPC response.  Unlike TWEAK, raised TNF alone has not been 
described to be sufficient for HPC activation.   
 
LT-, LT- and LIGHT are further members of the TNF superfamily and are well 
described in other organs to be involved in a variety of processes including influencing 
cell survival and proliferation (Tumanov et al., 2007).  Production of LT-, LT- and 
LIGHT is principally by lymphocyte populations.  LT- in similarity with TNF binds 
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TNF R1 which, as previously described, plays an important role in the control of the 
HPC response.  This receptor‟s role in HPC activation is suggested but not confirmed by 
the demonstration that LT-/TNF double knockout mice develop an attenuated HPC 
response following the CDE diet (Knight and Yeoh, 2005).  LT- may also act in 
combination with LT-β via the formation of a heterotrimer (LT12) which is the ligand 
for a separate receptor; LT- Receptor (LT-R).  LT- expression is upregulated both 
during rodent HPC activation and during chronic human liver disease.  Both LT- 
knockout and LT-R knockout mice show an partially impaired HPC response (Akhurst 
et al., 2005).  A further ligand for LT-R called LIGHT is therefore also implicated in 
HPC function via LT-R mediated signal transduction.  LIGHT is predominantly 
expressed by lymphocytes (Hansson, 2007) and although its effects on HPCs have not 
been directly investigated it is known to signal to hepatocytes via LT-R (Lo et al., 
2007).   
 
GP130 activators 
A variety of cytokines, including IL6, Oncostatin M (OSM) and Leukaemia Inhibitor 
Factor (LIF), act through the gp130 signalling pathway.  Activation of this pathway 
results from the homodimerisation of gp130, which in turn activates the JAK/STAT and 
ERK pathways.  STAT 3 and its targets are up regulated during the rodent HPC response 
and during human chronic liver disease (Sanchez et al., 2004; Subrata et al., 2005).   
 
Aside from TWEAK, gp130 is the only signal demonstrated to date capable of 
initiating an HPC response alone.  This was demonstrated in uninjured gp130
Y757F
 mice 
with constitutively active gp130 (Subrata et al., 2005; Yeoh et al., 2007) in which an 
expansion of A6
+
 HPCs is observed in the absence of other interventions.  Another of 
gp130‟s downstream targets, the ERK-1/2 pathway, was shown by the same 
investigators to be a negative regulator of HPC expansion (Yeoh et al., 2007).  Therefore 
gp130 is potentially a key element in the activation and expansion of hepatic HPCs.  
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Using hepatocyte specific knockout, gp130 has also been demonstrated to play a key 
role in protection from injury in the DDC diet with knockout resulting in greater 
hepatocellular injury and corresponding increased HPC activation (Plum et al.  2010). 
 
IL-6 is the best characterised of gp130‟s activators (Santoni-Rugiu et al., 2005).  It is 
produced by a variety of cell types including macrophages and Kupffer cells (Naugler et 
al., 2007), in addition to fibroblasts, and endothelia.  Recent studies have demonstrated 
that IL-6 is pro-proliferative to the HPC response and that IL-6 knockout mice 
demonstrate an attenuated HPC response (Fischer et al., 1997; Knight et al., 2000; Yeoh 
et al., 2007).  Treatment of HPC lines with IL-6 results in proliferation and migration 
(Matthews et al., 2004; Yeoh et al., 2007).   
 
IL-6 functions as the ligand to the type I cytokine receptor CD126 (IL-6R) along 
with the signal transducing gp130 homodimer principally activating STAT3 (Yeoh et 
al., 2007).  IL-6 expression increases in both acute and chronic human disease and 
rodent liver injury models (Akhurst et al., 2005; Fausto et al., 2006; Streetz et al., 2003).  
IL-6 is a key signal in hepatocyte proliferation but is not in itself capable of inducing an 
HPC response (Yeoh et al., 2007).  The source of IL-6 during liver injury is likely to 
arise from activated leukocytes including Kupffer cells and lymphocytes (Streetz et al., 
2003), however IL6 production has also been described from HPCs themselves, raising 
the possibility of autocrine stimulation (Matthews et al., 2004).  In further support for a 
role of IL6 in HPC function, IL6 appears to be a central player in the development of 
HCC (Naugler et al., 2007; Wands, 2007), which as discussed is a process which shares 
many similarities to the expansion of HPCs during regeneration (see section 1.34 HPCs 
and Cancer).   
 
LIF and OSM both participate in a variety of processes including regulation of growth 
and differentiation.  LIF‟s action is mediated via the LIF receptor (LIFR), which is 
composed of LIFR and gp130.  Its downstream action in HPCs is predominantly via 
STAT1 (Kirillova et al., 1999).  Both LIF and LIFR are upregulated during the HPC 
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reaction in the rat (Omori et al., 1996) and in human cirrhotic livers, with LIFR 
localising to proliferating CK7
+
 intermediate hepatobiliary cells (Znoyko et al., 2005).  
Although the effects of LIF on HPC proliferation are not clear it does have stimulatory 
effects on progenitor cells in other organs, including murine haematopoietic progenitors 
(Metcalf and Gearing, 1989).  LIF has also been described to have effects of hepatocyte 
differentiation.  Murine embryonic bodies when cultured with LIF are maintained in a 
undifferentiated state but differentiate into hepatocyte like cells upon its removal 
(Chinzei et al., 2002).   
 
OSM also activates gp130, either via its own OSM receptor (OSMR) subunit or via 
the LIFR (Heinrich et al., 2003).  OSM influences extrahepatic progenitor cell activity 
and extracellular matrix (ECM) deposition in addition to inducing an acute phase 
response and therefore may influence HPC behaviour via a number of distinct pathways 
(Knight et al., 2005a).  It is produced by hepatic macrophages in humans and is 
upregulated both during cirrhotic human liver disease (Znoyko et al., 2005) and the 
rodent HPC reaction (Matthews et al., 2005).  Both murine HPCs and human 
intermediate hepatobiliary cells express OSMR which induces activation of STAT3 
(Matthews et al., 2005; Znoyko et al., 2005).  OSM has been described to promote 
proliferation and differentiation of foetal hepatoblasts (Kinoshita et al., 1999) and HPCs 
lines respectively (Yin et al., 1999; Yin et al., 2002).  Conflicting data however has 
come from an immortalised p53 deficient HPC line (Matthews et al., 2005).  Further 
investigation is required to clarify the role of OSM in HPC activation.   
 
IFN 
Unlike the previous examples of signalling via gp130, IFN activates the JAK-STAT 
pathway via STAT1 rather than STAT3 (Croker et al., 2003).  There is strong evidence 
for a role of the inflammatory cytokine IFN in HPC activation.  It is characteristically 
expressed by T lymphocytes and NK cells.  IFN‟s role in HPC activation was initially 
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examined using a transgenic mouse with constitutive hepatic IFN expression using a 
serum amyloid P component gene promoter.  These mice demonstrated cords of small 
cells morphologically similar to HPCs in the context of progressive liver inflammation 
(Toyonaga et al., 1994).  Since then HPCs have been found to possess functional IFN 
receptors and IFN expression have been shown during the HPC reaction (Bisgaard et 
al., 1999).  Varying effects, including proliferation, are seen when IFN is administered 
to HPC lines (Brooling, Campbell et al.  2005).  More consistent effects have been seen 
using in vivo manipulation with a reduced HPC expansion seen in IFN knockout mice 
(Akhurst et al., 2005) and IFN treatment stimulated an HPC response following PH in 
mice (Brooling et al., 2005).  These observations are consistent with the impaired HPC 
response seen in BALB/c mice which lack Th1 signalling, of which IFN is a key 
component (Knight et al., 2007).  Caution however should be noted as reduced HPC 
expansion has also been noted in vitro (Brooling et al., 2005) and it is possible that IFN 
may have indirect effects upon the HPC response via inhibition of hepatocyte 
proliferation (Fausto et al., 2006).  IFN has been proposed to be a factor in determining 
hepatocyte versus HPC mediated regeneration although convincing data to support this 
hypothesis is lacking. 
 
Type I Interferons 
The effects of the type 1 interferons (IFN and IFNβ) on HPCs appear to differ 
significantly from that of IFN.  IFN signals predominantly through STAT3 in murine 
liver (Lim et al., 2006).  Analysis of paired biopsies in human liver biopsies reveals that 
either successful or unsuccessful IFN treatment of Hepatitis C virus is associated with 
a reduced number of HPCs (Lim et al., 2006; Tsamandas et al., 2006).  This effect is not 
reliant on Hepatitis C as IFN reduces HPC proliferation both in vitro and in vivo in the 
absence of Hepatitis C infection (Lim et al., 2006).  Furthermore IFN appears to 
promote differentiation particularly into hepatocyte like cells.  The effects of IFNβ on 
HPCs are unknown although in similarity to IFN it impairs regeneration following PH 
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(Theocharis et al., 1997; Wong et al., 1995).  Its role in HPC activation therefore 
warrants further investigation.   
 
Primary growth factors 
The role of Hepatocyte Growth Factor (HGF) in stimulating hepatocyte proliferation 
in the primed liver is well described (Fausto et al., 2006).  HPCs, in similarity to 
hepatocytes, also express the HGF receptor c-Met (Hu et al., 1993; Muller et al., 2002).  
The expression of HGF is increased following PH/AAF in the rat (Evarts et al., 1993; 
Hu et al., 1993), as is urokinase plasminogen (uPA) which can release HGF stored in its 
bound form on ECM(Nagy et al., 1996).  HGF levels are also increased in the serum of 
patients with chronic liver disease, and those experiencing acute injury, compared to 
healthy controls (Shiota et al., 1995).  HGF is both mitogenic to, and promotes 
differentiation of, HPCs in vivo (Hasuike et al., 2005; Nagy et al., 1996).  This is in 
concordance with similar effects on embryonic hepatic stem cells (Suzuki et al., 2003).  
There is therefore strong evidence for a role of HGF in influencing HPC behaviour; 
however it should be noted that elevations of HGF in the context of PH alone are 
insufficient to stimulate HPC expansion.   
 
Transforming Growth Factor  (TGF) and Epidermal Growth Factors (EGF) are 
structurally related membrane bound growth factors which bind the EGF receptor 
(EGFR) of adjacent cells, in turn initiating a variety of effects including upregulation of 
the EGFR and cell proliferation (Leahy, 2004).  Membrane bound pro-TGF may also 
be cleaved to release a soluble signal capable of autocrine and paracrine signalling.  In 
rodents TGF and EGF are produced predominantly by stellate cells which are known 
to line HPC ductules (Paku et al., 2001) whist the EGFR is expressed by HPCs (Evarts 
et al., 1992).  TGF is upregulated following AAF/PH injury in rodents (Evarts et al., 
1993) and both EGF and TGF localise to ductular reactions in human chronic liver 
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disease (Hsia et al., 1994; Komuves et al., 2000).  EGF is mitogenic to HPCs in vitro 
suggesting a role of both growth factors in HPC activation.   
 
FGFs 
The fibroblasts growth factors (FGFs) are a family of growth factors which bind their 
FGF receptors (FGFR) with the aid of heparin sulfate proteoglycans (Pellegrini, 2001).  
FGFs are involved in hepatic embryogenesis (Jung et al., 1999) and are up regulated in 
both the rats AAF/PH model (Marsden et al., 1992) and during human chronic liver 
disease (Jin-no et al., 1997).  While FGFR2 is upregulated both in a variety of liver 
injuries and is expressed by numerous cells types, FGFR1 in adult rats is upregulated 
specifically during HPC inducing injury and is expressed by HPCs (Hu et al., 1995).  In 
keeping with their role in organogenesis FGFs induce a hepatocyte like phenotype in 
BM derived „multipotent adult progenitor cells‟ in vitro (Schwartz et al., 2002). 
  
TGF-β 
TGF-β is well recognised to limit hepatocyte mediated regeneration by inhibiting 
hepatocyte proliferation while inducing apoptosis (Fausto et al., 2006).  TGF-β is 
actively expressed by myofibroblasts following HPC inducing injury (Park and Suh, 
1999).  Active expression of TGF-β in a transgenic mouse fed on the DDC diet results in 
a reduced HPC response (Preisegger et al., 1999), and concordantly TGF-β is inhibitory 
to HPC lines in vitro (Nguyen et al., 2007) although TGF-β is less inhibitory of mitosis 
in HPCs than hepatocytes.   
 
SDF-1 
The chemokine, Stromal Cell Derived factor 1 (SDF-1) uniquely binds to the CXCR4 
receptor, and plays a variety of roles including cell trafficking, proliferation, and 
organogenesis.  CXCR4 is expressed by a variety of progenitor cells and SDF-1 is 
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upregulated during human chronic liver disease (Terada et al., 2003).  There is however 
some disagreement over the source of SDF during the hepatic HPC response with 
reports suggesting either hepatocytes or periportal production (Hatch et al., 2002; 
Mavier et al., 2004; Zheng et al., 2006).  However, it is clear that SDF is upregulated in 
following HPC inducing rodent injury.  SDF has been shown to be both pro-proliferative 
(Pi et al., 2005) and chemotactic (Hatch et al., 2002) to HPCs.   
 
Wnt 
Metazoan development is controlled by a defined group of signalling pathways 
including but not limited to Hedgehog (Hh), Wnt/Wingless (Wnt), and Receptor 
Tyrosine Kinase (RTK) (Hayward et al., 2008; Ma et al., 2008; Pownall et al., 1996).  
All of these pathways are now appreciated to influence adult tissue stem cell behaviour 
in many organs including the liver.   
 
The name Wnt was coined after the combination of wingless (Wg) and int-1 
(Rijsewijk et al., 1987).  Wnts are secreted cell signals and are now believed to have a 
central role in both liver development and regeneration.  Having been originally 
described in Drosophila melanogaster, there are currently 19 Wnts described in the 
human and mouse, constituting a family of highly conserved secreted signalling 
molecules that regulate cell-to-cell interactions during embryogenesis, regeneration, 
aging and carcinogenesis (Brack et al., 2007; Micsenyi et al., 2004; Ober et al., 2006; 
Kirstetter et al., 2006).  In keeping with this Wnt has been described to play a central 
role in stem cell niches out with the liver (Fleming et al., 2008; Voog and Jones).   
 
The mechanism of Wnt signal transduction is summarised in Figure 1.5.  In general 
secreted Wnts bind to their receptors called Frizzled (Fz).  In the absence of Wnts, β-
catenin is phosphorylated by a destruction complex constituted by APC, axins, GSK3β 
and CK1, and then ubiquitinated, promoting its degradation by the proteasome.  Binding 
of soluble Wnts to the Frizzled receptors activates Wnt/β-catenin signalling (de La Coste 
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et al., 1998).  This results in the stabilisation of β-catenin by the inhibition the its 
destruction complex and subsequent β-catenin translocation into the nucleus where, in 
conjunction with members of LEF1/TCF transcription factor family, it activates the 
transcription of several target genes including cMyc, Axin2 and Cyclin D.  The effects 
of stablisation of β-catenin and resultant target gene activation, induces general effects 
such as cellular proliferation, and maintenance of stem cells.  However, the mechanism 
by which Wnt achieves its effects varies from cell type to cell type and organ to organ 
(Reed et al., 2008).   
 
Figure 1.5 Signal transduction in the Wnt pathway 
In the absence of Wnt the degradation of β-catenin renders the Wnt signalling transduction 
pathway inactive by the inhibition of target gene transcription by TCF-Groucho interactions.  In 
this instance, the destruction complex including APC, axins, GSK3β and CK1 promotes β-
catenin‟s destruction by the proteasome.  In the presence of Wnt, and signal transduction by 
Fz/LRP at the level of the cell membrane the activity of the destruction complex is inhibited 
resulting in accumulation of β-catenin and its transfer to the nucleus.  Here β-catenin replaces 











Many other pathways interact with Wnt/ β-catenin signalling.  Wnt may also activate 
so called non-canonical (β-catenin independent signalling), and β-catenin may be 
stablised in a Wnt independent manner (He, 2006).  For example HGF signalling is 
intricately coupled to β-catenin mediated signalling via the c-Met receptor (Apte et al., 
2006; Monga et al., 2002); TGFβ signalling promotes the nuclear localisation of β-
catenin (Jian et al., 2006).  Furthermore the association of cytosolic β-catenin with E-
cadherin, exposes it to cell-ECM interactions also.   
 
Characterisation of the Wnt gene expression signature of the resting and injured liver 
has been performed, revealing that in the resting state a large number of Wnts are 
produced by a variety of cell populations within the liver (Zeng et al., 2007).  While Wnt 
has been shown to play roles in a variety of hepatic processes including fibrosis and 
hepatic stellate cell activation (Cheng et al., 2008; Kordes et al., 2008; Myung et al., 
2007), Wnt appears to be a central signalling molecule influencing HPC behaviour, 
differentiation and specifying zonation of hepatocellular function (Gebhardt and 
Hovhannisyan, 2010).   
 
With regard to liver regeneration, Wnt signalling plays a role in the predominantly 
hepatocellular regeneration which occurs following partial hepatectomy (Sekine et al., 
2007; Sodhi et al., 2005).  Accordingly over expression of stable β-catenin results in 
hepatomegaly (Cadoret et al., 2001; Tan et al., 2005) while hepatocytic β-catenin 
knockdown results a reduction in liver size (Sekine et al., 2006).   
 
In the rat, following PH/AAF, nuclear β-catenin is observed in HPCs (Apte et al., 
2007).  In this study HPCs were shown to express the Wnt receptor Frizzled 2, in 
addition to dynamic changes in Wnt1 and WIF expression, consistent with an 
environment promoting Frizzled activation.  Nuclear β-catenin is also seen in HPCs in 
mice exposed to the DDC diet (Hu et al., 2007), with target gene activation confirmed in 
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these cells using a reporter transgenic mouse line (Hu et al., 2007).  In the same model 
when β-catenin is knocked out in a mature HPC/hepatocyte population a reduction in 
HPCs (A6
+
) is seen in the DDC diet (Apte et al., 2007).  In vitro work also supports a 
pro-proliferative role for Wnt in HPCs (Hu et al., 2007).   
 
The effects of Wnt in the development and behaviour of HCC also supports its role in 
modulating HPC behaviour.  Increased canonical Wnt signalling has been demonstrated 
in metastatic vs.  non-metastatic HCC (Qin et al., 2007) and the tendency of hepatic 
adenoma to progress to HCC is strongly dependent on their β-catenin status (Bioulac-
Sage et al., 2007).  None-the-less, mutations of APC are relatively rare in HCC in 
comparison to their prevalence in intestinal cancer. 
 
HPC fate also appears to be strongly influenced by Wnts.  During development the 
fate decisions of hepatoblast are Wnt dependent (Monga et al., 2003; Nejak-Bowen and 
Monga, 2008).  Similarly Wnt appears to influence hepatocyte phenotype across the 
lobule in the adult mammal.  Here Wnt signalling follows a stable gradient within the 
hepatic lobule with a reduction in active Wnt signal transduction observed in periportal 
zone 1 (Burke and Tosh, 2006).  The source of Wnt within the normal adult liver is not 
elucidated but may arise at least in part from endothelia.  High Wnt signalling exists in 
the relative absence of APC in zone 3 while the opposite occurs in zone 1 ( low active β-
catenin and high APC; Benhamouche et al., 2006).  These changes act directly with 
HNF4 to promote the differences in hepatocytic phenotype observed across the liver 
lobule (Colletti et al., 2009).  HNF4 plays a similar role in promoting a zone 1 
hepatocellular phenotype (Stanulovic et al., 2007). 
 
While not directly analogous the increasing use of Wnts, in particular Wnt 3, in the in 
vitro differentiation of pluripotent stem cell populations (both ES and iPS) supports the 
central role of applied Wnts in promoting hepatocellular differentiation from their 
precursors (Ober et al., 2006).  In these instances the use of Wnts following endodermal 
differentiation and immediately prior to the generation of hepatocytes implies their 
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particular role in controlling stem/progenitor cell fate at an analogous stage to that of 
HPC differentiation (Hay et al., 2008). 
 
Notch 
In vertebrates the Notch signalling pathway consists of four Notch receptors (Notch 1-
4).  These receptors are large multi-domain, single pass, membrane receptors and receive 
signals from the DSL family of membrane associated ligands.  These DSL ligands fall 
into two distinct classes: Delta and Jagged comprised of 3 and 2 homologues 
respectively (Artavanis-Tsakonas et al., 1999).  During intracellular production the 
notch receptor is cleaved to form its active isoform in the endoplasmic reticulum by a 
furin-like convertase (S1 cleavage), and is then trafficked to the cell surface as an 
inactive receptor (Logeat et al., 1998).  Upon ligand binding this functional receptor is 
cleaved by a membrane bound ADAM-family metalloproteinase (S2 cleavage).  This 
cleavage event permits Notch signalling with the aid of further proteolytic cleavage by 
-secretase (S3) which facilitates subsequent liberation of the cytoplasmic domain of 
Notch receptor (N
icd
 domain) from its membrane anchor and allows it to translocate into 
the nucleus. 
 
Once within the nucleus the N
icd
 domain interacts with RBP-J.  As Notch target genes 
are normally repressed by RBP-J along with a series of co-repressors upon interaction 
with N
icd
 this transcriptional repressor is converted to a transcriptional activator.  This 
switch from repression to activation facilitates the expression of the Hairy/Enhancer of 
split (Hes) genes in mammals which themselves regulate further gene transduction 
(Bray, 2006).  One critical function of Notch described to date of Notch in variety of 
systems is its control of cell differentiation.  Using cell-cell contact signalling between 
Notch and Notch ligand and a process of lateral inhibition cells receiving Notch 
signalling remain in a dedifferentiated state while promoting the differentiation of their 




The HPC marker Dlk1 (also known as Pref-1) is a recently described atypical Notch 
ligand, which is structurally related to both Notch and Delta but is not involved in the 
facilitating the classical Notch cleavage events.  Instead Dlk-1 can bind via the EGF 
repeats on both itself and Notch receptor can negatively regulate the normal action of 
Notch (Bray et al., 2008). 
 
There are multiple lines of evidence suggesting and important role for the Notch 
signalling pathways in HPC biology.  Firstly Notch signalling has been heavily 
implicated in both the development of the foetal liver and certain conditions which 
involve aberrant signalling.  During development the ductal plate is located between the 
portal mesenchyme and the hepatic parenchyma as a continuous layer which undergoes 
focal dilations and gives rise to epithelial bile ducts some of which are incorporated into 
the portal mesenchyme (Lozier et al., 2008).  At this time Delta-like1 (Dlk1) is a known 
marker of hepatoblasts in the developing liver (Tanimizu et al., 2003).  These cells are 
the developmental corollary of adult HPCs.  Indeed Dlk1 is an accepted marker of adult 
HPCs (Jensen et al., 2004).  As these cells express a negative regulator of Notch 
signalling, it feasible to suggest that these cells are also expressing the Notch receptor 
and that Notch signalling may play a key role in the differentiation and development of 
these cells. 
 
Functional evidence for the role of Notch signalling in the developing liver has been 
shown by a number of means.  Firstly over embryonic over-expression of N
icd
 was 
shown to down regulate hepatocyte differentiation genes and protein suggesting Notch 
inhibits hepatocellular differentiation from precursor cells (Tanimizu et al., 2004).  
When cultured in contact with laminin cells upregulate known cholangiocyte markers 
such as CK7, CK19 and HNF1β implying a synergy between activated Notch and the 
Integrin signalling pathway in defining cholangiocyte and hepatocyte differentiation 
(Tanimizu et al., 2004).  The link between Notch signalling and hepatic development in 
the developing liver is mediated by a plethora or liver-enriched transcription factors such 
as HNF and C/EBP (Tanimizu et al., 2004).  Most crucially, a human condition known 
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as Alagilles syndrome results in the aberrant development of multiple organs including 
the liver, heart, and eye together with cranio-facial malformations (Kodama et al., 2004).  
A key hepatic feature of Alagilles is bile duct retardation, with sufferers often requiring 
a liver transplant as a result of liver failure (Kasahara et al., 2003).  Alagilles syndrome 
results from aberant Notch signalling during development and is classically associated 
with a mutation in the jag1 gene, which typically encodes the Notch ligand Jagged1 
(Yuan et al.  2006).  Multiple mutations in this gene are implicated in an altered 
transcript which fails to function as the WT (wild type) protein.  It is this haplo-
insufficiency which results in attenuated Jagged1 activation of Notch (McCright et al., 
2002).  There are multiple cases of Alagilles patients who have normal Jagged1 but who 
phenotypically appear to suffer from Alagilles.  Current lines of study are also focusing 
on the presence of mutations in the Notch receptor.  In a mouse model of Alagilles, 
mutations or heterozygous knock outs of jag1 do not result in the typical hepatic and 
cardiac deficiencies commonly associated with Alagilles (McDaniell et al., 2006).  It is 
only when a hypomorphic allele of Notch (in this case N2) is introduced that the typical 
Alagilles phenotype is observed, suggesting that Alagilles is a heterogeneous disorder of 
the Notch signalling pathway. 
 
Gene knockout studies in mice have also revealed the importance of Notch signalling 
in both development and adult liver homeostasis.  Conditional knockouts of Notch1 
and/or 2 and Jagged 1 have been investigated when Cre is expressed under an Albumin 
(Alb) promoter (Geisler et al., 2008; Loomes et al., 2007).  These studies imply that 
certain Notch homologues are required for correct hepatobiliary specification.  
Conditional Notch2 resulted in delayed and impaired development of the biliary network 
with cells rarely forming any organised tubular structures.  Notch 1 appears to play a 
less crucial role (Loomes et al., 2007).  In keeping with a key role of Notch 2 in 
differentiation, knocking out its ligand Jagged 1, results in marked bile duct proliferation 
in the adult (Geisler et al., 2008).  In the context of hepatocyte mediated regeneration, 
changes in Notch signalling have been described in the adult mammal.  In a partial 
hepatectomy model of liver injury and regeneration in the rat, Jagged levels increase 
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dramatically in the early period following resection (Kohler et al., 2004).  During this 
time, and in spite of reduced expression of Notch 1 there is a considerable increase in 
nuclear N
icd
.  Interesting in the early phase of regeneration the Jagged 1 target, Notch 2, 
is upregulated in periportal hepatocytes where early proliferation is known to occur 
(Michalopoulos and DeFrances, 1997).   
 
Hedgehog 
Hedgehog (Hh) signalling is recognised as a fundamental pathway in regulation and 
patterning in embryogenesis.  More recently the description of Hedgehog's involvement 
in the remodeling of adult tissues following injury in combination with its activation in 
HPC has highlighted its potential in affecting HPC mediated liver regeneration (Sicklick 
et al., 2006).  Liver injury may induce Sonic Hedgehog ligand and several downstream 
targets such as patched (Jung et al., 2008).  To my knowledge no detailed functional 
studies have been performed examining the effects of Hh manipulation on adult HPC 
biology either in in vitro or in vivo, however work with foetal hepatoblasts suggests that 
Hh acts to maintain an undifferentiated phenotype of hepatocyte precursors (Hirose et 
al., 2009).   
 
Hippo 
Hippo has been described as a key factor in control of the specification of organ and 
tissue size during development in Drosophila.  Its mammalian homologues Mst1 and 
Mst2 have more recently been identified in controlling liver size during both 
development and regeneration.  In addition to developing HCC (Zhou et al., 2009) when 
Mst1 and Mst2 are deleted under an albumin-Cre promoter system, large scale HPC 





The thyroid hormone tri-iodothyronine (T3) is a known mitogen for hepatocytes which 
has been used experimentally for a number of years, both alone (Forbes et al., 1998) or 
in combination with other mitogens (e.g. HGF) with which it acts synergistically (Forbes 
et al., 2000).  HPC express T3 receptors and following PH/AAF model show enhanced 
incorporation of BrdU (Laszlo et al., 2008) following T3 administration.  Additionally 
BrdU pulse-chase in this model has suggested that laminin encased HPCs become small 
hepatocytes with hepatocellular function, therefore implying a role for T3 in promoting 
differentiation of this transit amplifying population.   
 
Neural input 
Fewer intermediate hepatobiliary cells are seen in liver transplant graft livers which 
develop recurrent disease than matched liver biopsies taken from untransplanted 
patients.  This provocative observation lead to hypothesis that denervation as result of 
transplantation directly affects the HPC response.  Expression of both adrenoreceptors 
and muscarinic receptors corresponding to the sympathetic and parasympathetic nervous 
system respectively has been described by HPCs.  Inhibition of the sympathetic or 
parasympathetic nervous systems in rodents results in expansion or contraction of the 
HPC response respectively (Cassiman et al., 2002; Oben et al., 2003).  The mechanism 
of action of neurotransmitters upon HPCs, together with a demonstration that neurons 
make direct functional contract with these cells are questions that remain to be 




Laminins are a family of ECM proteins, composed of 3 different polypeptide chains, 
termed ,  and  (Aumailley et al., 2005).  At present, 5, 4 and 3 chains are 
described in mouse and human (Miner and Yurchenco, 2004), which can combine to 
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form at least 15 different trimers.  Expression of different laminins varies between 
organs and at different stages of development (Yurchenco et al., 2004).  Each laminin 
trimer contains binding sites for several receptors, which are predominantly but not 
exclusively integrins (Yurchenco et al., 2004).   
 
The integrin receptor is a heterodimer, composed of α and β subunits.  18 and 8β 
chains have been described in mammals, forming at least 21 different dimers.  Integrins 
that bind laminin include α1β1, α2β1, α3β1, α6β1 and α6β4.  Non-integrin laminin-binding 
receptors also exist and include syndecan, dystroglycan and lutheran. 
 
Laminin is associated with the stem cell niche in other organs (Lathia et al., 2007; 
Schlotzer-Schrehardt et al., 2007) and is present within the liver in contact with HPCs 
(Dudas et al., 2006; Paku et al., 2001).  Stem cells in other systems have been described 
to express many integrins particular the α6β1 integrin (Nagato et al., 2005; Tate et al., 
2004), blockade of which disrupts stem cell behaviour (Shen et al., 2008).  Work in 
hepatocytes suggests that integrin linked kinases play a key role in regulating liver 
regeneration (Apte et al., 2009).  In human liver disease, increases in laminin and 
integrins have been noted consistently across a variety of disease states (Volpes et al., 
1991) with corresponding changes observed in both HCC and cholangiocarcinoma 
(Volpes et al., 1993).  When integrin linked kinase function is lost, dysregulation of liver 
regeneration is observed, with ongoing regeneration resulting in excessive liver growth.  
Increased expression of hepatic α6β2 integrin has been observed concurrently with HPC 
activation in the DDC diet along with laminin and ICAM1 a further integrin ligand (Wu 
et al., 2005).   
 
Fibronectin  
Fibronectin is a heterodimeric extracellular matrix glycoprotein which also binds to 
cells via integrins.  In addition to integrins, fibronectin also binds extracellular matrix 
components such as collagen, fibrin and heparin sulfate proteoglycans (e.g. syndecans).  
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While produced from a single gene alternative mRNA splicing leads to the creation of 
several isoforms which may be either soluble or insoluble.  Insoluble fibronectin is a 
major component of the extracellular matrix and is secreted by a variety of cells 
including fibroblasts and myofibroblasts.  Fibronectin plays a major role in cell 
adhesion, growth, migration and differentiation, and is important for processes such as 
wound healing and embryonic development.  Within the liver, fibronectin localises to 
HPCs during regeneration (Zhang et al., 2009).  During embryogenesis fibronectin in an 
in vitro system appears to promote the differentiation of hepatocyte precursors into 
functional hepatocytes (Sanchez et al., 2000), implying that fibronectin may also 
promote hepatocellular differentiation of HPCs in the adult liver.   
 
1.33 The role of bone marrow in liver regeneration 
 
Hepatic parenchymal regeneration by the BM 
 
Over the last decade it has become apparent that HPCs express a variety of markers 
such as c-kit and sca-1 that have been previously thought of as haematopoietic (Petersen 
et al., 2003), see Table 1.1.  Furthermore BM derived stem cells could be shown to 
differentiate into hepatocyte-like cells in vitro (Yamada et al., 2006; Yamazaki et al., 
2003).  When hepatocytes were identified that expressed extrahepatic markers in both 
rodent (Petersen et al., 1999) and human liver (Alison et al., 2000; Theise et al., 2000) 
the exciting possibility that BM derived cells were transdifferentiating into hepatocytes 
was raised.  Examination using Y chromosome tracking in human liver specimens from 
either female patients with previous BM transplant from male donors, or male patients 
who had received a liver transplant from female donors, demonstrated that a number 
(varying from 0-40% depending upon the study) of hepatocytes possessed a Y 
chromosome (Thorgeirsson and Grisham, 2006).  The implication was, therefore, that 
BM derived cells were crossing lineage boundaries via transdifferentiation to form 
hepatocytes.  This was investigated in detail in rodents included the FAH
-/-
 mouse. This 
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murine system is a model for human hereditary type I tyrosinaemia in which the hepatic 
injury may be inhibited at will by the administration of a protective chemical (NTBC).  
NTBC prevents hepatotoxicity by blocking the formation of fumarylacetoacetate.  When 
FAH
-/-
 mice were given BM and the protection of NTBC was gradually withdrawn, 
hepatocytes expressing markers of the transplanted BM were seen to reconstitute the 
mouse liver (Lagasse et al., 2000).  Subsequent work however has convincingly shown 
that instead of plasticity, monocyte-hepatocyte fusion was the mechanism by which BM 
cells were rescuing a genetically deficient phenotype in the FAH
-/-
 mice (Alvarez-
Dolado et al., 2003; Camargo et al., 2004; Vassilopoulos et al., 2003; Wang et al., 
2003b; Willenbring et al., 2004).  These monocyte-hepatocyte fusion events are rare, but 
rescue in the FAH
-/-
 model is due to proliferation of these fusion cells (Wang et al., 
2002).  This occurs as selective pressure is applied against native hepatocytes lacking 
the correcting wild-type genes.  In the absence of such selective pressure however, 
significant hepatocytes replacement is rarely seen and at most occurs at a level far below 
that of native hepatocytes turnover (Thorgeirsson and Grisham, 2006; Yannaki et al., 
2005).  Despite initial reports that HPCs may be in part BM derived (Petersen et al., 
1999), more recent studies suggest that this does not occur to any significant degree 
(Menthena et al., 2004; Vig et al., 2006; Wang et al., 2003a).  HPCs from BM 
transplanted mice neither express the BM tracking marker to any significant degree nor 
show clustering suggestive of expansion of BM derived HPCs.  Importantly 
transplantation of an HPC fraction into the FAH
-/-
 mouse in one study showed that 
transplantable cells were not BM derived (Wang et al., 2003a).  There is some ongoing 
uncertainty in this area however as a recent report suggests that HPCs may be BM 
derived (Oh et al., 2007).  This study investigated DPPIV
+
 cells after DPPIV
 
deficient 
rats were transplanted with wild type BM.  AAF/PH was used in these animals to induce 
an HPC response and resulted in DPPIV
+
 cells within the liver.  DPPIV is however not a 
specific hepatocyte marker and is expressed by sinusoidal endothelia (Koivisto et al., 




Similar questions regarding the origin of HPCs have also been raised.  The majority of 
work in this field is consistent demonstrating that HPCs defined by a variety of markers 
and in a variety of models are not BM derived (Wang et al., 2003a; Kubota et al., 2008; 
Tonkin et al., 2008; Vig et al., 2006).  Alternatively a report, in other another less 
commonly used HPCs model (again using DPPIV mismatch), has suggested that HPCs 
may be BM derived (Oh et al., 2007).  While this seems unlikely, a compelling recent 
study in the rat using whole liver transplantation suggests that HPCs may be BM derived 
under certain circumstances (Sun et al., 2009).  While liver transplantation is well 
tolerated in this circumstance, it may well be that the presence of a minor 
histocompatability mismatch between donor and recipient in this model drives the 
selection of donor derived HPCs.  Whether the source of HPCs in this case may be out 
with the BM transplantable population remains a distinct possibility.  Nonetheless it 
seems that in the absence of selection, the BM does not generate HPCs to a 
physiologically relevant degree.   
 
The role of extrahepatic stem cells activation during liver disease 
 
Over the last decade the importance of BM stem cell (BMSC) activation during liver 




 cells appear to be upregulated 
following liver transplantation or PH in the diseased liver (De Silvestro et al., 2004; 
Gehling et al., 2005; Lemoli et al., 2006).  Similarly cells with haematopoietic stem cell 
markers are mobilised following liver injury in rodents (Fujii et al., 2002) and in this 
context are recruited to the liver (Kollet et al., 2003).  There has been considerable 
interest in the possibility that the BM contributes to liver parenchymal and non-
parenchymal cells.  Furthermore current data points towards a role in modulating hepatic 
fibrosis in addition to the control of HPC behaviour outlined above.   
 




An important consideration regarding the activation of stem cells during liver disease 
relates to their potential role in carcinogenesis (Alison et al., 2008).  The chronic 
activation of hepatic progenitor cells occurs at a time when liver cancer develops.  
Inhibition of the rodent HPC response during long term CDE diet was associated with a 
reduction in the incidence of cancerous lesions (Knight et al., 2000).  The occurrence of 
mixed forms of liver cancer with features of both hepatocellular carcinoma and 
cholangiocarcinoma is consistent with a bipotential HPC origin (Alison, 2005; Roskams, 
2006).  Furthermore, a proof of concept study, has demonstrated that inhibition of HPCs 
via the c-Kit receptor not only reduces HPC expansion but inhibits the formation of 
HCC in the chronic CDE diet model (Knight et al., 2008).  Clearly these observations 
not only link HPC to carcinogenesis but also have implications for the use of HPC 
directed therapies in the development of HCC.   
 
1.4 The liver stem/progenitor cell niche 
1.41 Introduction to the stem cell niche 
 
Whilst there has been a large amount of work published on the molecular signals 
which may influence the behaviour of HPCs, much less is known regarding the cellular 
source of such signals.  While some of the signalling environment sampled by HPC may 
have originated from distant cells either within or out-with the liver.  Some of the signals 
discussed to date take the form of direct cell-cell signalling necessitating cellular 
contact.  It is probably the case that the major proportion of the paracrine signalling 
milieu provided to HPCs is produced locally. 
 
Such a local environment is in keeping with the concept of a stem cell niche.  A stem 
cell niche is the restricted compartment in a tissue that maintains and regulates stem cell 
behaviour, supporting self-renewal and maintaining the balance between quiescence, 
proliferation and differentiation required in response to injury (Fuchs et al., 2004; 
Ohlstein et al., 2004; Spradling et al., 2001).  Stem cells niches have now been 
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described in all of most studied stem cell systems (Voog and Jones, 2010).  A highly 
provocative study recently demonstrates that stem cell niches not only provide the 
environment for adult tissue stem cells but can also integrate circulating signals, 
including the age of organism, to influence stem cells contained within the niche 
(Mayack et al., 2010).   
 
If such a niche exists in the liver for hepatic stem cells and HPCs remarkably little is 
known regarding its composition and function.  Early work in the description of HPCs 
suggested that certain cell populations (mesenchymal desmin
+
 cells) and matrix proteins 
(laminin) are found in close proximity to HPCs (Paku et al., 2001).  Recently work in 
the field suggest HPCs exist in the context of a particular environment, both spatially 
(Sawitza et al., 2009; Yovchev et al., 2009) and temporally (Van Hul et al., 2009).  
However, the consistency of this environment between the various models studied and 
whether or not the presence of such a milieu imposes any functional significance upon 
HPC behaviour remains a key question.  Clearly until hepatic stem cells themselves can 
be specifically identified then the existence and nature of the hepatic stem cell niche will 
remain elusive.   
 
An important observation from the work in the intestinal stem cell field that single 
intestinal stem cells may be cultured into distinctive three dimensional organoids 
suggests that stem cells do not require a specialised niche; at least not in the form of 
living cells (Sato et al., 2009).  These findings are consistent with the ability of iPS or 
ES cells to be differentiated into hepatocyte-like cells in cell free media (Hay et al., 
2008; Si-Tayeb et al., 2010; Sullivan et al., 2010).  While there is no absolute 
requirement in this system for a cellular niche, albeit in the context of a specialised 
matrix and growth factor rich environment, this does not mean that the niche does not 
play a crucial physiological role in influencing both stem cells and the transit amplifying 




1.42 Cellular candidates in the HPC niche 
Mesenchyme 
 
While approximately 80% of the liver mass is comprised of parenchymal epithelial 
cells, a number of other non-parenchymal cell types play a variety of key physiological 
roles within the liver.  Of these the most frequently referred to are Kupffer cells (KCs), 
sinusoidal endothelial cells (SEC) and hepatic stellate cells.   
 
Mesenchyme appears to play an important role in hepatic development.  While as 
previously discussed mesenchyme is not essential for stem cell differentiation, 
mesenchyme has the ability affect stem cell behaviour.  For example liver mesenchyme 
imposes an hepatic cord phenotype on epithelial lung buds, which may also be instructed 
to form not only bronchial epithelia, but also gastric glands in the presence of stomach 
mesenchyme or intestinal villus epithelia by intestinal mesenchyme (Birchmeier and 
Birchmeier, 1993).  The main mesenchymal element of the adult liver is comprised of 
hepatic stellate cells, and their activated counterparts myofibroblasts.  These cells are 
central in the deposition and remodelling of collagen and other components of the ECM 
(Henderson and Iredale, 2007).  Studies in rodent models using labeled BM 
transplantation (Baba et al., 2004; Russo et al., 2006) or human studies following sex 
mismatched liver or BM transplants (Forbes et al., 2004) have shown a significant BM 
contribution to both hepatic stellate cell and myofibroblast populations, and this process 
does not appear to occur through cell fusion.  Other studies using the BDL model have 
reported that only a small proportion (5-10%) of collagen producing cells were BM 
derived (Kisseleva et al., 2006).  In addition to their effects on the ECM, hepatic stellate 
cells and myofibroblasts may produce a number of secreted and cell surface bound 
signals including Wnts (Zeng et al., 2007), Notch (Kordes et al., 2009; Oakley et al., 






Originally described by von Kupffer in 1876, Kupffer cells (KCs) constitute 
approximately 80% of the tissue macrophages in the reticuloendothelial system and 
approximately 15% of the total liver cell population (Bouwens et al., 1986).  They are 
mainly found in the periportal area of the lobule (approximately 45%), but exist 
throughout the hepatic lobule.  Despite the view that KCs are fixed tissue macrophages 
of the liver, there is good evidence that they have the ability to migrate along sinusoidal 
walls with a mean speed of approximately 5 microns/minute.  Transplantation studies 
suggest that KCs are mostly, if not all, BM derived (Paradis et al.,1989; Abe et al., 
2003; Higashiyama et al., 2007), although a significant proportion may be capable of 
limited intra-hepatic self renewal (Naito et al., 2004; Klein et al., 2007).  Perhaps as a 
feature of this transition between circulating precursor macrophages and tissue resident 
KCs a precise definition of each population is somewhat arbitrary.  In the rat cell surface 
markers ED1 and ED2 (CD163) are associated with monocytes and resident tissue 
macrophage respectively (Bilzer et al., 2006).  For the purposes of clarity and given the 
continuum between monocytes and Kupffer cells this population will for brevity‟s sake 
be dealt with as a whole under the title macrophages for the remainder of this work 
(unless otherwise stated).   
 
 Macrophages are implicated in a variety of processes during hepatic disease including 
inflammation, regeneration, fibrosis, and ECM remodeling (Henderson and Iredale, 
2007; Martinez et al., 2009; Boulton et al., 1998; Fausto et al., 2006).  Administration of 
Gadolinium Chloride, which inhibits macrophages, prevents MPK-positive HPC 
expansion in response to BDL in rats (Olynyk et al., 1998).  This is consistent with the 
intimate spatial relationship between Kupffer cells and HPCs (Yin et al., 1999).  
Similarly Gadolinium Chloride treatment is also able to reduce fibrosis in thioacetamide 
treated rats (Ide et al., 2005) consistent with the putative role of macrophages in the 
process of hepatic fibrosis and ECM remodeling.  This role has been corroborated using 
an inducible, macrophage specific depletion model (DTR) in mice during or following 
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CCl4 injury.  This work demonstrated that both the generation and resolution of fibrosis 
are macrophage dependent (Duffield et al., 2005).  The mechanism of tissue remodeling 
may include expression of the matrix remodeling metalloproteinase MMP-9 by BM 
derived F4/80
+
 macrophages during the resolution of fibrosis following CCl4 injury 
(Fallowfield et al., 2007; Higashiyama et al., 2007). 
  
Macrophages (and related populations) have recently been described to play a role in 
the influence of stem cells in other organs.  It appears that macrophages in the intestine 
(Pull et al., 2005; Seno et al., 2009), mammary gland (Gyorki et al., 2009) and 
osteoclasts in the BM (Kiel and Morrison, 2008) play roles in their respective stem cell 
niches, while evidence against a role for macrophages comes from an alternative model 
of macrophage deficiency in the skin (Martin et al., 2003).  Experimentally, alternatively 
activated macrophages are thought to be particularly important in such roles 
(Stappenbeck and Miyoshi, 2009) with a recent report suggesting that M2 macrophages 
are critical in the regenerative response in skeletal muscle (Ruffell et al., 2009).   
 
Other leukocyte populations, in particular T cells and NK cells, appear to play a role in 
HPC biology.  Work using mice with a variety of leukocyte population deficiencies, has 
demonstrated impaired expansion of the HPC population in response to the CDE diet 
(Strick-Marchand et al., 2008).  Lymphocytes (both CD4+ and CD8+) localise in 
proximity to HPCs, possibly in direct contact, however whether such cells act directly 
via the production of stimulatory cytokines or cell-cell signalling or whether they act 




A final cellular population which is an attractive candidate as a constituent of the HPC 
niche is the vascular endothelium.  These cells are known to be involved in other stem 
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cell niches (Kiel and Morrison, 2008).  The vascular endothelium is involved in liver 
organogenesis (Matsumoto et al., 2001). 
 
1.5 Functions of BM derived stem cells during human liver disease 
 
As all of the candidates of the HPC niche discussed above may be BM derived 
(Paradis et al.,1989; Miyata et al., 2007; Russo et al., 2006; Gao et al., 2001), it is 
important to assess the role the BM is known to have on liver regeneration aside from its 
contribution the regenerating epithelial cells directly.  To date a handful of clinical trials 
have investigated the role of stem cell mobilisation therapy or stem cell infusion in 
adults.  G-CSF (Granulocyte colony stimulating factor) has been used to induce 
haematopoietic stem cell mobilisation to the peripheral blood of patients with cirrhosis 




 cells was 
observed, only 2 of 8 patients showed moderate improvement in liver function.  Clearly 
further studies are warranted investigating the effects of G-CSF upon cellular 
mobilisation and hepatic engraftment during human liver disease to investigate this 
potential therapeutic modality.   
 
In addition to mobilisation strategies, autologous BM has been examined in a number 
of studies (Houlihan and Newsome, 2008).  These studies include a cohort of patients 
with liver cancer in whom portal vein embolisation was used to induce compensatory 
hypertrophy in the contralateral liver lobe prior to surgical resection.  Thirteen patients 
underwent portal vein embolisation, six of whom received an infusion of autologous 
CD133
+
 Bone Marrow Cells (BMCs).  This non randomised trial demonstrated a 
marginal but significant increase in liver volume and reduced time to surgery in patients 
receiving autologous BMC infusions (Furst et al., 2007).  Another uncontrolled study in 
five patients with cirrhosis investigated the effects of autologous CD34
+
 BMCs.  Three 
of these patients showed transient improvements in biochemical markers, such as 
bilirubin and albumin, over the following 2 months (Gordon et al., 2006).  A case report 
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describes clinical improvement following infusion of autologous G-CSF mobilised 
CD34
+
 BMCs in a single patient with hepatic failure (Gasbarrini et al., 2006).  
Autologous monocyte therapy has also been attempted using a larger number of 
unsorted cells extracted from the BM of cirrhotic patients.  In the nine patients receiving 
BMCs there was an improvement in Child-Pugh score with an increase in intrahepatic 
cell proliferation in the patients biopsied after treatment (Terai et al., 2006).  Despite 
these encouraging reports caution must be noted.  Only one of these trials was used 
controls, and in none were patients randomised.  These studies were, understandably for 
preliminary reports, performed in a small number of patients.  Engraftment or 
colonisation of infused cells was not investigated in any of the studies, nor has the 
mechanism by which an improvement in liver function is derived been examined in 
detail.   
 
Should therapeutic manipulation of HPCs be achievable it may provide a mechanism 
to promote regeneration of the severely damaged liver without recourse to liver 
transplantation (Alison et al., 2009).  Although HPC transplantation studies in rodents 
HPCs have provided some success (Schmelzer et al., 2007; Wang et al., 2003a), the 
isolation of human HPCs is currently not a practical therapeutic option, particularly on 
an individual patient basis.  Furthermore this therapeutic strategy offers little advantage 
over mature hepatocyte transplantation.  Therefore the manipulation a patient‟s own 
endogenous HPCs currently represents both a more realistic approach and, crucially, one 
likely to yield more immediate success (Knight et al., 2008; Spahr et al., 2008).   
 
The recent studies using intravenous delivery of whole (BMCs) in patients with liver 
injury have suggested various possible beneficial effects, including improved liver 
function and regeneration (Houlihan and Newsome, 2008).  BMC therapy is clinically 
attractive from several perspectives.  Firstly, BM is accessible via a minimally invasive 
procedure and provides an autologous source of cells with associated immunological 
advantages.  Furthermore, the donor BMC population may be expanded and manipulated 
in vitro, either through culture, selection, or modification, to potentially enrich for 
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beneficial characteristics of these cells.  A large body of evidence shows that BMCs do 
track to the liver and will engraft without exogenous manipulation, and do not 
themselves form hepatic parenchyma as discussed previously.  The effects of BMC on 
hepatic regeneration therefore may be via paracrine signalling to indigenous liver cell 
populations.  If a greater understanding of the mechanism by which BMCs are able to 
influence liver regeneration can be achieved, it may be possible to manipulate these 
processes to enable effective regenerative therapy.   
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1.6 Hypotheses and Aims 
 
The hypotheses for this work were that  
 
 HPCs are surrounded by a stereotypical and functional niche consisting of 
macrophages and myofibroblasts 
 
 Extrahepatic, bone marrow derived cells, are recruited into this niche and 
influence HPC behaviour 
 
To test these hypotheses I aimed 
 
 To study the characteristics of the HPC niche by analysing candidate cell 
populations and extracellular matrix in a variety of animal models in analogy to 
human disease. 
 
 To investigate the role of recruitment of cells into the HPC niche during liver 
injury 
 
 To study whether any of these niche cell populations may functionally influence 
HPC behaviour 
 





Chapter 2: Methods 
 
2.1 In vivo experimental models 
 
Animals were housed in a specific pathogen free environment and kept under standard 
conditions with a 12-hour day/night cycle and access to food and water ad libitum.  All 
animal experiments were carried out under procedural guidelines and with ethical 
permission from the Home Office (UK).   
 
2.11 HPC models  
 
In order analyse the hepatic progenitor cell response and its niche, comparison was 
made across a number of model systems and in different species.  In order to assess 
tracking BM derived cells or to measure the effects of cellular depletion during HPC 
activation the models below were combined with cellular manipulation strategies 
outlined later.  Furthermore in order to label or track proliferating cells in such models 
BrdU (Cell Proliferation Labeling Reagent, Amersham UK; delivered at 50µg/g) or EdU 
(Invitrogen, UK, delivered at 50µg/g) were administered by intraperitoneal (i.p.) 
injection.   
 
2.11A Mouse models 
The CDE dietary model 
The Choline Deficient Ethionine supplemented (CDE) dietary protocol used C57Bl/6 
mice which were fed a diet composed of powdered choline deficient chow (MP biomed) 
with sweetened water containing 0.15% (working concentration) DL-ethionine (Sigma, 
UK) unless otherwise stated.  Water was sweetened with orange squash (Robinsons) in a 
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1:5 ratio with ethionine supplemented water.  A modified version of the CDE diet, called 
the 50% CDE diet, was used in BM transplantation studies to reduce mouse morbidity.  
The 50% CDE diet contained choline deficient chow (MP biomed) mixed in a 1:1 ratio 
with normal powdered chow supplemented with DL-ethionine at 0.15% in sweetened 
water. 
 
The DDC dietary model 
A further dietary model using Diethyl 1,4-dihydro-2,4,6-trimethyl-3,5-
pyridinedicarboxylate (DDC) to induce a liver injury was also utilised.  DDC (Sigma, 
UK, 0.1% w:w) was added to normal chow (DBM Scotland) and fed ad libitum to 8 
week old, initially C57Bl/6 and latterly S129S2 mice.  Mice had access to normal 
drinking water and were assessed daily.   
 
HBsAg Retrorsine model 
Twenty-six–week old female mice, transgenic for the hepatitis B surface antigen 
(HBsAg) were used.  These mice have hepatocyte specific expression of the HBV BgIII-
A fragment and develop hepatocellular injury.  To induce HPC proliferation animals 
were treated with the pyrolizidine alkaloid, retrorsine, (70mg/kg i.p, Sigma-Aldrich, 
UK) with a further injection 2 weeks later.  Liver tissue was analysed 6 months later.  
Liver from age matched C57/B6 animals was used as control.  Blocks of animal tissue 

















 littermates as controls and performed in collaboration with 
Professor Owen Sansom (Beatson Institute, Glasgow).  Induction of genetic deletion 
used the intraperitoneal injection of β-Napthoflavone at 40-80mg/kg.  β-Napthoflavone 
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work was performed in collaboration with Professor Alan Clarke and Trevor 




 mice were generously 
provided by Professor Gigi Lozano, Department of Cancer Genetics, University of 
Texas. 
2.11B Rat AAF/PH model 
 
Male Fischer rats weighing 200g were treated with 2-acetylaminofluorene and 
subsequent partial hepatectomy (2-AAF/PH model) as previously described (Vig et al., 
2006).  Livers were analysed from 3 to 13 days after PH.  Livers from normal rats were 
used as controls. 
 
2.11C Human tissue  
 
Human tissue was provided by the pathology department Edinburgh Royal Infirmary 
with informed patient consent and under the approval of the local ethical committee.  
The human tissue analysed belonged to one of the following categories: 1.  control liver 
tissue obtained from a pre-perfusion liver biopsy (n=1); 2.  hepatitis C virus (HCV) 
related chronic hepatitis (n=10); 3.  hepatitis B virus (HBV) chronic hepatitis (n=10); 3.  
biopsies performed from 0-6 months after liver transplant in a patient who received a 
liver transplant for hepatitis C and developed recurrent fibrosing cholestatic hepatitis 
post-transplant (n=1).   
 
2.12 Cell manipulation models 
 
2.12A Bone Marrow Transplantation 
 
To enable BM tracking, 6 week old female mice were irradiated with whole-body 
gamma irradiation (10.5 Gray) followed by i.v. injection with 1x10
7
 BM cells extracted 
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from 6 week old male femurs.  Mice were allowed to reconstitute for 6 weeks and then 
started the 50% CDE diet for 2 weeks prior to tissue analysis.  Mice were treated for one 
week prior to and for 4 weeks following BM transplantation with Baytril antibiotics 
(W&J Dunlopes Ltd.  Veterinary Wholesalers). 
 
When BM transplantation was combined with the CDE dietary model of HPC 
activation modifications were made to the CDE diet.  These modifications were made 
due to increased morbidity observed upon use of the 100% choline deficient diet and 
0.15% ethionine which were observed in the context of excessive growth of incisors in 
BM transplanted recipients.  This incisor growth limited the ability of experimental 
animals to eat even normal chow and resulted in weight loss.  As a result significant 
concern was raised when a trial of CDE diet was used in these mice resulting in further 
significant weight loss and morbidity.  As a result a modified 50% CDE diet where 
choline deficient chow was delivered as a mashed diet to recipients.  Such a diet has 
been used by other groups in the past as a successful means of HPC induction (Akhurst 
et al., 2001).  In keeping with this, I observed HPC induction in this diet, albeit to a 
lesser extent than the full CDE diet used in other models this study (see Figure 4.3). 
 
Whilst other reports of similar lethal irradiation followed by BM transplantation have 
not observed or reported the side effects observed in this study (Tonkin et al., 2008; Vig 
et al., 2006) multiple reports of dose dependent irradiation induced incisor injury have 
been previously reported (Coady et al., 1967; Larsen et al., 2006; Pearson and Phelps, 
1981; Upton et al., 1956).  None-the-less previous studies have used lower irradiation 
doses (e.g. 8G in divided doses in Balb/c mice) to achieve BM reconstitution (Russo et 
al., 2006) and therefore if further studies were to be performed in mice the efficacy of 




2.12B Bone Marrow Transfer 
BMC transfer 
Male and female C56Bl/6 mice, 6 weeks of age, were purchased from Harlan (UK), 
female Fn14
-/-
 (Jakubowski et al., 2005) and female TgTP6.3 tauGFP (MacKay et al., 
2005) and respective female wild type littermates were from internal colonies.  Fn14
-/- 
work was performed in collaboration with Owen Sansom (Beatson Institute, Glasgow) 
and were generously provided by Biogen Idec.  In addition to genotyping GFP protein 
expression was assessed in skin and BM of GFP
+
 animals (Figure 2.1).  Donor BMCs 
were extracted from the femurs and tibias of mice with PBS and a single cell suspension 
prepared by passing the cells through a 21-guage needle prior to a 40m filter (BD 
Falcon), after which the cells were pooled and centrifuged at 400g for 5 minutes, washed 
with PBS, and resuspended in PBS for injection at 5x10
7
 cells/ml following 
quantification using Turks medium in a haemocytometer.  Healthy female recipient mice 
received 1x10
7
 BMC via tail vein injection.  Prior to injection recipient mice had no 
intervention such as irradiation.  For irradiated cell controls, cells were exposed to 30 
gray from a GammaCell 40E (MDS Nordian, Fleuvus, Belgium) with a Caesium 137 
source.  BrdU (50g/g w/w: Cell proliferation reagent, Amersham UK) was 
administered by i.p. injection as stated in figure legends.   
 
Figure 2.1 Assessment of GFP protein expression in skin and bone marrow  
(A) Ear notches were examined under a fluorescent microscope for GFP expression.  (B) 
Histogram of extracted BMCs from 4 representative animals was assessed by flow cytometry for 
GFP expression ( >99% GFP
+







 macrophage cultures were generated from BMC in vitro as described 
(Macrophage Differentiation).  Following filtering through a 40µm filter they were 
injected via tail vein into healthy recipient mice.  For irradiated macrophage controls, 
cells were exposed to 30 gray irradiation prior to injection as previously described.  
Purity of culture was assessed by immunocytochemistry and was routinely >99% 
(Figure 2.2) 
 
2.12C Myofibroblast depletion 
Gliotoxin myofibroblast depletion  
The fungal toxin gliotoxin was used as previously described (Douglass et al., 2008a; 
Plumpe et al., 2000) to deplete/inhibit myofibroblasts in vivo in combination with HPC 
induction models.  Briefly gliotoxin (Sigma) was dissolved to 2mg/ml in DMSO.  A 
working solution was then produced by dissolving DMSO in sterile PBS to a final 
gliotoxin concentration of 60µg/ml.  Mice undergoing the CDE diet were then 
administered 0.6µg/g gliotoxin by i.p. injection every 72 hours.  Control animals 
received vehicle control of DMSO in PBS. 
  
C13-G myofibroblast depletion  
C13-G (Douglass et al., 2008a; Douglass et al., 2008b) was generously provided by Dr 
Matthew Wright, Newcastle University, UK and was administered at 0.04 mg/g body 
weight (from a 1 mg/ml PBS stock) by i.p. injection after 9 days of CDE diet.  Mice 




2.12D Macrophage depletion  
Liposomal Clodronate 
Clodronate Liposomes were kindly supplied by Nico van Rooijen 
[nvanrooijen@clodronateliposomes.org] (Van Rooijen et al., 1990; Van Rooijen and 
Sanders, 1996).  Clodronate Liposomes were shaken and warmed to room temperature 
before 200µl was injected via tail vein injection.  Volume matched PBS Liposomes and 
PBS injections were used as controls.   
 
DTR transgenic mouse depletion model 
An independent model of macrophage depletion was also trialed for use in depleting 
hepatic macrophages as previously described (Duffield et al., 2005).  Briefly 8 weeks 
old DTR mice and wild type littermates were tail bled prior to administration of 5-20ng 
Diptheria Toxin by i.p. injection.  Mice were killed by CO2 inhalation and peripheral 
blood and liver analysis performed.   
 
2.13 Hepatocellular mitogen administration 
 
Whilst capable of acting individually, HGF (Takayama et al., 1996) and T3 (Tri-
iodothyrodine; Forbes et al., 1998) have been described to play a synergistic role as 
hepatocellular mitogens in rodents (Forbes et al., 2000).  Sterile hrHGF (R and D 
technologies) was dissolved in sterile PBS at 0.05µg/µl and stored at -20C.  HGF 
(250g/kg) was administered via tail vein injection.  T3 (Sigma) was dissolved in 
solution (0.01M NaOH, 0.9M NaCl) at 0.4mg/ml.  This solution was then neutralised 
with 2M HCl to just prior to T3 precipitation and stored at -20C.  T3 was administered 




2.14 Tissue harvesting and preparation 
 
Mice were killed by CO2 inhalation or cervical dislocation.  Unless livers were 
perfused, blood was harvested by cardiac puncture.  Organs were harvested and stored 
following fixation in 10% formalin (in PBS) for 6 hours or methacarn (60% methanol 
30% chloroform 10% glacial acetic acid) for 24 hours prior to embedding in paraffin 
blocks.  Samples of liver were taken and snap frozen in an ethanol bath in dry ice in 
OCT media, RNAlater or directly for later analysis.   
 
2.2 In vitro work 
2.21 HPC and NPC purification 
 
Mice were euthanised using CO2 for 5 minutes.  The livers were excised and minced in 
Leibovitz-15 medium containing Collagenase B and DNase I for 45 minutes at 37°C.  
Digested liver was passed through a 40µm cell strainer and spun at 50xG for 5 minutes.  
Supernatant was removed to a clean tube and the 50xG spin was repeated twice more.  
The final supernatant was spun for 10 minutes at 120xG.  This cell pellet was 
resuspended in Ammonium Chloride red cell lysis buffer (160mM NH4Cl 10mM 
KHCO3 containing 0.01% EDTA ) on ice for 5 minutes.  Erythrocyte depleted cells were 
then pelleted and resuspended in HPC medium (50% Dulbecco's Modified Eagles 
Medium 50% Hams-F12 Nutrient Mix, 10% FCS, Insulin, Hydrocortisone, Sodium 
Pyruvate Gentamicin).  Resuspended cells were underlaid with a discontinuous layers of 
20% and then 50% percoll (Sigma), diluted in PBS.  Cells were then spun at 1400xG for 
20 minutes at 4C.   
 
Cells were collected from the 20%/50% percoll interface and washed twice using 
culture medium.  The resulting cells were sorted either by FACS or using magnetic 
beads.  For magnetic bead purifications, cells were first pelleted by centrifuging at 
120xG for 5 minutes and resuspended with CD45R iMag magnetic beads (BD 
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Biosciences), which were incubated for 20 minutes at 4C.  Bead labelled cells were 
removed using an iMag magnet for 15 minutes at room temperature.  CD45 depleted 





 on tissue culture plastic which had been incubated with laminin for 2 hours 
at 37C.  Non-adherent cells were washed off 12 hours after initial plating with PBS and 
fed with medium containing 10% FCS for 48 hours after which the amount of FCS was 
reduced to 5% for the remainder of time in culture to remove endothelial contamination.  
Typically HPCs were cultured for 7-14 days to remove contaminating hepatocytes and 
endothelia.  HPC differentiation into hepatocytes was induced by transfer to a 
differentiation media of Williams E with 5% FCS, 50ng/ml EGF, 2% matrigel, 1% 
Pen/Strep for 5 days.   
 
2.22 Culture of the BMOL Progenitor Line 
 
Cryopreserved BMOL (Tirnitz-Parker et al., 2007) cells were resuscitated into BMOL 
culture media (Williams E Medium containing 5% Foetal Bovine Serum, 2mM L-
Glutamine, 2.5µg/ml Fungizone, 10U/ml Penicillin; 100µg/ml Streptomycin, 30ng/ml 
IGF2, 20ng/ml EGF and 10µg/ml insulin).  These cells were grown until 70% 
confluency and were then trypsinised and either passaged or replated for use. 
 
2.23 Hepatocyte purification 
 
Animals were sacrificed by CO2 inhalation and their livers digested in situ using a 
modified retrograde perfusion technique (Tirnitz-Parker et al., 2007) consisting of: 1) 
Liver Perfusion Medium (Gibco) for 5 minutes; 2) Liver Digest Medium (Gibco) for 10 
minutes.  The liver was then excised and the capsule disrupted to yield a cell suspension 
which was collected in Liver perfusion medium (Gibco) and passed through a 50m 
filter (BD Bioscences).  Hepatocytes were pelleted by centrifugation at 135xG for 1 
minute followed by resuspension in Williams Medium.  The cell suspension was then 
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purified as described previously (Goncalves et al., 2007).  Briefly cells were 
underlayered with 1.06, 1.08 and 1.12g/ml Percoll in PBS.  The 1.08mg/ml layer was 
spiked with phenol red to aid visualisation.  Cells were then spun at 750xG for 20 
minutes at 20C without the brake.  The cell layer collected between the 1.08 and 
1.12mg/ml percoll layers was harvested, and resuspended in Williams Medium.  This 
suspension was then purified a further 2 times using percoll layers as previously 
described.  Finally cells were quantified using a haemocytometer and prepared for 
cytospins and future DNA, RNA and protein analysis via resuspension in TriSOL 
reagent (Invitrogen). 
  
2.24 Macrophage differentiation 
 
Macrophage differentiation was performed using 2x10
7
 isolated BMC cultured for 7 
days in Teflon pots (Roland Vetter Labs) in DMEM containing penicillin and 
streptomycin, 10% FCS and 20% L929 media as previously described (Boltz-Nitulescu 
et al., 1987).  Purity was assessed by F4/80 immunocytochemical analysis and was 
consistently >99% (Figure 2.2).   
 
 
Figure 2.2 Typical efficiency of macrophage differentiation  
Immunocytochemistry for the F4/80 antigen performed on cytospin of cells following 
macrophage differentiation.  (A) shows typical expression of F4/80 by all cells, (B) isotype 





2.25 Bone marrow colony culture in nitrocellulose 
 
To assess the colony forming capacity and nature of Haematopoietic Stem Cells a 
whole BMC was cultured in a methylcellulose based medium containing rmSCF, rmIL3, 
rhIL6, and rhEpo (Methocult
®
 M3434, Stem Cell Technologies) according to 




 BMC extracted as 
previously described from mouse femurs were added to 1.5ml Methocult® media and 
cultured for 7 days at 37C.  Colonies were identified depending on morphology and 
counted and the number of discrete colonies per culture.  Results were normalised to 
input cell number.   
 
2.3 Tissue and cellular analysis 
2.31 Immunohistochemistry and immunocytochemistry 
 
Paraffin embedded sections (3m thick), were dewaxed in xylene for 10 minutes at 
room temperature and sequentially rehydrated through sequential ethanols (100%, 75%, 
60%) for 5 minutes each, and then finally rehydrated in water for 10 minutes.  Antigen 
retrieval where required was performed, see Table 2.2.  Sections were then washed in 
PBS containing 0.05% Tween 20 for 5 minutes.  All further washes were performed 
using PBS alone.  Endogenous peroxidase activity was blocked by incubating in 1% 
H2O2 for 10 minutes.  Sections were then washed and mounted in Sequenza racks using 
PBS.  Endogenous avadin and biotin were blocked using an avadin and biotin blocking 
kit (DAKO) for 15 minutes each; sections were thoroughly washed between blocks.  
Non-specific binding of the secondary antibody was prevented using 20% species 
specific serum to block sections for 30 minutes at room temperature.  Sections were then 
incubated with primary antibody diluted in 20% species specific serum for 1 hour or 
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overnight at 4C.  Prior to incubating with secondary antibody for 30 minutes, sections 
were washed with PBSx3.  If required, following a further 3 PBS washes a tertiary 
reagent was added.  For DAB development this consisted of incubation for 30 minutes 
with Vector RTU following which after a further 3 PBS washes visualisation used DAB 
chromagen (DAKO) for 3-5 minutes.  Development was stopped by washing with PBS.  
Subsequently slides were counterstained with Harris Haematoxylin by 10 seconds of 
immersion in Haematoxylin followed by 10 seconds in Scotts Tap Water.  Following 
dehydration through graduated ethanols slides were washed with Xylene and mounted 
using Portex hard set mounting medium and stored in the dark at room temperature.  For 
immunohistochemistry using fluorescent detection slides were mounted in DAPI 
containing Vectashield mountant (Vector, UK) to aid identification of cell nuceli; or 
where DAPI was not required, Aqueous mountant (DAKO).   
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Table 2.1 Antibodies and antigen retrieval used 
Antibody list
Antigen Source Species Supplier Ref no. Dilution Antigen retrieval
HPC markers panCK Rabbit DAKO Z0622 1:300 5mins * 5mins ***
Dlk1 Rabbit Abcam Ab21682 1:150 5mins *
EpCAM Rabbit Abcam Ab32392 1:200 10mins *
Cytokeratin 7 Mouse DAKO M7018 1:200 5mins *
Proliferation BrdU Rat Abcam Ab6326 1:100 10mins *
BrdU Mouse Exalpha X1028 1:200 10mins *
Ki67 Rabbit Novocastra 301112 1:500 10mins *
MCM2 Rabbit Cell Signalling Tech #4007 1:300 5mins*
Hepatocyte markers CYP2D6 Sheep Prof R Wolfe 1:400 10mins *
CYP1A2 Mouse Prof R Wolfe 1:200 10mins *
CYP2C Rabbit Prof R Wolfe 1:200 10mins *
HNF4a Rabbit Santa Cruz SC8987 1:100 5mins * 5mins ***
Asialoglycoprotein Rabbit
Other cell populations SMA Mouse Sigma A6228 1:6000 10mins *
CD45 Rat R and D systems MAB114 1:100 10mins **
CD11c Rat Serotec MCA1369GA 1:100 15mins *****
CD11b Hamster Serotec MCA711G 1:100 15mins *****
F4/80 Rat Abcam AB6640 1:200 Nil
vWF Rabbit DAKO A0082 1:50 15mins *
Other antigens Laminin Rabbit DAKO Z0097 1:50 10mins * 5mins ***
Caspase 3 Rabbit Abcam Ab13847 1:50 10mins *
Notch1 Abcam Ab27526
Numb Abcam
p53 Mouse Lab Vision MS-104 - P1 1:25 10mins **
p21 Rabbit Santa Cruz BMK-2202 1:500 20mins *
anti Rabbit biotinylated Swine DAKO E0353 1:200 NA
anti Rabbit HRP Swine DAKO P0399 1:200 NA
anti Rat biotinylated Rabbit DAKO E0468 1:200 NA
anti Sheep Alexa 350 Donkey Invitrogen A21097 1:200 NA
anti Rabbit Alexa 488 Goat Invitrogen A11008 1:200 NA
anti Rabbit Alexa 488 Donkey Invitrogen A21206 1:200 NA
anti Rat Alexa 488 Donkey Invitrogen A21208 1:200 NA
Alexa 488 strepatividin Invitrogen S32354 1:200 NA
anti Rat Alexa 546 Goat Invitrogen A11081 1:200 NA
anti Hamster 546 Goat Invitrogen A21111 1:200 NA
anti Rabbit Alexa 555 Goat Invitrogen A21425 1:200 NA
Alexa 555 strepatividin Invitrogen S32355 1:200 NA
anti Sheep Alexa 650 Donkey Invitrogen A21448 1:200 NA
* Microwave at 800W in 0.1M NaCitrate pH6.0
** Heated under pressure in Borg decloaker RTU solution
*** Proteinase K 0.0125% (w/v) in PBS
**** Microwave at 800W in 0.1M EDTA
***** Paraformaldehyde 4%  
 
 
For frozen sections liver tissue was excised and mounted in OCT fixative.  These 
samples were embedded in OCT and frozen in an 100% ethanol bath on dry ice.  
Samples were stored at -80C.  Frozen sections were cut at 10µm thickness.  Cytospins 
were prepared by spinning 1000-5000 cells at 300rpm for 3 minutes onto superfrost plus 
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slides using a Cytospin2 centrifuge (Shandon) prior to fixing for 5 minutes in methanol 
followed by air drying overnight and storing at -20C.  Cytospins and frozen sections 
were initially rehydrated in PBS followed by processing for immunocyto/histochemistry 
as outlined in Table 2.1.   
 
 
Where dual staining involving multiple primary antibodies from the same source 
species, tyramide deposition was used to amplify an antibody signal prior to stripping of 
the antibody complexes.  In these cases an HRP conjugated secondary antibody was 
introduced instead of a biotinylated secondary for 30 minutes.  Sections were incubated 
with Cy5 or Flourescin conjugated tyramide for 10 minutes.  Antibody complexes were 
then stripped by boiling in 0.01M NaCitrate for 3 minutes followed by resting for 30 
minutes prior to repeat staining with further antibodies.  Appropriate no primary, and 
isotype controls were performed to ensure no cross reactivity between antibody 
complexes. 
  
2.32 β-Galactosidase detection 
 
Lac-Z staining was performed on 10m thick frozen sections which were initially 
fixed for 5 minutes (0.5M NaH2PO4, 0.5M Na2HPO4, 25% (w/v) gluteraldehyde, 
100mM EGTA (pH 7.3), 1M MgCl2) followed by 3x5 minute washes in wash solution 
(0.5M NaH2PO4, 0.5M Na2HPO4 1M MgCl2).  Sections were then incubated at 37C 
overnight in X-gal staining solution (0.5M NaH2PO4, 0.5M Na2HPO4, 25mg/ml X-gal in 
dimethyl formamide, potassium ferrocyanide, potassium ferricyanide, 1% (w/v) 
deoxycholate, 2% (v/v) nonidet-P40, 1M MgCl2).  Slides were then rinsed in wash 
buffer and allowed to stand in wash buffer for a further 6 hours at 4C.  Sections were 
then counterstained with Eosin prior to dehydration using graded ethanols and mounting 




2.33 EdU detection 
 
Following initial antigen detection, using standard immunohistochemistry and directly 
fluorophore conjugated secondary antibody, slides were washed in PBS with 0.5% 
Triton X for 20 minutes and a further 3x5 minute PBS washes.  Slides were then 
removed from sequenza racks and prior to placing in a dark box, the sections were 
outlined using a hydrophobic pen.  100µl of fixative buffer was then added.  5 minutes 
later a further 100µl of reaction cocktail was added (1 vial of alexa labelled click-it 
reagent, 200µl of 1x reaction buffer, 200µl of reaction buffer additive, and 600µl of 
13.3mM CuSO4 (8mM final concentration) and left for 30 minutes for detection.  
Sections were then washed 3 times in PBS before mounting with DAPI containing 




Donor derived cells in sex mismatched (male to female) transfer experiments were 
confirmed by FISH for the Y chromosome (STARFISH 1189-YMF; Cambio, UK) 
according to the manufacturer‟s instructions.  Briefly immunohistochemistry was 
performed followed by detection using 1:200 Streptavidin-AP and VectorRed (Vector 
UK) following manufacturers instructions.  Following IHC, sections were washed in 
PBS and incubated in 1M sodium thiocyanate in distilled water for 10 minutes at 80°C, 
then washed in PBS, and digested in 0.4% w/v pepsin in 0.1M HCl at 37ºC for 5 
minutes, followed by quenching in 0.2% glycine in double 2x PBS for 2 minutes.  
Samples were post-fixed in 4% paraformaldehyde for 2 minutes, and then dehydrated 
through graded alcohols before air drying.  A FITC-labeled Y chromosome paint (Star-
FISH, Cambio® no.  1189-YMF) was added to sections, sealed under a glass cover slip, 
denatured at 60°C for 10 minutes before overnight incubation in a 37°C water bath.  
Slides were then washed in formamide (50%w/v)/2x saline sodium citrate (SSC) at 
37°C, then washed with 2x SSC, then washed with 4x SSC/Tween-20 (0.05% w/v) at 
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37°C.  The slides were rinsed in 0.5x SSC at 37°C, then PBS before mounting with 




Apoptosis was assessed using the DeadEnd Colorimetric or Fluorometric (Alexa 
488) TUNEL System (Promega #TB199) according to manufacturer's instructions.  
Briefly formalin fixed tissue sections were deparaffinised in xylene and rehydrated 
through graded alcohols before washing in 0.85% NaCl for 5 minutes.  They were then 
washed 3 times in PBS before fixing in 10% buffered formalin for 15 minutes.  
Following a PBS wash sections were digested for 5 minutes in 20µg/ml Proteinase K 
prior to 3 further PBS washes before further fixation in 10% buffered formalin for 5 
minutes.  Slides were washed prior to the addition of equilibration buffer for 10 minutes.  
Biotinylated Nucleotide mix containing rTdT Enzyme and biotinylated nucleotides was 
prepared and added to the sections followed by incubating at 37°C for 60 minutes to 
allow nucleotide incorporation to 3‟-OH DNA ends.  Slides were washed with 2xSSC 
for 15 minutes and then PBS prior to peroxidase blocking with 1% H2O2.  After further 
PBS washes development used Streptavidin-HRP and DAB following which slides were 
counterstained with Harris Haematoxylin and mounted using pertex mounting media.  
Positive control slides used DNase1 treatment (7units DNaseI in 100ml 40mM Tris HCl 
(pH 7.9), 10mM NaCl, 6mM MgCl2, 10mM CaCl2).  Negative controls were performed 




Analysis and sorting was performed using a FACSVantage, equipped with a Coherent 
INNOVA Enterprise II laser (Becton and Dickinson, Oxford, UK).  Propidium Iodide 
(PI) (Sigma Aldrich, Dorset, UK) was added to the cells prior to sorting at a final 
concentration of 2g/ml to distinguish and exclude dead cells in the BM population.  
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Cells were also immunophenotyped using PE conjugated CD45 (BD Biosciences, 
Pharmingen, Oxford, UK).   
 
2.37 Cell counting and image analysis 
2.37A HPCs 
 
Images were obtained on a Zeiss Axiovert 200 microscope using a Zeiss Axiocam 
MRc camera.  Cell counts were performed on blinded and randomised slides by 
manually counting panCK positive progenitor cells in 30 consecutive non overlapping 
fields with liver parenchyma at all boundaries at x200 magnification.  Fields were 
included that contained vascular structures or bile ducts in the field.  Small 
(approximately 10m) panCK
+
 cell with oval/cuboidal morphology with high nuclear to 
cytoplasmic ratio were counted.  Cells with hepatocyte like morphology e.g. larger (over 
20m) with low nuclear to cytoplasmic ratio were not counted even if they have weak 
staining for panCK as they were considered morphologically typical for intermediate 
hepatocyte-like cells.  Interlobular bile ducts, defined as small panCK positive cells 
directly abutting a lumen, were excluded as previously described (Oben et al., 2003).  
Results are expressed as mean number of HPCs per high powered field.   
 
Validation of the method of quantification of the HPC compartment is a vital 
prerequisite to further HPC quantification.  Variation in the number of HPCs is noted 
based on the choice of HPC markers used (panCK, Dlk1, and EpCAM), in addition to 
variation between liver lobes and between peripheral and hilar regions.  Therefore it was 
necessary to sample a larger area than is used in a number of published studies.  It is also 
vital to assess a number of lobes so that an accurate representation is achieved.   
 
To assess the area of liver that should be assessed a preliminary study was performed 
in which 120 fields (40 from each of 3 lobes) was performed.  Analysis was performed 
taking the first 10, 15, 20, 25, 30, 35 and 40 fields, which were compared to next group 
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of an equal number.  When this was performed on multiple mice (n=3) it was seen that 
at least 30 fields are required to be analysed in order to provide a representative sample 
(Figure 2.3).  As a result of such preliminary study a total of 30 fields were chosen to 
provide a representative sample for quantification.   
 
To validate this method of quantification the intra and inter-observer error was 
assessed by the counting of a blinded sample twice by the same and different individuals 
(Figure 2.3). 
 
2.37B Niche myofibroblasts 
 
In order to analyse changes in the myofibroblasts within the HPC niche, quantification 
of niche myofibroblasts was performed in contrast to whole liver myofibroblasts.  Here 
dual immunohistochemistry for αSMA and panCK was performed using Alexa 555 and 
Alexa 488 respectively for visualisation.  Images of 20 non-overlapping x200 fields 
containing HPCs were taken from at least 3 lobes.  These images were then assessed for 
the number of αSMA
+
 myofibroblasts in direct contact with panCK
+
 HPCs.  Results are 




To quantify the number of hepatic F4/80
+
 macrophages a total of 10 x200 
magnification fields were analysed corresponding to >1300 macrophages in non-
depleted animals.  If <1300 macrophages were seen then a total of 10 fields were 
counted.  Results are expressed as mean number of F4/80
+
 macrophages per x200 




Figure 2.3 Validation of cellular quantification methods 
  
(A) To quantify the 
number of fields 
required to accurately 
assess HPC number 
following 
immunohistochemistry a 
series of field numbers 
were assessed from two 
separate and 
independent counts of 






are shown as white and 
shaded bars 
respectively. Whilst at 
lower numbers of fields 
non-significant changes 
in results were obtained 
it is clear that for 
accurate assessment of 
cell number counts in 
excess of 25 fields are 
required.  To assess 
intraobservor error and 
interobservor error and 
series of slides were 
assessed by either the 
same observer multiple 
times or different 
observers respectively.  
HPC counts were 
consistent upon repeated 
assessment by either the 
same (B) or different 
observers (C)).  All data 
is presented as 





2.37D Hepatocytes  
 
While many previous studies have often relied upon a morphological criteria of 
hepatocytes, in these studies an immunohistochemical definition of hepatocytes has been 
used.  The rationale for this approach is that whilst using counterstained tissue, 
hepatocytes may be identified (due to their and their nuclei‟s characteristic shape), when 
immunofluorescence is used alone large nuclei can often be seen which upon further 
investigation are clearly not hepatocytes. These cells represent other large cells within 
the sinusoids (Figure 2.4).   
 
Due to its panlobular distribution, (Figure 2.4), CYP2D6 positivity was used to 
identify hepatocytes.  In order to quantify the status of hepatocytes Image J was used 
incorporating its cell counter feature and colour channel control.  Hepatocytes were 
counted manually with the independent characteristic channel (eg p53 status) removed.  
Then once hepatocytes had been identified this latter channel was returned and the 
hepatocyte status assessed.   
 
2.37E Image analysis 
 
Sections were stained in a single batch with picro-sirius red.  At least 22 images were 
taken at x200 magnification under standardised conditions (up to 40 images were taken, 
tissue permitting).  Images were analysed using Adobe Photoshop choosing a single 
colour and fuzziness permitting accurate identification of collagen staining.  Results are 




Figure 2.4 Utility of immunohistochemical identification of hepatocytes by 
CYP2D6 
(A) CYP2D6 is expressed throughout the hepatic lobule with expression extending to the central 
vein (arrowhead) and limiting plate (arrow).  The use of cell and nuclear morphology alone 
(DAPI channel) is helpful for definition of hepatocytes but is greatly added by addition of a 
specific marker such as CYP2D6.  (B) Confocal analysis of DAPI CYP2D6 shows that nuclear 




2.4 Serum Analysis 
 
Blood was collected by cardiac puncture and left overnight at 4C to clot.  The 
following day blood was centrifuged at 5 minutes at 8,000xG and serum removed.  
Haemolysed samples were identified visually and excluded from analysis.  Specific 
biochemical analysis was performed as follows: 
 
2.41 Serum Albumin 
 
Mouse or rat serum albumin measurements were determined using a commercial 
serum albumin kit (Alpha Laboratories Ltd., Eastleigh, UK) adapted for use on a Cobas 
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Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK).  The 
measurement of serum albumin is based on its quantitative binding to bromocresol green 
(BCG).  The albumin-BCG-complex absorbs maximally at 578nm, the absorbance being 
directly proportional to the concentration in the sample.  Within run precision was CV < 
2.5% while intra-batch precision was CV < 4%. 
 
2.42 Alanine Aminotransferase 
 
ALT was measured using the method described by Bergmeyer et al.  (1), utilising a 
commercial kit (Alpha Laboratories Ltd., Eastleigh, UK) adapted for use on a Cobas 
Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK).  Within 
run precision was CV < 4% while intra-batch precision was CV < 5%.  (Bergmeyer  et 
al., 1978)  
2.43 Aspartate Aminotransferase  
 
AST was determined by a commercial kit (Randox Laboratories, UK) adapted for use 
on a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, 
UK).  -oxogluterate reacts with L-aspartate in the presence of AST to form L-glutamate 
plus oxaloacetate.  The indicator reaction utilises the oxaloacetate for a kinetic 
determination of NADH consumption.  Within run precision was CV < 4% while intra-
batch precision was CV < 5%.   
 
2.44 Serum Alkaline Phosphatase  
 
ALP was determined by a commercial kit (Randox Laboratories, UK) adapted for use 
on a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, 
UK).  The substrate p-nitriphenyl phosphate is hydrolysed by ALP from the sample, in 
the presence of magnesium ions, to form p-nitophenol which is yellow in colour and its 
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production can be monitored at 405nm.  Within run precision was CV < 4% while intra-
batch precision was CV < 5%. 
 
2.45 -Glutamyltransferase  
 
GT was determined by a commercial kit (Randox Laboratories, UK) adapted for use 
on a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, 
UK).  The substrate L--glutamyl-3-carboxy-4-nitroanilide, in the presence of 
glycylglycerine is converted by GT, in the sample, to 5-amino-2-nitrobenzoate which 
can be measured at 405nm.  Within run precision was CV < 4% while intra-batch 
precision was CV < 5%. 
 
2.46 Total Bilirubin 
 
Total bilirubin was determined by the acid diazo method described by Pearlman and 
Lee (Clinical Chemistry 1974; 20:447-453) using a commercial kit (Alpha Laboratories 
Ltd., Eastleigh, UK) adapted for use on a Cobas Fara centrifugal analyser (Roche 
Diagnostics Ltd, Welwyn Garden City, UK).  In this method a surfactant is used as a 
solubiliser.  Conjugated and solubilised unconjugated bilirubin react with diazotised 
sulphanilic acid to produce an acid azobilirubin, the absorbance of which is proportional 
to the concentration of bilirubin in the sample and can be measured at 550nm.  Within 
run precision was CV < 4% while intra-batch precision was CV < 5%. 
 
2.5 DNA and RNA analysis  




Genomic DNA was extracted from perfused whole liver using DNA Blood Mini Kit 
(Qiagen UK).  DNA resulting from PCR or restriction digests was processed using the 
Qiagen Gel Extraction Kit according to the manufacturer‟s instructions.  Typically DNA 
was eluted in 30µl TE buffer.   
 
Genomic DNA from mouse ear notches or tail snips to be used for genotyping only 
was extracted by incubating the fresh tissue in 100µl of 50mM Tris (pH 8.5) containing 
12mM MgCl2 and 50µg proteinase K (Sigma, UK) at 60C overnight.  The following 
morning samples were vortexed and centrifuged at 8000xG for 10 minutes and the 
supernatant containing DNA removed to a fresh Eppendorf tube and stored at -20C. 
 
2.52 RNA extraction and reverse transcription 
 
RNA derived from whole liver was extracted from liver frozen after harvesting in 
RNAlater (Sigma) according to manufacturer's instructions.  30-50mg liver tissue was 
then added to 300µl of TRIsol reagent (Invitrogen) in a 1.5ml Eppendorf and mixed 
thoroughly and homogenised using a pestle.  RNA derived from cell populations was 
processed from up to 10
7
 cells which were added to 300µl TRIsol reagent.  Once in 
TRIsol RNA could be stored, or further processed for extraction by adding 60µl of 
chloroform and the solution centrifuged at 12 000xG for 15 minutes at 4C.  The 
aqueous phase was removed and the RNA purified using RNAeasy mini columns 
(Qiagen) according to manufacturer's instructions.  RNA was eluted in 30l ddH20 and 
analysed using a nanodrop spectrophotometer (ThermoScientific) for RNA 
concentration and purity (260/280 and 260/230 ratios).  Yield was typically 
approximately 500ng/µl and purity >2 and >1.8 for 260/280 and 260/230 ratios 
respectively.   
 
Reverse transcription was performed on 1g RNA using Qiagen QuantiTect
®
 Reverse 
Transcription Kit according to manufacturer's instructions, including a DNA degradation 
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step prior to reverse transcription.  No RT, and no RNA template controls were 




Real time PCR was performed using either gDNA or cDNA.  Real time RT-PCR and 
melt curve analysis was performed in a ABI Prism 7500 fast cycler using SYBR green 
detection and Qiagen primers (Table 2.1) and QuantiFast SYBR Green PCR reagents 
(Qiagen UK).  Y chromosome analysis used SRY primers and β-actin control primers 
(ABI).  Generation of standard curves for qPCR: cDNA from each sample was 
combined and this was diluted 1:10 with RNAse free water.  Serial 1:1-4 dilutions were 
produced giving a final range of concentrations.  Samples of cDNA were diluted 1:100 
for analysis of gene expression.  Data were managed and analysed using the 
LightCycler® system and Microsoft Excel following normalisation to PPIA mRNA 
content and a calibrator.  All samples were run in triplicate alongside positive murine 
controls of adult liver, spleen, thymus or E15 liver.   
 
Wnt Pathway focused gene expression profiling was performed using the RT
2
 
Profiler PCR array system (SAB Bioscience; Cat no.  PAMM-043A), according to the 
manufacturer‟s instructions.  Briefly RNA was prepared using a Trizol based extraction 
and purification as previously followed by further clean-up using RNeasy columns 
(Qiagen) and elution in 30l RNase free water.  Samples were used only if the A260:280 
and A260:230 were >2.0 and 1.8 respectively.  Reverse transcription including gDNA 
elimination was performed from 1.5g RNA using SuperArray‟s RT
2
 First Strand Kit 
(SAB Bioscience; Cat no.  C-03).  cDNA was then stored at -20C until further use 
within 1 week.  Mouse Wnt Signalling Pathway PCR plates were run on an ABI Prism 
7900HT thermal cycler including a melt curve analysis.  Data was analysed using 
software provided by SAB Bioscience.   
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Table 2.2 Primers used for qRT-PCR 























































PPIA QT00247707  
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2.54 Southern blotting 
2.54A Probe generation 
 
A 353bp probe from the Murine MDM2 exon 7 was amplified by PCR using in house 
primers Exon 7 F1 and R1 to amplify a region of murine MDM2 Exon 7 (Table 2.3 and 
Figures 2.5 and 6.1).  The resulting product was excised from a 1% agarose gel and 
purified using the Qiagen Gel Extraction Kit (Qiagen no 28704) according to 
manufacturer‟s instructions.  25ng of DNA was then inserted into the pGEM®-T Easy 
plasmid at a 2:1 ratio using T4 DNA Ligase (Promega), concurrent positive and negative 
ligation controls were used.  Following overnight ligation at 4C One Shot® MAX 
Efficiency® DH5 -T1® Competent cells (Invitrogen) were transformed with 10l of 
plasmid using Heat Shock at 42C for 45 seconds following by culture in SOC medium 
(Invitrogen) for 90 minutes at 37C.  Transformed bacteria were then plated onto LB 
Agar containing 100g/ml Ampicillin for overnight incubation at 37C and resistant 
colonies selected.  Colonies containing the desired 353bp insert were assessed by PCR 
using primers F1 and R1 and subsequently grown in LB broth for DNA purification 
using Midi prep columns (Qiagen) according to manufacturer‟s instructions.  DNA was 
digested using NotI and SacII restriction enzymes (New England Biolabs).  The 
resulting products were separated on a 2% agarose gel and the 353bp bands removed 
and purified using the Qiagen Gel Extraction Kit.  PCR using primers F1 and R1 in 
addition to DNA sequencing was performed to confirm probe sequence (Figure 2.5).   
 
The probe was labelled with 
32
P dCTP using Ready to Go labelling beads 
(Amersham) according to manufacturer's instructions.  Briefly the probe was initially 
denatured by boiling for 3 minutes prior to the addition of DNA labelling bead and 5µl 
of [-
32
P] dCTP (3000Ci/mmol) and the final 50µl mixture incubated at 37C for 15 




Table 2.3 In house primers used for PCR  
No. Name Species Direction Sequence Size Tm Combines with Product size
1 LacZ F Mouse F CGGTGATGGTGCTGCGTTGGA 21 68 LacZ R 385
2 LacZ R Mouse R ACCACCGCACGATAGAGATTC 21 66  
3 YFP common Mouse F AAAGTCGCTCTGAGTTGTTAT 21
4 YFP mutant Mouse R AAGACCGCGAAGAGTTTGTC 20 YFP common 320
5 YFP wild type Mouse R GGAGCGGGAGAAATGGATATG 21 YFP common 600
6 AhC Mouse F CCTGACTAGCATGGCGATAC 20 Cre B 1000
7 Cre A Mouse F TGACCGTACACCAAAATTTG 20 Cre B 1000
8 Cre B Mouse R ATTGCCCCTGTTTCACTATC 20
9 Gigi F1 Mouse F TGTGGAGAAACAGTTACTTC 20 20
10 Gigi R2 Mouse R CTGTGCTCCTTCACAGAG 18 Gigi F1 342/474
11 Gigi R3 Mouse R TGAGATGAGTCAAAGCCTGG 20 Gigi F1 2314
12 Mdm Exon 7 F1 Mouse F CTTCAGACTCTGGCACATCG 20 Mdm Exon 7 353
13 Mdm Exon 7 R Mouse R AACATTGGCTGTTCCACACC 20
14 Mdm Exon 7 F2 Mouse F CATCGCTGAGTGAGAGCAGA 20 Mdm Exon 7 338
15 Mdm Exon 5 Mouse F ACGAGAAGCAGCAGCACATTG 21 Mdm Exon 5 R 113
16 Mdm Exon 5 Mouse R TTATAACCCACCACGCACAAGG 22
17 Mdm Exon 2 Mouse F AACCTGGATTATCGCACAGTCG 22 Mdm Exon 2 R 90
18 Mdm Exon 2 Mouse R TCGCAGTGACCACTCTCTAATGC 23
 
 
Table 2.4 PCR conditions for in house PCR 
Reaction AC MF Exon 7 YFP mut YFP wt BATgal Mdm2 Exon 2 Mdm2 Exon 5
Genotyping AhCre Genotyping Mdm2 flox/wt Making Southern probe Genotyping R26YFP + alleles Genotyping R26YFP - alleles Genotyping BATgal mice Testing Mdm2 control Testing Mdm2 flox
Buffer x10 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
dNTPs (10um) 0.4 1 0.2 0.2 0.2 1 1 1
Taq 0.4 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Primer (100uM) 0.05 0.5 0.2 0.24 0.24 0.5 0.5 0.5
MgCl (50mM) 0 0.5 0 0.25 0.25 2 2 1
H2O 18.6 16.8 18.7 18.37 18.37 17.3 15.3 16.3
DNA template (ON Prot K from ear notch) 3 3 3 3 3 1 3 3
Total volume 25 25 25 25 25 25 25 25
Forward primer AhCre Gigi1 Mdm Exon 7 F1 YFP common YFP common LacZ F Mdm Exon 2F Mdm Exon 5F
Reverse primer Cre B Gigi2R Mdm Exon 7 R YFP mutant YFP wild type LacZ R Mdm Exon 2R Mdm Exon 5R
 
 
2.54B Southern blotting 
 
Whole liver or purified cell population DNA was prepared using DNA Blood Mini Kit 
(Qiagen UK).  10µg DNA was restricted overnight at 37C with 50U Pst1 (New 
England Biolabs) according to manufacturer's instructions.  The following morning a 
further 10U Pst1 was added to ensure complete DNA restriction.  The resulting 
fragments were run for 5 hours on a 1% agarose gel.  The gel was then washed in 0.25M 
HCl for 10 minutes to fragment DNA following by washing for 2x20 minutes in 
denaturation solution (1.5M NaCl, 0.5M NaOH) and subsequently a further 20 minutes 
in neutralising solution (1.5M NaCl, 0.5M Tris HCl, 1mM EDTA @ pH 7.2).  
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Following this the gel was loaded onto 3mm Watman paper wicks above a 20xSSC 
solution.  The gel was covered in positively charged nylon membrane which was 
previously soaked in 2xSSC.  A further layer of Watman paper was placed above this 
and layers of absorbent tissue; and the stack left overnight to transfer the DNA to the 
nylon membrane. 
 
Figure 2.5 Generation of southern blot probe for MDM2 
A DNA probe for Southern Blotting was produced by amplifying a segment of Exon 7 of the 
murine MDM2 gene using primers MDM2 Exon 7F and MDM2 Exon 7R to yield a 353bp 
fragment (A).  This fragment was then inserted into the pGEM®-T Easy vector (B).  Colonies 
were expanded and the presence of the insert tested by PCR (C).  A colony containing the 
specified insert was then used to generate DNA which was restricted using NotIHF and SacII 
(D).  This fragment was then purified by size to yield a final probe of approximately 353bp(E).  
This probe was sequenced (F) and the sequence compared to known MDM2 exon 7 sequence 
confirming 100% homology (G) within the probe sequence (G).  Primer sites are marked in bold.   
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 The following day the nylon membrane was removed and baked at 80C for 2 hours 
prior to hybridisation.  The membrane was then incubated for 3 hours at 65C in 25mls 
of hybridisation buffer (0.5M phosphate buffer pH7.2, 7% (w/v) SDS, 10mM EDTA) 
containing 100l of ssDNA.  The labelled probe was then added in hybridisation buffer 
and left to incubate overnight at 65C.  After washing with wash buffer 1 (20mM 
Na2HPO4 ph7.2, 1mM EDTA, 5% SDS) at 65C for 15 minutes, the membrane was 
washed with wash buffer 2 (20mM Na2HPO4 ph7.2, 1Mm EDTA, 1% SDS) 3 times for 
10 minutes each.  The film was then developed for 72 hours using radiographic film. 
 
Stripping membranes prior to rehybridisation was performed using 3x15 minute 
washes at 65C in pre-boiled stripping solution (0.2M NaOH, 0.1% (w/v) SDS).  
Following this the membrane was washed for 15 minutes in 2xSCC before returning to 




All transgenic mice were genotyped using standard qualitative PCR (Tables 2.3 and 
2.4).  Genomic DNA was extracted from ear or tail samples as described previously.  
PCR utilised DNA Taq polymerase (New England Biolabs, UK) with 5x PCR buffer, 
dNTPs (10µM working concentration: New England Biolabs, UK) and MgCl2 (50µM).  
PCR products were assessed on a 2% agarose gel in 1xTBE (0.089M Tris Base, 0.089M 
Boric Acid, 2mM EDTA, pH 8.3), containing Gel Red (Biotium) for visualisation and 
run for 30 minutes at 80mV.  Images were obtained using VersaDoc imaging system.  






Figure 2.6 Representative examples of PCR based mouse genotyping 
Examples are given for gel electrophoresis of products of PCR based genotyping of R26R-YPF 
(A), BATgal (B), AhCre and MDM2
flox
 (C) transgene constructs.  The transgenic (mut) and 
wild-type loci for the R26R-YFP gene amplify 320bp and 600bp fragments respectively.  The 
BATgal transgene results in a 385bp product.  AhCre results in a 1kp product.  The amplification 
of both wild type and MDM2flox loci may result in detection of heterozygotes by a single 







DNA sequencing was performed using BigDye® Terminator Sequencing Kit (ABI 
biosystems, UK) and run on an ABI3730 capillary analyser.  Briefly, approximately 5ng 
of template DNA was added to 3.2pmol primer in a final volume of 6µl.  Forward and 
reverse sequence primers were used.  Data analysis was performed using Vector NTI 
Advance 11 software (Invitrogen) following extraction using ABI sequence scanner 




Prism software (GraphPad Software, Inc) was used for all statistical analysis.  Mean 
HPCs per field from 30 fields for each mouse were compared.  For comparison of 
parametric data sets where previous data had shown a consistent directional trend the 
one tailed Student‟s t test was used, otherwise direct comparison used a two tailed 
Student‟s t test.  Parametric distribution was assessed using D‟Agostina and Pearson 
omnibus testing (p<0.05).  Comparison between multiple groups was performed using 
one-way analysis of variance with parametrically distributed data being sub-analysed 
using Bonferroni testing.  Comparison between multiple groups of non-parametrically 
distributed data was performed using Kruskal-Wallis testing with Dunn analysis 
performed between individual data points.  In all cases *, ** and *** denote p<0.05, 
<0.01, and <0.001 respectively. 
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Chapter 3: Establishment and characterisation of in 




 During liver regeneration HPCs are surrounded by a stereotypical niche 




 To develop, optimise and characterise HPC activation and their surrounding 
environment in an in-house murine model of HPC activation 
 
 To compare HPC activation and its associated niche in multiple models of HPC 
activation in rodent and humans 
 
3.3 HPCs in healthy mice 
 
Prior to commencing work on HPC induction, it is important to appreciate HPCs in the 
uninjured liver.  Examination of healthy livers from C75/Bl6 mice revealed that in 
young mice there is very little evidence of HPC activation with portal tracts containing 
usually one and occasionally more intralobular bile ducts (Figure 3.1A).  Occasional 
HPCs were seen infiltrating away from the intralobular bile ducts and into the adjacent 
hepatic parenchyma.  When mice of varying ages was examined a striking increase in 
HPCs was observed in elderly mice beginning at approximately 4-6 months of age and 
increasing dramatically over the subsequent 12 months (Figure 3.1B).  In light of these 
observations all subsequent work was carried out with contemporaneous age matched 
controls unless otherwise stated. 
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Figure 3.1 HPCs in healthy liver with varying age  
Comparison between healthy C57Bl/6 mice of 8 weeks ranging to 84 weeks demonstrates a 
progressive expansion of HPC both morphologically (A) and when quantified (B).  *p<0.05 by 
T test.   
 
 
3.4 The CDE dietary model of HPC activation 
3.41 Trial using 100% choline deficiency and 0.165% ethionine resulted in 
excess morbidity and mortality.   
 
Following on from multiple previous reports using the CDE diet with 100% choline 
deficient diet and 0.165% ethionine in water, age and sex matched mice C57Bl6 mice 
were initially trialed with this CDE diet.  From as early as 36 hours after commencing 
the diet significant weight loss was observed, together with other associated adverse 
clinical effects including hunching, social withdrawal and piloerection.  Two days after 
diet initiation, mortality was first noted despite careful monitoring.  With ongoing 
monitoring a careful regime of humane euthanasia was instituted when morbidity was 
excessive.  This resulted in either the death or culling of the entire cohort by day 6 
(Figure 3.2A).  Variation in weight loss was noted within the group with some mice 
undergoing dramatic (>20%) weight loss in as little as 2 days, while others lost virtually 
no weight (Figure 3.2B).  Microscopic analysis of the mice revealed, even as early as 6 
days, extensive liver injury along with expansion of HPCs (Figure 3.2C-E).  
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Additionally the development of an HPC-associated, panCK
-
 non-parenchymal cell 
„niche‟ became apparent (Figure 3.2C). 
 
 
3.42 Optimisation of the CDE  
 
In order to create a diet which, in my hands, resulted in the required HPC activation 
and expansion without the adverse side effects a series of diets were tested in male 
C57Bl6 mice of >6 weeks age.  Initially, the effects of ethionine alone were tested at 
0.075% and 0.15% in combination with water which was sweetened with orange juice.  
No adverse effects were noted either by clinical status or weight loss in either group 
(Figure 3.3A).  Histological analysis demonstrated no changes in portal areas compatible 
with HPC activation (Figure 3.3B).   
 
Following this, a preparation of a choline sparse diet was prepared and used in 
combination with ethionine administration.  When given either 0.12% or 0.15% 
ethionine alongside the choline sparse diet, mice did not lose weight (Figure 3.3C), nor 
was any significant panCK
+ 
HPC activation observed (Figure 3.3D and E respectively).   
 
Using fully choline deficient chow, either in combination with 0.15% or 0.165% 
ethionine in 8 week old male C57Bl6 mice, weight loss was once again observed (Figure 
3.3F).  This time in the older mice there was no spontaneous mortality in either group, 
however 2/12 in the 0.165% group required euthanasia on clinical grounds between days 
2 and 7.  In contrast to mice treated with CDE diet initially (with 0.165% ethionine), 
mice in these groups were not only 2 weeks older at diet initiation but also were 
maintained on sweetened water throughout the diet.  Sweetening the water improves 
mouse fluid intake of water alone, but also appears prevent the reduction of intake seen 
upon addition of ethionine to the drinking water (Figure 3.3H).   
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Figure 3.2 Mortality and morbidity with the CDE diet with 0.165% ethionine 
 (A) Survival in a group (n=18) of 6 week old male C57Bl6 mice following commencing CDE 
diet (0.165% ethionine).  Of these mice 2 died spontaneously while other mice with clinical 
signs of significant morbidity were euthanised.  (B) Significant weight loss in this group of mice 
from baseline, individual weights are shown along with mean±SEM for the group (black line).  
Liver analysis by H&E (C; with magnified insert) panCK (D and E) showed significant 
expansion of small cells (arrows) consistent with published reports of HPCs.  Whilst HPCs 
extend predominantly in single file columns into the parenchyma, H&E reveals an association of 
panCK
-
 NPCs adjacent to the panCK
+
 HPC.   
Chapter 3-Establishment and characterisation of in house HPC induction models 
 108 
Figure 3.3 Increased tolerance of CDE diet without HPC activation with reduced 
dietary ethionine  
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Normal weight gain (A) but an absence of HPC expansion (B) followed administration of 
ethionine only to 6 week old male C57Bl6 mice (n=5 each group).  Following combination of a 
choline sparse deficient diet with either 0.12% or 0.15% ethionine normal weight gain (C) and 
only minor HPC activation (D and E respectively) were seen or quantified (F) at up to 14 days 
(n=5 each group).  (G) In 8 week old male C57Bl6 mice, the combination of choline deficient 
diet and either with sweetened 0.15% or 0.165% ethionine resulted in early weight loss and a 
failure of weight gain over 2-4 weeks (n<4 each group).  (H) Mouse fluid usage per day 
compared between various fluid preparations.  Usage calculated by reduction of weight of cage 
bottles and extrapolated on a per mouse per day basis.  All scale bars denote 50m.  Data points 






In both groups treated with CDE diet with sweetened water hepatic effects were 
observed both macroscopically and microscopically.  Macroscopically livers appeared 
pale (Figure 3.4A) and were larger than controls.  A corresponding increase in liver 
weight was observed after 3 weeks of the CDE diet (Figure 3.4B).  Microscopic analysis 
of liver revealed prominent microvesicular steatosis.  Small isolated areas of hepatocyte 
necrosis were noted intermittently but no generalised hepatitis was present.  Minor portal 
inflammatory infiltrate was present, predominantly formed by lymphocytes and 
monocytes.  A progressive expansion of small cells, morphologically consistent with 
HPCs, was observed extending from portal tracts and confirmed as HPCs by panCK
+
 
expression.  Consistent with previous observations in the CDE diet, a panCK
-
 non 
parenchymal cell (NPC) expansion is seen alongside the HPCs (Figure 3.4D).  HPC 
expansion was observed over a two week period beyond which the number of HPCs 
plateaus but remains elevated (Figures 3.4D and E).  A strong correlation is seen 
between the extent of hepatic injury (serum Alt) and the degree of HPC expansion in 
mice within the cohort (Figure 3.4F).    
 
Chapter 3-Establishment and characterisation of in house HPC induction models 
 110 
Figure 3.4 HPC expansion in the optimised CDE diet  
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8 week old male mice were fed choline deficient chow with sweetened water containing 0.15% 
ethionine.  At post mortem mice livers were pale in colour (A) and were enlarged in size and 
weight (B).  Liver weight is presented as liver/body weight n<5 each group.  Serum Alt is raised 
during the CDE diet (C), n<4 each group.  A progressive expansion of panCK
+
 HPCs (arrows) is 
observed from the portal tracts (arrowheads) of treated animals (D and E), (n<4 each group).  
Furthermore on an individualised analysis there is strong correlation between liver injury (F) and 
HPC expansion.  Injury was assessed at post mortem assessed by serum Alt and compared to 
HPC activation using a Pearson‟s correlation coefficient (r).  All graphs represent mean±SEM 






Further examination of the cell characteristics during the CDE diet revealed ongoing 
proliferation of HPCs during the period of HPC expansion with large number of 
proliferating panCK
+
 HPCs identified at 10 days following diet initiation (Figure 3.5A).  
Other cellular proliferation is identified alongside the HPCs, including hepatocytes and 
non-parenchymal cells.  Notably non-parenchymal cells adjacent to the HPCs are 
frequently Ki-67
+
 (Figure 3.5A).  Other recognised HPC markers (see Chapter 1) were 
also assessed by immunohistochemistry.  Expansion of both Dlk1 and EpCAM
+
 HPCs 
was also observed in the CDE diet (Figure 3.5B and C respectively).  TUNEL and 
activated Caspase 3 expression (Figure 3.5D and E respectively) also revealed marked 
apoptosis in the hepatic parenchyma and in the periportal regions during CDE diet 
compared to control mice.   
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Figure 3.5 HPC characterisation in the CDE diet 
 (A) During this expansion of HPCs (Day 10) ongoing proliferation (Ki-67 red) is seen within 
the HPC population (panCK green; Solid Arrows) as well as proliferation of hepatocytes 
(Arrowheads) and other non-parenchymal cells (Hollow Arrows).  Expansion of Dlk1
+
 HPCs (B) 
and EpCAM
+
 HPCs (C) is also observed during the CDE diet.  Increased apoptosis is observed 
throughout the hepatic parenchyma by TUNEL (D) and also associated with cells in the portal 
tract by Caspase 3 (E).  (F) BrdU
+
 hepatocytes adjacent to panCK
+
 HPCs after 12 days of CDE 
diet when 50µg/g i.p. BrdU is given at day 9.  All scale bars denote 50m.   
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3.43 Recovery from the CDE diet 
 
Having demonstrated that a reproducible expansion of HPC may be seen upon 
exposure to the CDE diet, I then asked whether return to a normal diet would result in 
reversal of liver injury and resolution of HPC expansion.  Age, weight and sex matched 
mice were then exposed to 12 days of the CDE diet followed by return to normal chow 
and drinking water for a varying period of time prior to tissue analysis.  Surprisingly 
rapid resolution of hepatocellular injury is observed within 3 days with a loss of steatosis 
(Figure 3.6).  Furthermore identification of HPC reveals a remarkably rapid loss of HPC 
expansion with complete reversal seen within 1 day or return to a normal diet (Figure 
3.6B).  Consistent with a resolution of injury serum Alt levels fall back to baseline by 3 
days recovery (Figure 3.6C).  Serum Alkaline Phosphatase however remains elevated for 
greater than 1 week following CDE diet cessation (Figure 3.6D). 
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Figure 3.6 Resolution of injury and loss of HPCs following CDE diet reversal 
 
Following 12 days of CDE diet, mice were returned to normal chow to investigate the resolution 
of injury and HPC expansion following CDE diet cessation.  (A) Histologically there is 
resolution of steatosis within three days of return to a normal diet and panCK
+
 HPCs are quickly 
lost.  (B) Quantification of HPC numbers demonstrates their return to normal within 1 day of 
return to normal diet.  Serum Alt also returns to normal (C), however resolution of raised Alk 
Phos is considerably slower (D).  Each mouse group n3.  All scale bars denote 50m. 
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3.5 DDC diet establishment 
 
A further model discussed previously which has gained increasing use over the last 
decade is the DDC diet (see Section 1.32).  To test this method of HPC activation, 
normal chow containing 0.1% DDC was fed to C57Bl/6 mice for up to 2 weeks.  During 
this period universal weight loss of between 3-30% was observed together with clinical 
side effects requiring humane euthanasia of the experimental cohort.  Subsequent work 
performed using the 0.1% DDC was performed with S129 mice and whilst resulting in 
weight loss did not lead to adverse side effects nor the requirement for humane 
euthanasia.  Analysis of livers taken following 6-18 days of the DDC diet revealed a 







 (Figure 3.7).   
 
3.6 Paracetamol overdose model 
 
Paracetamol is a frequent modality of fulminant hepatic failure in humans and has also 
been used in a variety of animal models of acute liver injury.  HPCs have been described 
in human paracetamol overdose and also in a murine model of liver injury (Kofman et 
al., 2005).  Mice injured with varying doses of paracetamol (courtesy of Dr N 
Henderson and Dr K Simpson) were assessed for HPC activation.  
Immunohistochemical staining for HPCs using panCK revealed no significant HPC 
activation even in lethal doses of paracetamol in this model (Figure 3.8).  Resolution of 
injury with near complete restoration of liver architecture is achieved in 1 week post 
paracetamol administration.   
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Figure 3.7 HPC expansion in the DDC diet  
 
 
Following exposure to the DDC diet for upto 18 days, an expansion of biliary ducts is noted on 
H&E (A).  Cells on the luminal surface of these ducts express the HPC markers panCK (B), 
EpCAM and Dlk1 (C).  All scale bars denote 50m. 
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Figure 3.8 HPC expansion in paracetamol toxicity model 
Inbred S129 were administered 350mg/kg paracetamol via i.p. injection.  Immunohistochemistry 
for panCK in livers over time following paracetamol administration reveals no significant 
periportal panCK
+
 HPC activation in this model despite overt liver injury particularly in zone 3 
(Arrows).  Onset of injury begins at approximately 1 day after paracetamol administration with 
peak hepatocellular injury at 5 days following by gradual resolution by day 7.  Insets highlight 
high power images of areas of liver injury (bottom left) and the portal tract (top right) where an 
absence of panCK
+
 HPCs is observed throughout injury and recovery.   
 
3.7 Characterisation of the composition of the HPC niche 
 
3.71 HPC activation in human liver disease 
 
Having therefore established a number of models in which to study HPC biology, I 
wanted to address the question of whether a stereotypical niche existed around HPCs in 
these models and whether this was consistent not only with other rodent models but also 
and most importantly to human disease.   
 
I therefore sought to examine a variety of human liver specimens taken either at 
protocol biopsy or at explant of the liver during liver transplantation.  In the example of 
Hepatitis C Virus (HCV) infection, a profound HPC expansion was observed (Figure 
3.9).  Here, HPC cords are identified extending from the portal tract into the hepatic 
parenchyma analogous to those seen in the murine CDE (Figure 3.4) and DDC diets 
(Figure 3.7).   
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3.72 Identification of a stereotypical HPC niche composed of 
myofibroblasts, macrophages and endothelial cells  
 
I therefore set out to investigate whether myofibroblasts, macrophages and endothelial 
cells are seen in colocalisation with HPCs in the various models described above.  These 
cellular associations, observed in these models, were compared to alternative rodent 
models of HPC activation (both rat and mouse). These were also compared to examples 
of human chronic liver disease in order to assess the stereotypical nature of this 
environment between these different examples of liver regeneration.   
 




 HPC expansion also known as ductular reaction observed in a patient with 
recurrent HCV infection following cadaveric transplantation.  Pre-perfusion biopsy taken of the 
donor liver prior to surgical implantation and HCV infection with normal bile duct expression of 
CK7.  Biopsies of the same liver at 1 and 4 and 7 months respectively post transplantation show 
marked and progressive expansion of HPC cords extending from the portal tract into the liver 
parenchyma.   
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3.72A Myofibroblasts in the HPC niche 
 
In the normal liver tissue from healthy humans and uninjured rats and mice no 
expansion of HPCs is observed and while myofibroblasts are present, particularly in 
association with the vasculature, there is no apparent association between any HPC and 
myofibroblasts (Figure 3.10A-C).  Upon HPC activation in the various models or human 
disease, a close association between myofibroblasts and HPCs is observed in each 
model, including the murine CDE and DDC dietary models developed as part of work 
presented earlier in this chapter (Figure 3.10D-H).  It is striking how many of the HPCs 
are in direct contact with myofibroblasts which in many instances form a near 
continuous lining to the HPC cords.   
 
3.72B Macrophages in the HPC niche 
 
In healthy liver, hepatic macrophages are scattered throughout the parenchyma.  Once 
again in this instance there is no discernable association between these cells and bile 
ducts or HPCs (Figure 3.11A-C).  In contrast, in each species and model examined, upon 
HPC activation macrophages are seen in close proximity to HPCs. In most cases 
macrophages frequently make direct contact with HPCs (Figure 3.11D-G).   
 
Given the close association observed between both myofibroblasts and macrophages to 
HPCs I set out to investigate the relationship of these two cell populations to one 
another.  In murine models a close association is observed between the macrophages and 
myofibroblasts (Figure 3.12).  This association between myofibroblasts and 
macrophages is also observed in the context of HPC activation during human liver 
disease.  When examination of macrophages and myofibroblasts was performed on 
serial 3μm sections taken either side of a section stained for HPCs, this close association 
is observed between all three cellular populations with a tendency of each to associate 
with each other (Figure 3.13).  This frequent association of all three cell populations was 
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however by no means exclusive and areas were easily identifiable where any two of the 
three populations was in close association at the exclusion of the other. 
 
Following the observation that macrophages are found in the HPC niche over time in 
the CDE diet, I sought to examine whether a corresponding increase in hepatic 
macrophages is observed in the whole liver over this period.  Unexpectedly 
quantification of total hepatic macrophages during HPC expansion in the CDE diet 
revealed a significant reduction in the number of hepatic macrophages over the period of 
HPC expansion in this model (Figure 3.11C).  Further examination of the sections 
reveals the explanation for the apparently discordant results with a relative paucity of 
hepatic macrophages in zone 2 of the liver during HPC expansion compensating for the 
accumulation of macrophages observed in the periportal area (Figure 3.11B).   
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Figure 3.10 Myofibroblast association with activated HPCs  
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Identification of myofibroblasts using αSMA immunohistochemistry.  (A) In normal control 
liver from rat, mouse and human (pre-perfusion biopsy from donor without liver disease) only 
small numbers of myofibroblasts are seen in periportal areas but no identifiable association with 
HPCs (red).  In contrast in each species, upon injury and during HPC induction, intimate contact 
between HPCs and myofibroblasts is observed (HPC are identified by CK19, panCK and CK7 in 
rat, mouse and human respectively; Staining performed by Dr S Lorenzini; rat day 9 following 
PH in 2AAF/PH model, mouse HBsAg-tg/retrorsine model, human HCV related cirrhosis.  (B) 
In the CDE diet there is again portal expansion of myofibroblasts.  (C) Quantification of niche 
myofibroblasts in the CDE diet reveals a significant increase in the number of myofibroblasts in 
contact with HPCs per field (n=5 each group, p value denotes Mann Whitney test).  (D) 
Comparison between the spatial localisation of myofibroblasts in CDE diet and DDC diet to 
normal control reveals that myofibroblasts contact panCK
+
 HPC in the CDE model but a thicker 
layer of myofibroblasts surround panCK
+
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Figure 3.11 Macrophage association with activated HPC 
Chapter 3-Establishment and characterisation of in house HPC induction models 
 124 
Identification of macrophages using immunohistochemistry (mouse-F4/80, rat-ED1, and human-
CD68).  (A) In normal control liver from rat, mouse and human (preperfusion biopsy from donor 
without liver disease) only small numbers of macrophages (brown) are seen in scattered within 
the periportal area with no identifiable association with HPCs (red).  In contrast in each species, 
upon injury and during HPC induction, intimate contact between HPCs and myofibroblasts is 
observed.  HPC are identified by CK19, panCK and CK7 in rat, mouse and human respectively; 
Staining performed by Dr S Lorenzini (rat day 9 following PH in 2AAF/PH model, mouse 
HBsAg-tg/retrorsine model, HCV related cirrhosis).  (B) In the CDE diet models macrophages 
are seen in close proximity to HPC in the periportal region.  (C) Quantification of total hepatic 
macrophages over time in the CDE diet.  Results are expressed as mean numbers of cells per 





 HPC reveals their close association in the CDE and DDC diets but not 
uninjured control.  (E) Confocal microscopy reveals contact between macrophages and HPCs in 
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Figure 3.12 Association between macrophages and myofibroblasts in murine 
HPC models 
Dual immunohistochemistry for myofibroblasts (SMA;red) and macrophages (F4/80;green) in 
the CDE and DDC dietary models of HPC activation in the mouse (12 and 18 days respectively).  
All scale bars denote 50m.   
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Figure 3.13 Association between macrophages, myofibroblasts and HPCs in 
human disease 
 
Examination of serial sections from a 6 month biopsy of a patient with aggressive post-transplant 
recurrent HCV infection reveal the intimate co-localisation of HPCs (A; CK7), macrophages (B; 
CD68) and myofibroblasts (C; SMA) at low power and high power (D, E and F respectively) .  
Sections were aligned using a series of architectural structures included the bile ducts (arrow).  
(G) False colouring of HPCs (red) macrophages (yellow) and myofibroblasts (green) revealed 
the association of all three cell types in relation to expanding HPCs. 
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3.73 Laminin is universally present in the HPC niche 
 
In addition to examination of the cellular component of the HPC niche, I also wished 
to examine the role of specialised extracellular matrix components within the niche.  
Laminins, as previously discussed, are ECM components which are not only described 
to play a crucial role in stem cell biology (Domogatskaya et al., 2008) but are also 
described in certain rodent HPC models to be localised with HPCs (Paku et al., 2001).  
Given the striking findings described by Paku et al. of a near complete laminin sheath 
around the HPCs in the PH/AAF model, I wished to exam whether a similar relationship 
is observed in the CDE diet.  Using immunohistochemistry this strikingly consistent 
association of laminin and HPCs is preserved in the CDE diet (Figure 3.14).  Further 
examination in other models also demonstrated consistent association across models and 






3.8 Discussion  
 
The activation of HPCs has been described in previous work by many groups in a 
variety of human diseases and animal models (Roskams et al., 2003b; Alison et al., 
1996; Arends et al., 2009; Preisegger et al., 1999).  In order to examine the relationship 
of HPCs to candidate cells within the stem cell niche I first examined the HPC response 
in a variety of models and compared this to the HPC reaction observed in human 
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Figure 3.14 Laminin associates with and encases activated HPCs 
Identification of laminin by immunohistochemistry.  (A) In normal control liver from rat, mouse 
and human (pre-perfusion biopsy from donor without liver disease) laminin is observed 
particularly associated with the vessels in the periportal tract.  During HPC induction laminin 
extends from the portal tract and surrounds cells with an HPC morphology.  Staining performed 
by Dr S Lorenzini.  Injury models and disease: rat day 9 following PH in 2AAF/PH model, 
mouse HBsAg-tg/retrorsine model, HCV related cirrhosis.  (B) In the CDE diet model a 
progressive expansion of laminin is observed from the portal tracts mirroring the expansion of 
HPCs.  (C) Dual immunohistochemistry for panCK
+
 HPCs and laminin in the HBsAg/retrorsine 
and CDE diet models reveals intimate association between the two in both murine injury models.  
All scale bars denote 50m.   
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3.81 HPCs in normal mammals 
 
An important initial consideration with regard to the examination HPCs in all studies 
is the accurate identification of these cells.  As previously discussed (Chapter 1) many 
markers have been identified in numerous models.  It is important to note that while 
many „stem cell like‟ attributes have been ascribed to individual (and often impure) 
populations based on these markers, no current consensus regarding HPC markers exists 
with many studies using a 'strength in depth' approach by examining multiple markers 
(Jelnes et al., 2007; Wang et al., 2003a).  In this work I have principally used panCK as 
a marker of HPCs on the basis of historical acceptance of this marker (Kofman et al., 
2005).  In this work I demonstrate that, in the widely used CDE diet, that there is a 
numerical expansion of panCK
+
 HPCs and that this population is actively expanding in 
vivo rather than arising through a dedifferentiation event. 
 
A complicating factor for the identification of HPCs, using any of the currently 
ascribed HPC markers, is the issue of concurrent identification of cholangiocytes.  When 
immunohistochemical analysis is used, this only represents a modest problem, as 
intralobular or larger bile ducts are easily identifiable by eye.  However when examining 
cells by immunocytochemical methods, the contamination of the HPC population by 
cholangiocytes becomes a significant problem which may interfere dramatically with the 
interpretation of results.  Accordingly I have used immunohistochemistry as the 
cornerstone of identification of HPCs in this work and when HPCs are quantified the 
methodology has been designed to minimise this problem of false positive 
cholangiocytes.  Additionally in this study examination of HPC with multiple markers 
was performed in each model to validate the identity of HPCs as accurately as possible.   
 
This work has confirmed the presence of the EpCAM and panCK as HPC markers in 
the mouse but also is to my knowledge the first description of reproducible Dlk1 
immunohistochemistry in murine HPC models.  My work has also shown that these 
markers to not identify identical populations and while some cells simultaneously 
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 populations.   
 
While very little evidence is seen of any HPCs in young adult mice, it is interesting to 
note the reproducible and consistent expansion of HPCs which occurs as mice age.  This 
observation is the first report of this effect.  It is well described that the regenerative 
capacity of most organs including the liver is impaired with increasing age (Kirkwood, 
2005).  In the liver, specifically in the context of partial hepatectomy, regeneration is 
impaired (Timchenko et al., 1998) and this process appears to be mediated through 
inhibition of c-Myc by C/EBP in elderly mice (Iakova et al., 2003).  It is not known 
whether similar changes in C/EBP occur with age in the HPC population; however it is 
likely that a reduction in hepatocyte turnover related to such inhibition may be a 
stimulus for HPC expansion in elderly mice even in the absence of specific injury.   
 
3.82 Optimisation of the CDE diet for use as a model of HPC activation 
 
Optimisation of the CDE diet aimed to generate a dietary model which reproducibly 
activates HPCs but does not result in the intolerable morbidity or mortality as observed 
using higher concentrations of ethionine (>0.15%).  Initially, it was necessary to 
optimise the CDE diet due to considerable weight loss and even unexpected mortality in 
male mice on the original CDE diet (with 0.165% ethionine).  The reason the apparent 
discrepancy between the morbidity/mortality observed in our unit versus that of other 
units worldwide remains unclear.  Certainly many other investigators use this higher 
concentration of ethionine in C57Bl6 male mice, even without the additional benefits of 
sweetened water, and yet do not report the toxicity I have observed in this work.  The 
most probable explanation for this discrepancy is variability between strains of C57Bl6 
mice although I cannot rule out alterations between preparations of the CDE diet; 
although the supplier remained consistent between ourselves and other research groups. 
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The demonstration here of a failure for ethionine to expand HPCs over 2 weeks at 
concentrations up to 0.15% demonstrates the necessity of inclusion of ethionine to 
choline deficiency in order to stimulate HPCs and is in keeping with a report in rats 
when the CDE diet was initially developed; even over a ten week period (Shinozuka et 
al., 1978).   
 
The rapid weight loss seen in the initial trial of the CDE diet (0.165% ethionine) was 
presumed to be principally due to poor oral intake of water due, the dramatic weight loss 
and apparent dehydration of the experimental animals.  Reduced oral intake may have 
also played a role.  Whilst large daily weight fluctuation are not seen in larger mammals, 
small animals are required to eat a much larger proportion of their body weight per day.  
In my experience a 25g C57Bl6 mouse will eat approximately 3.5g of chow per day.  
This therefore raises the possibility of poor intake of food played a significant part in 
animal weight loss and morbidity.  None-the-less the attenuation of weight loss with 
reducing ethionine concentration implies that higher doses of ethionine are the principle 
factor causing the observed side effects.   
 
Consistently upon commencing the CDE diet, the greatest predicting factor for 
development of clinical side effects or mortality was significant weight loss (>20%).  In 
no instance did mice die or develop clinical signs (hunching, pilo-erection, or social 
withdrawal) in the absence of >20% weight loss.  As a result changes were instituted to 
the Animal Project License permitting weight loss >20% in the absence of clinical signs, 
provided that twice daily assessment revealed no clinical deterioration and that mouse 
weight improved to <20% loss within 72 hours.  If at any time mouse weight fell below 
>30% mice were euthanised. 
 
As a result of optimisation of the CDE diet the working concentration of ethionine was 
reduced from the frequently published 0.165% to 0.15%.  In addition water was 
sweetened with orange squash which was demonstrated to improve animal oral intake.  
Following these changes, consistent HPC activation was achieved in combination with 
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hepatocellular injury.  These changes along with the infiltrating morphology of HPC 
migration was analogous to that previously reported with the CDE diet (Akhurst et al., 
2001). 
 
Measurement of oral intake in mice is for many reasons fraught with difficulty making 
such analysis difficult.  Intake is measured on the basis of reduced weight in cage bottles 
and thus reflects cage rather than individual mouse use.  Furthermore losses from bottles 
during cage handling make this inaccurate although attention was paid to monitor each 
cage identically to minimise any cage/cage variation in these measurements.   
 
Due to the addition of orange squash it is not possible to guarantee complete choline 
deficiency was achieved.  Unfortunately no data was available regarding choline content 
of this. Nonetheless choline is typically found in oranges although only at 2mg/100g and 
therefore the choline content in added artificial orange squash is likely to be negligible 
(typically 1g/day; recommended daily amount approximately 100g/day; Zeisel and 
Blusztajn, 1994).  As previously discussed, the addition of ethionine in rodents results in 
only very minimal HPC expansion (Shinozuka et al., 1978).  Therefore the HPC 
expansion in our CDE diet model is consistent with functional choline deficiency.   
  
3.83 HPC and niche characterisation in the CDE diet 
 
Having characterised the limited toxicity and HPC response to fully choline deficient 
chow in combination with 0.15% ethionine, this diet was used to investigate a variety of 
features of HPC activation in the mouse.  This optimised diet did not result in any 
unexpected mortality and only a very small number of mice (<1%) required euthanasia 
due to poor clinical status.   
 
Examination of the HPC response in the CDE diet demonstrates an expansion of HPCs 
identified by either panCK, Dlk1 or EpCAM.  The panCK population actively expands 
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by proliferation in response to the CDE diet.  The mode of action of the CDE remains 
uncharacterised, however in line with previous studies, HPCs in the CDE diet expand 
alongside widespread liver injury as demonstrated by raised serum transaminases, 
histological evidence of damage and widespread hepatocyte apoptosis (Figures 3.3 and 
3.4; Knight et al., 2005a).  Additionally, when mice are individually analysed there is a 
strong correlation between the degree of liver injury and HPC activation; again 
supporting the role of HPC mediated regeneration in injury (Figure 3.4).  Other reports 
using alternative analyses have demonstrated links between severity of injury and degree 
of HPC activation in humans disease (Libbrecht et al., 2000; Lowes et al., 1999; 
Roskams et al., 2003a).   
 
The recovery from withdrawal of the CDE diet and return to normal diet in this work 
is striking.  Previous observations in this field have looked over longer periods (>7 days 
recover) and have shown resolution of HPC response and serum transaminases (Knight 
et al., 2005a).  In this report, the authors conclude that the disappearance of HPCs 
together with a lack of HPC apoptosis is evidence for differentiation into parenchyma.  
The rapidity with which both fall has, to date, not previously been reported.  Additional 
examination during in the immediate time following CDE diet withdrawal may provide 
further insight into whether early HPC apoptosis occurs.  Furthermore whether HPCs 
number reduction is due to differentiation into hepatocytes could be investigated during 
this time using lineage tracing, either with transgenic reporter activation or more crudely 
through BrdU pulse-chase labelling.  Initial study in this area in this work using BrdU 
administered at day 9 to mice during the CDE diet followed by examination 3 days later 
showed many BrdU labelled hepatocytes are observed in periportal regions (Figure 
3.5F).  However as hepatocytes are also labelled during the BrdU pulse no definitive 
statement linking HPCs and the periportal BrdU
+
 hepatocytes observed at day 12 may be 
made from this work at this time.   
 
Examination of archival tissue from mice treated with paracetamol was performed 
given the recent description of marked panCK
+
 HPC expansion in this model (Kofman 
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et al., 2005).  I was unable to reproduce this effect.  I believe this contrast between my 
findings and those published by Kofman et al. are due to the lower doses of paracetamol 
administered in our study (350mg/g vs. ≤1000mg/g).  The use of 350mg/g still resulted 
in severe hepatocellular injury and even a mortality rate of approximately 20%.  For this 
reason further experimentation with higher doses of paracetamol was not performed.   
 
An interesting observation to come to light from the examination of the tissue from 
paracetamol treated mice is the presence of a number of intermediate-like small 
hepatocytes observed at the front of hepatocellular necrosis during injury.  These cells 
often express high levels of panCK.  There are however geographically distinct from the 
portal tract and there is no expansion of panCK
+
 HPC connecting the two regions.  For 
this reason, I believe that panCK expression is seen in injured hepatocytes and therefore 
panCK expression alone is not a definitive marker of an HPC.  Again the methodology 
of HPC identification in this work has been developed to exclude such false 
identification.   
 
3.84 Characterisation of the cellular HPC niche 
 
While a large literature exists regarding HPC biology there is little data regarding their 
surrounding environment which is likely to act as a niche and therefore strongly 
influence HPC behaviour.  The work presented in this chapter describes the systematic 
examination of HPC reactions in multiple rodent models and human liver disease.  Here 
I demonstrate that HPCs are closely accompanied by a cellular niche composed of 
myofibroblasts, and macrophages throughout the progenitor cell response.  These 
associations remain consistent throughout a range of diverse rodent models and human 
disease.  The description of HPCs with mesenchymal cells expressing desmin or 
vimentin has been previously reported (Paku et al., 2001).  Myofibroblasts are known to 
express these intermediate filaments, and therefore the work presented here regarding 
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niche myofibroblasts contributes to this previous work by describing their mesenchymal 
phenotype.   
 
The work presented up to this point demonstrates the association of macrophages, and 
myofibroblasts with HPCs but clearly does not address the functional importance of 
these cells.  Nevertheless the consistence of this stereotypical niche implies that its 
formation is not a random event and argues for a functional role of these cells.  The 
exact role of these progenitor-associated macrophages and myofibroblasts is unknown. 
However, it is tempting to speculate that these NPCs may act as a link between tissue 
injury and progenitor cell activation.  Indeed, hepatic macrophages and myofibroblasts 
can express a variety of signals critical for controlling liver development and hepatic 
stem/progenitor cell behaviour (Bird et al., 2008).  Recent inhibition of myofibroblast 
activation in the PH/AAF model has implied a functional role of the niche 
myofibroblasts promoting HPC activation (Pintilie et al., 2010).  In addition, 
myofibroblasts make and macrophages remodel ECM and therefore these cells may be 
necessary for the extension and resolution of the HPC response through effects on the 
stereotypical basement membrane observed with HPC activation (Duffield et al., 2005; 
Fallowfield et al., 2007; Henderson and Iredale, 2007).   
 
In addition, or as an alternative, to the niche provide signalling to the HPCs there may 
also be reciprocal passage of signals from the HPCs to the niche cells.  It is possible that 
the profound activation of HPCs in diseases such as fibrosing cholestatic hepatitis may 
account for the local activation of myofibroblasts and macrophages and thus provide a 
link between the dramatic HPC activation and the rapidity and severity of hepatic 
fibrosis observed in this condition.  This hypothesis would require further examination 
to establish a direct and causative link between HPC activation and fibrosis. 
 
The work presented here, has focused on the role of the intrahepatic macrophages 
(including Kupffer cells).  The monocyte-macrophage lineage is a complex and 
heterogeneous population and is characterised by expression of a variety of cellular 
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markers.  I chose the accepted macrophage/Kupffer cell marker F4/80 to identify 
macrophages/Kupffer cells in this system.  The F4/80
+
 antigen (which is also recognised 
by the BM8 monoclonal antibody) is observed on all known macrophage populations 
,including Kupffer cells (Hashimoto et al., 1996) and bronchoalveolar macrophages; and 
is absent from any cell types that are definitely not mononuclear phagocytes (Hume et 
al., 1984).  F4/80 is a member of the EGF seven transmembrane-spanning family of 
hormone receptors, little is currently known regarding its ligands and biological function 
although it appears to play a role in the generation of efferent CD8
+
 regulatory T cells 
(van den Berg and Kraal, 2005).  F4/80 is not crucial to macrophage formation as 
demonstrated by the development of macrophages in the absence of F4/80 in transgenic 
studies (Schaller et al., 2002).   
 
The observation that macrophages associate with HPCs in injury models is particularly 
intriguing.  Work in the field of hepatocyte mediated regeneration has demonstrated 
many roles for macrophages in the regenerative process, particularly the production of 
multiple stimulatory cytokines such as TNF and IL6 (Fausto et al., 2006).  None-the-less 
depletion of macrophages in such models has shown varying effects depending on the 
model system investigated.  In either the normal liver or following partial hepatectomy 
in the rat, depletion of macrophages results increased hepatocyte proliferation (Boulton 
et al., 1998).  However, in other studies depletion by the same method resulted in 
delayed regeneration following partial hepatectomy (Takeishi et al., 1999).  The 
conflicts in these results are likely to lie in differences in the depletion protocols used.  
However the observation that constitutively macrophage deplete mice display impaired 
liver regeneration compared to wild type mice suggests a stimulatory role for 
macrophages in hepatocyte regeneration.  This observation therefore supports a role for 
macrophages in hepatocyte mediated liver regeneration (Amemiya et al., 2009).  It is 
likely that macrophages may not simply play a stimulatory role but may be capable of 
both up and down regulation of hepatocyte mediated regeneration, possibly depending 
on different stimuli, and the presence or absence of different macrophage subsets.   
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A particularly important question relating to the observations reported in this work is 
why macrophages fail to associate with HPCs in the DDC model and does this lack of 
association result in alteration of HPC behaviour? The failure of macrophages to 
associate may be an active process which blocks their association, such as the exclusion 
of macrophages by another cell population which fails to grant entry of macrophages to 
the newly formed HPCs.  Alternatively macrophage homing to HPCs which appears to 
be an active process in other model may be inhibited in some fashion, whether this may 
occur by a failure of production of chemotactic ligands or the absence of chemotactic 
receptors or inhibition of their downstream signalling a very interesting potential 
question for the future.   
 
It is possible that macrophage chemotaxis is at least in part mediated by the 
CXCR4/SDF-1 axis, itself implicated in HPC function (see Chapter 1).  SDF-1 is known 
to be produced in the periportal area and appears to play a role in guiding CXCR4
+
 cells 
to this area (Kollet et al., 2003).  SDF is known to be upregulated following liver injury 
(Terada et al., 2003).  Macrophages which are well characterised to express CXCR4 and 
may in part be attracted to HPCs by this axis.   
 
Similarly an important question, which is not fully addressed by this work, is what is 
the nature of the cells which lie between the macrophages and the HPCs in the DDC 
model and do they differ in identity or function to the cells of the HPC niche in other 
models where macrophages contact HPCs? Certainly a large proportion of cells 
sandwiched between the macrophages and the HPCs in the DDC model are 
myofibroblasts (Figure 3.10G) as they lie in direct juxtaposition to the HPCs.  Further 
characterisation of this model is required to assess whether these are the only cells in this 
layer or indeed whether they are functionally analogous to the myofibroblasts seen in the 
niche in other models where macrophages penetrate this layer. 
 
While in this study I have investigated the associations of macrophages, 
myofibroblasts and HPCs, other cell populations may occur in association with HPCs.  
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Work by Dr Stefania Lorenzini in collaboration with this work has shown that both B 
and T lymphocytes are also found in association with HPCs (Lorenzini et al., 2010), and 
is in keeping with the previous description of expansion of lymphocytes in the CDE diet 
(Knight et al., 2005a).  This work is further supported by the observations of others that 
lymphocytes and in NK cells may play an influential role in manipulating HPC biology 
in vivo (Strick-Marchand et al., 2008).   
 
The association of laminin with HPCs has been previously reported in the rat AAF/PH 
model (Paku et al., 2001).  Detailed confocal analysis in this study demonstrated the 
appearance of a laminin rich basement membrane encasing cytokeratin
+ 
HPCs.  Whilst 
this membrane surrounded these cells, small holes were present in the membrane 
through which the HPCs make contact with non-parenchymal cells, which themsleves 
typically were desmin
+
.  The work presented here in the rat is consistent with the 
laminin encasement of HPCs in the rat PH/AAF model, but extends this observation to 
other murine models and human disease.  A recent publication has also corroborated this 
work and has implied, although not definitely shown, that the expansion of laminin in 
the CDE diet model precedes the expansion of HPCs (Van Hul et al., 2009).  This report 
is consistent with work presented here, and also from others in the Forbes Group, which 
demonstrates a beneficial effect of laminin in maintaining a dedifferentiated state in 
HPCs in vitro (Lorenzini et al., 2010). 
 
 




In summary this work has established and characterised local model of mouse HPC 
activation and compared them to archival tissue from human disease and other rodent 
models of HPC activation.  I show that the CDE and DDC dietary models reproducibly 
activate HPCs and do so with alternative phenotypes; the CDE with invasive cord-like 
structures, while the DDC does so with a periportal ductular expansion.   
 
Upon characterising these models, there is a consistent association of myofibroblasts 
and laminin in direct contact with HPCs.  While macrophages are in most instances 
found in direct contact with HPCs they are closely associated but excluded from direct 
contact in the ductular DDC model of HPC activation.   
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 The macrophages and myofibroblasts in the HPC niche are in part derived from 





Having demonstrated that the cellular niche is stereotyped across a wide variety of 
species, diseases and animal models, I sought to answer the question of how this niche 
forms.  To do this I aimed to: 
 
 Examine the intrahepatic proliferation of cells of the HPC niche 
 
 Examine the recruitment of BM derived cells to the HPC niche  
 
 
4.3 Proliferation of niche cells during HPC activation 
 
Having previously demonstrated reproducible HPC activation using the CDE diet I 
sought to investigate whether there was evidence of in-situ proliferation of the niche 
components.  Previous work in this study has demonstrated that a large number of cells 
associated with the panCK
+
 HPCs are proliferating (Ki-67
+
) in-situ (Figure 3.5).  
Utilising the benefits of EdU as a nucleoside analogue, in that it can be used with 
minimal antigen retrieval unlike BrdU or other markers of proliferation such as MCM2 
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or Ki-67, I investigated whether there was any evidence of proliferation of 
myofibroblasts and macrophages during CDE diet induced HPC activation by delivering 
EdU during the early phase of HPC expansion.  Along with proliferation of HPCs 
proliferation of intrahepatic myofibroblasts and macrophages was observed (Figure 4.1).  
In a small proportion of instances these proliferating cells appeared to be in contact with 
cells morphologically compatible with HPCs.  Therefore, there appears to be a role for 
active expansion of the HPC niche along with expansion of HPCs themselves.   
 
 
Figure 4.1 In situ proliferation of macrophages and myofibroblasts 
 
Mice were fed the CDE diet to induce liver injury and regeneration resulting in expansion of 
panCK
+
 HPCs.  Labeling of proliferating cells was assessed by administering EdU 2 hours prior 
to tissue harvest at 3 days.  Colocalisation of cellular markers PanCK (A), SMA (B) and F4/80 
(C) was performed along with EdU detection showing active proliferation within each of these 
cell populations.  All scale bars denote 50m.   
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4.4 Cell tracking demonstrates macrophage recruitment to the HPC 
niche 
 
As the BM is a source of both macrophages and hepatic myofibroblasts I chose to use 
a sex-mismatched BM transplantation model as a method of tracking the contribution of 
the BM to the HPC niche.  The transplantation of BM in mice is well established and 
relies on the ablation of endogenous haematopoietic stem cells by a lethal dose of 
irradiation.  An infusion of donor derived cells including haematopoietic stem cells is 
then delivered, and these donor derived cells are then able to engraft within the BM and 
reconstitute the haematopoietic system.  This therefore affords the possibility of using 
antigens or markers in the donor haematopoietic stem cells which are not present in the 
recipient as a method of tracking BM derived cells from the point of haematopoietic 
reconstitution.  The methodology I employed used whole BM from inbred C57Bl6 male 
mice to reconstitute inbred female C57Bl6 mice.  Therefore the only antigenic difference 
between donor and recipient is the presence of the Y chromosome and its associated 
proteins.  Following a period of recovery sex-mismatched BM transplanted mice were 
given either the CDE diet or control diet (Figure 4.2).  Efficacy of reconstitution was 
assessed by examining the spleen of transplanted animals to ensure repopulation with 
male derived BM by using fluorescence in-situ hybridisation (FISH) directed again the 
Y-chromosome.   
 
Examination of livers from mice following the CDE diet once again demonstrated 
expansion of HPCs.  Using dual analysis of HPCs and BM derived cells it is apparent 
that HPCs themselves are not BM derived.  No convincing evidence of a BM derived 
panCK
+
 HPC was observed in any of the mice at confocal microscopy (Figure 4.3).  It is 
also apparent from these images that a large number of BM derived cells have been 
recruited to lie around the HPCs (Figure 4.3 arrows).   
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Figure 4.2 Scheme of bone marrow cell tracking and HPC activation 
Following BM transplantation with male BM and a period of recovery HPCs were induced in 
female mice using the 50% CDE diet (A).  To assess the degree of reconstitution the spleen was 
assessed in each animal to confirm repopulation with cells possessing the Y chromosome by 
FISH and confocal microscopy (B).  To assess specificity of Y chromosome detection male and 
female mice which had not undergone BM transplantation were assessed in each instance.  
Representative Y chromosome analysis by confocal microscopy using FISH (FITC) combined 
with immunohistochemistry for panCK (Vector Red) in female (C) and male (D) controls 
demonstrates that intrahepatic cells are either Y chromosome negative or positive respectively.  
Scale bars denote 50m.   
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Figure 4.3 HPC associated niche cells are frequently BM derived 
Dual analysis of panCK+ HPCs by immunofluorescence (Vector Red, red) and Y-chromosome
+
 
BM derived cells by FISH (FITC, green).  Arrows mark BM derived cells lying in direct contact 
with panCK
+




Having demonstrated that BM derived cells are recruited to the stem cell niche I then 
sought to identify the nature of these cells.  To do this candidate BM derived cell 
populations were analysed along with FISH for the Y-chromosome.  The majority of 
intrahepatic macrophages were identified as BM derived following 2 weeks of CDE diet 
(Figure 4.4A).  Smaller numbers of myofibroblast were BM derived (Figure 4.4B), 
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while hepatic stellate cells were not (Figure 4.4C).  A significant number of intrahepatic 
endothelial cells were BM derived; particularly those within the hepatic parenchyma 
(Figure 4.4D). 
 
The identity of the BM derived niche component identified previously was examined 
using analysis of serial sections for the markers of non-parenchymal cell populations in 
combination with identification of HPCs and BM derived cells.  In all instances BM 
derived macrophages could be identified in contact with panCK
+
 HPCs, however there 
was no evidence of BM derived myofibroblasts, hepatic stellate cells, or endothelia in 
direct contact with HPCs (Figure 4.5).  Therefore macrophages are actively recruited to 




As previously highlighted, the reproducible expansion of a stereotypical HPC niche is 
observed in a variety of rodent models in addition to human disease.  This niche, 
consisting of macrophages and myofibroblasts, is not apparent in the healthy liver tissue, 
but instead appears to form synchronously along with HPC expansion.  While each of 
these cell populations is present within the healthy liver and therefore may migrate into 
juxtaposition with expanding HPCs during regeneration it is apparent that a large 
proportion of HPC niche cells are actively proliferating in-situ (Figure 3.5).  Certainly 
both cell populations in question are capable of intrahepatic proliferation and moreover 
appear to do so within the HPC niche (Figure 4.1).  These observations are in 
accordance with published studies in other disease models demonstrating active 
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Figure 4.4 Hepatic myofibroblasts and macrophages may be bone marrow 
derived 
Following BM transplantation and CDE diet induction, (see Figure 4.2), non-parenchymal cell 
populations were investigated for potential BM origin by immunofluorescence and FISH.  (A) 
The majority of F4/80
+
 macrophages are BM derived (arrows) whilst a significant minority 
apparently do not possess a Y chromosome.  (B) Most myofibroblasts (SMA) do not possess a 
Y-chromosome; however a small number, particularly perivascularly, are BM derived (arrow).  
(C) Hepatic stellate cells (GFAP) are not BM derived, nevertheless a significant proportion are 
found to be in direct contact with BM derived cells (arrow).  (D) A minority of endothelial cells 
(vWF) are BM derived (arrow).  All scale bars denote 50m 
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Given also that both macrophages and hepatic myofibroblasts may be BM derived it is 
possible that elements of the HPC niche may be recruited from out with the liver in 
response to injury to form the HPC niche.  In addition to intrahepatic proliferation I also 
find evidence that both populations may be derived from circulating cells which are 
most likely to be BM stem cell derived.  Once again these observations are in line with 
previous BM transplantation studies (Klein et al., 2007; Russo et al., 2006).  This study 
however is performed in a characterised model of HPC activation and therefore is a 
significant addition to our understanding of cellular recruitment in the context of 
intrahepatic stem/progenitor cell activation.   
 
 
Figure 4.5 Niche macrophages are the recruited element in the CDE diet 
(A) and (B) Confocal analysis of serial sections of sex-mismatched mice treated with the CDE 
diet.  Staining with panCK demonstrated closely localised cells positive for GFAP, vWF, F4/80 
and aSMA positive cells.  (B) F4/80 but not GFAP, aSMA, or panCK cells are Y chromosome 
positive.   
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For all assessment of the Y chromosome by FISH confocal microscopy was used in 
order to prevent the false association of chromosomes from one cell with that of an 
overlying nucleus of another.  Using confocal microscopy and thin tissue sections (3m) 
even in untransplanted male mice controls not all nuclei appear to contain a Y 
chromosome due to the three dimensional structure of the nucleus and its two 
dimensional analysis.  For accurate quantification of the numbers of BM derived cells 
previous studies have used a correction factor based on the probability of finding a Y-
chromosome positive cell but failing to identify the Y chromosome in that two 
dimensional plane (Russo et al.., 2006).  Accurate quantification therefore is dependent 
also on the size of the nucleus in question.  In order to track cells to the HPC niche I 
have been interested to observe whether this phenomenon occurs and not necessarily to 
what extent it occurs.  While the identification of a Y-chromosome in any given male 
nucleus is relatively high I would predict that I have failed to identify every single BM 
derived cell in each individual image.  Crucially I have not made attempts to quantify 
the extent to which this occurs, but merely have aimed to use this tool to identify both 
the presence of recruited cells as well as their nature in this study. 
 
Using BM transplantation in this study it was possible to demonstrate that BM derived 
cells are recruited into juxtaposition with HPCs.  It seems logical that this recruitment 
occurs during the period of HPC induction. Although this study does not directly address 
that question, it is possible although unlikely that the recruitment of niche cells and in 
particular macrophages occurred during the period of recovery when haematological 
repopulation had occurred but in the absence of injury.  It seems likely however, that 
macrophages are directly recruited from the circulating pool during injury.  The 
disproportionately high proportion of Y-chromosome negative macrophages seen in the 
liver during injury is testament to the longevity of these cells, as has been observed by 
other studies (Klein et al., 2007).  If the recruitment of intrahepatic macrophages to the 
HPC niche were occuring by stochastic process, a low proportion of niche macrophages 
would be expected to be observed throughout the liver, and yet examples of Y-




 niche macrophages are easily identifiable implying that this is not the 
case.   
 
The observation that panCK
+
 HPCs are not BM derived is consistent with previous 
reports both in the CDE diet (Tonkin et al., 2008) and other models (Wang et al., 
2003a).  As discussed previously HPCs are not believed, in most models, to be derived 
from the BM (Chapter 1).  While some convincing reports using alternative 
methodologies of transplantation have demonstrated BM derived HPCs (Sun et al., 
2009), it is probable that strong immunological pressure towards selection of BM 
derived vs.  transplanted HPCs in such models may be responsible for this phenomenon 
in this model system.  The work presented in this thesis adds to the field, not only as a 
further report that HPCs in the models used in this work are not BM derived, but 
additionally also addresses the question of whether retrorsine or other toxins used in 
previous HPC induction regimes in some way inhibits the generation of HPCs from the 
BM (Vig et al., 2006).  These concerns regarding toxin effects on HPCs were raised 
regarding the discrepancy between the two sets of previous reports. In this work we have 
disproved that the use of such toxins is responsible for the failure to observe BM derived 
HPCs in the murine models such as those by Vig et al.   
 
The demonstration in this thesis that HPCs are intimately surrounded by macrophages 
of BM origin provides a potential link between the BM and the intrahepatic 
stem/progenitor cells during injury, whereby the BM does not directly contribute to 
these cells but may influence their behaviour.  Intriguingly whilst there is localisation 
and recruitment of macrophages to the HPC niche during injury, there is not a 
corresponding increase in hepatic macrophages.  Indeed while macrophages appear to 
localise with HPCs there is a reduction in total hepatic macrophages during CDE diet 
HPC induction (Figure 3.11).  This may be due to emigration or death of other 
parenchymal macrophages in the context of liver injury.  This overall reduction in the 
hepatic macrophage population makes the presence and association of macrophages with 
the HPC niche even more striking.   
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In contrast to previous work in using BM tracking strategies with models of fibrosis in 
which significant numbers of myofibroblasts are noted to be of BM origin (Russo et al., 
2006) only a handful of BM derived myofibroblasts were observed in this study in the 
CDE diet.  While this was the case no instance of BM derived myofibroblasts in direct 
contact with HPCs were observed.  This work is therefore not at odds with the previous 
observations that scar associated myofibroblasts may be BM derived.  Instead it provides 
a potential argument for differential populations of hepatic myofibroblasts within the 
liver with scar associated myofibroblasts being a more mobile population than those 
associated with HPCs.  It is however possible that over the longer term HPC induction 




 HPC niche elements are capable of intrahepatic proliferation during HPC 
activation 
 
 HPCs are not bone marrow derived 
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 As a constituent of the HPC niche, macrophages play a functional role in 




Based on the results of the previous chapter where active recruitment of macrophages 
to positions directly juxtaposed to HPCs during injury was observed, I wished to 
examine the functional effects of macrophages in the niche on HPC activation.  To do 
so, methods of manipulating macrophage function in the liver were used including: 
 
 Depletion of macrophage in vivo during HPC activation 
 
 
 Adoptive transfer of bone marrow and macrophages to healthy liver  
 
 
5.3 Introduction to models of macrophage manipulation 
 
Depletion of macrophages provides an experimental approach to examine their 
functional roles in modulating HPC behaviour.  Currently a number of depletion 
methods are described for macrophages including Liposomal Clodronate, Gadolinium 
Chloride and the DTR transgenic mouse system (Duffield et al., 2005; Lee et al., 2004; 
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Van Rooijen and Sanders, 1996).  These varying depletion techniques have individual 
advantages and disadvantages.  Liposomal clodronate, for example, is a substance that is 
selectively taken up by phagocytes which then die by apoptosis (van Rooijen et al., 
1996).  It acts rapids and specifically and has been used successfully in the past to ablate 
hepatic macrophages/Kupffer cells in both rats (Sturm et al., 2005; Van Rooijen and 
Sanders, 1996) and mice (Rivera et al., 2007; Yamamoto et al., 1996).   
The effect of liposomal clodronate is related to the ingestion of clodronate by 
phagocytes by means of a liposomal vehicle.  Neither clodronate, nor liposomes, are 
themselves toxic.  Free clodronate, as a large molecule will not readily cross cell 
membranes.  As liposomes are actively phagocytosed by macrophages, ingestion of 
liposomes results in uptake of clodronate which, once delivered into phagocytes will not 
escape from the cell.  Therefore clodronate is accumulated intracellularly resulting in 
eventual toxicity and death by apoptosis (van Rooijen et al., 1996). 
 
The CD11b-DTR transgenic mouse system has been used successfully to deplete 
hepatic macrophages also (Duffield et al., 2005).  This system employs the use of a 
human EGF receptor (a relative of F4/80) which is the target for the highly toxic 
diphtheria toxin (DT).  Whilst humans are highly susceptible to DT, normal mice are 
not.  By expressing hEGF receptor under the control of the CD11b promoter, murine 
macrophages express hEGF thus rendering them susceptible to the toxic effects of DT.  
This therefore allows the depletion of CD11b
+
 macrophages resulting in the incomplete 
deletion of hepatic macrophages depletion in a chronic liver injury model (Duffield et 
al., 2005).   
 
Given the variety of options for experimental hepatic macrophage depletion I initially 
set out to test the efficacy of macrophage depletion in the liver by the various methods 
available.   
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To test the CD11b-DTR system transgenic mice and WT controls were exposed to a 
range of DT doses.  Liver analysis by immunohistochemistry for the F4/80 antigen 
revealed only partial depletion 24 hours after toxin administration (Figure 5.1C).  
Furthermore additional analysis revealed significant off-target effects of the transgenic 





 T lymphocytes (Figure 5.1F).   
 
Given the only partial depletion and particularly the non-specific nature of the CD11b-
DTR system I elected to trial liposomal clodronate delivered by i.v. injection.  Analysis 
was performed at 24 to 72 hours post injection in otherwise healthy mice and revealed 
complete hepatic macrophage depletion over this time period (Figure 5.2A and B).  
Depletion of splenic macrophages was also observed over this time period although 
partial recovery was seen within the spleen only at 72 hours (Figure 5.2B).  Having 
demonstrated effective and complete depletion of hepatic macrophages for over 72 hours 
following injection of liposomal clodronate, a trial of repeated dosing was used to assess 
whether ongoing complete hepatic macrophage depletion could be achieved following 
repeated liposomal clodronate administration.  To exclude an improved reconstitution of 
hepatic macrophages following such repeated dosing, liposomal clodronate was given by 
injection every 72 hours.  Tissue analysis was once again performed 72 hours following 
the last dose in this repeated dose strategy.  Using the repeated dosing, ongoing and 
complete depletion of hepatic macrophages was achieved and occurred in the absence of 
clinical side effects (Figure 5.2C). 
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Figure 5.1 Transgenic DTR mouse mediated deletion of hepatic macrophages 
Chapter 5-Macrophages as functional cells within the HPC niche 
 155 
 
The Diphtheria Toxin Receptor (DTR) transgenic mouse construct places the human DTR under 
the CD11b promoter.  (A).  (B) DTR heterozygote mice and wild type controls were assessed 24 
hours following a variety of doses of i.p. DT.  (C) No significant depletion of hepatic F4/80
+
 
macrophages were observed following 24 hours in DTR mice treated with up to 20ng/g DT.  (D) 
No significant variation is seen in peripheral monocyte numbers at baseline between animals, but 
a significant and dose dependent reduction in circulating monocytes is observed 24 hours 
following DT administration.  (E) No significant changes in circulating neutrophil number is 
observed following DT treatment, while reductions of circulating B220
+





 lymphocytes are noted in DT treated animals vs. control (F).  FACS 
analysis performed with the help of Dr Tiina Kipari (p values denote Mann Whitney tests 







To examine the functional role of macrophages in modulating HPCs behaviour an 
experimental protocol combining complete hepatic macrophage depletion with CDE diet 
mediated HPC activation was used over a 12 day period (Figure 5.3A).  Firstly the 
efficacy of macrophage depletion by liposomal clodronate was assessed in this scenario.  
Complete depletion of hepatic macrophages was once again observed when repeated tail 
vein injections of liposomal clodronate were delivered every 72 hours during the CDE 
diet model.  This depletion was seen both at early (Day 6) and late (Day 12) time points, 
each of which were 72 hours after the last liposomal clodronate injection (Figure 5.3B 
and C).  Quantification of macrophages at sacrifice at day 12 reveal exceptionally 
efficient long lasting depletion of macrophages with a mean of 225 F4/80
+
 macrophages 
per field in vehicle control mouse liver reduced to 0.72 per field in liposomal clodronate 
treated animals.  There was no difference in the administration of PBS to untreated 
controls with 225 versus 234 F4/80
+
 macrophages per field respectively. 
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Figure 5.2 Liposomal clodronate mediated deletion of hepatic macrophages 
Liposomal clodronate was delivered via tail vein injection to healthy C57Bl6 mice to assess the 
efficacy and duration of deletion of F4/80
+
 macrophages by immunohistochemical analysis as 
outlined in each panel.  (A) One day following injection complete depletion of hepatic 
macrophages was observed compared to control.  (B) Similarly 3 days following a single 
injection of liposomal clodronate complete depletion of both hepatic macrophages and splenic 
macrophages is observed vs.  control.  (C) Using repeated injections to assess the efficacy of a 
prolonged macrophage depletion regime, complete depletion was once again observed 3 days 
but not 6 days (D) following final dose of liposomal clodronate.  All scale bars denote 50μm. 
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5.4 Macrophages are not required for HPC expansion but influence 
HPC cell fate  
 
The effect on HPC behaviour of continuous macrophage depletion during CDE diet 
induced HPC activation was then assessed.  Examining HPC number in 3 repeated 
experiments (each n10) there was consistently no effect of the macrophage depletion 
on HPC expansion as assessed by the number of panCK
+
 HPCs (Figure 5.3D and E).  
Quantification of panCK
+
 HPCs confirms no effect of liposomal clodronate on HPC 
number following 12 days of CDE diet (mean per field 14.7 versus 10.57; n=10 each 
group; p=0.182 T test). 
 
Other features were also examined in the context of macrophage depletion during the 
CDE diet.  Dramatic increases were noted in serum transaminases with ALT increased 
from a mean of 228 to 735IU/L when CDE treated mice were treated with liposomal 
clodronate (Figure 5.3F).  Significant increases were also observed in AST, Alkaline 
Phosphatase and Albumin following liposomal clodronate treatment (Figure 5.3G-I).  
Liver weights showed a consistent but non-significant trend towards enlargement 
following macrophage depletion.  Mean relative liver weights at 6 and 12 days were 
0.052 versus 0.046 (p=0.1; Mann Whitney) and 0.066 versus 0.58 (p=0.19) for 
Liposomal Clodronate and vehicle control animals receiving the CDE diet respectively 
(Figure 5.3J).  No off target effects of liposomal clodronate were observed on 
morphology or cell number using in vitro HPCs culture versus PBS control (Personal 
Communication: Luke Boulter).   
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Figure 5.3 Macrophage depletion using CDE diet plus Liposomal clodronate 
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Following an experimental protocol (A) combining repeated liposomal clodronate injections 
during the CDE diet, highly efficient macrophage depletion (B) is noted by F4/80 
immunohistochemistry at 6 and 12 days (C).  Each group n= 5, p values denote one way Anova 
with Bonferroni multiple comparison, ***=P<0.001.  No change in panCK
+
 HPC number during 
the CDE diet in the presence of complete macrophage depletion (D and E).  Each group n=15, p 
value denote T test result.  Changes are noted in serum biochemistry at both 6 and 12 days.  (F) 
Alt mean 384 vs.  137 (n=3; p<0.0001) at day 6 and 736 vs.  228 (n=5; p=0.0037) at day 12.  (G) 
AST mean 719 vs.  191 (n=3; p<0.0001) at day 6 and 1317 vs.  536 (n=5; p=0.0195) at day 12.  
(H) Alk Phos mean 487 vs.  191 (n=3; p=0.0009) at day 6 and 414 vs.  132 (n=5; p=0.0107) at 
day 12.  (I) Albumin mean 44.3 vs.  38.0 (n=3; p=0.004) at day 6 and 39.32 vs.  32.41 (n=5; 
p=0.0024) at day 12.  Values are given for liposomal clodronate vs. vehicle control.  (J) Liver 
size as assessed by liver weight/body weight demonstrates a consistent trends towards liver 
enlargement following liposomal clodronate treated livers vs. vehicle control p=0.10 and 0.19 





A striking feature of macrophage depletion on HPC activation was noted when 
EpCAM
+
 HPCs were analysed.  While CDE diet consistently produces infiltrating cords 
of HPCs in the presence of macrophages, when macrophages were depleted areas were 
present with a markedly altered phenotype (Figure 5.4A).  Here a ductular proliferation 
of EpCAM
+
 cells surrounding a small and tortuous central lumen was observed.  These 
changes were noted sporadically and were scattered throughout the liver parenchyma, 
but did not occur entirely at the exclusion of the infiltrating EpCAM
+
 cells.   
 
As the ductular morphology was particularly prominent on EpCAM identification but 
less so when assessment used panCK or Dlk1 as an HPC marker, the colocalisaiton of 
these markers was assessed.  Due to the antibodies being raised in the same species a 
serial section approach was used to address this question.  When serial sections stained 
with Dlk1, panCK, and EpCAM were examined in the macrophage replete and 
macrophage deplete CDE diet models striking overlap between the three HPC markers is 
observed (Figure 5.4B).   
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The ductular morphology of HPC expansion in the CDE diet is reminiscent of that 
observed previously in the DDC diet where EpCAM
+
 cells also expand in a ductular 
morphology.  Therefore I hypothesised that the absence of macrophage led to this 
altered morphology via a signalling mechanism which directs the fate choice of HPC 
down a biliary rather than hepatocellular differentiation pathway.  While effects of 
certain signalling pathways discussed previously (Chapter 1) are known to influence 
HPC differentiation, a central candidate in this pathway is Notch signalling.   
 
In collaboration with Luke Boulter, I therefore asked whether any consistent 
differences could be identified distinguishing HPCs in the DDC and CDE dietary 
models.  The Notch inhibitor Numb was chosen as a potential candidate as it may link 
paracrine signalling from macrophages to alterations in the Notch signalling pathway 
which is known to be a crucial regulator of biliary differentiation (Chapter 1).   
 
Using immunohistochemical examination Numb is identified in HPCs in the resting 
liver and is also present in HPCs in the CDE diet.  Notably upon activation of HPCs in 
the DDC diet these cells markedly reduce Numb expression (Figure 5.4C), 
corresponding with a reduction in whole liver Numb gene expression (Figure 5.4D).  To 
examine the effects of macrophage depletion upon Numb expression by HPCs from the 
CDE dietary model, HPCs were isolated using a liver perfusion technique followed by 
density centrifugation, and purification by FACS isolation of the CD45
- 
HPC fraction.  
When this fraction from liposomal clodronate treated mice and PBS treated controls 
were compared a marked reduction in Numb expression was observed in HPCs from the 
macrophage depleted livers (Figure 5.4E).   
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Figure 5.4 Altered phenotype following macrophage depletion and Numb 
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Following 12 days of the CDE diet with concurrent macrophage depletion as outlined in Figure 
5.3A immunohistochemical analysis of EpCAM
+
 HPCs was performed (A) and compared to 
DDC treated mice.  A ductular morphology is seen in both macrophage depleted CDE diet and 
control DDC diet but not in control CDE diet.  (B) HPC markers Dlk1, panCK, and EpCAM 
were assessed in serial sections revealing co-localisation of the HPC markers.  (C) 
Immunohistochemical identification of Numb in HPCs.  After 8 days of DDC diet there is 
widespread reduction of Numb expression by HPCs.  A small number of DDC induced HPCs 
continue to express Numb (Arrow).  Infiltrating HPCs in the CDE diet continue to express 
Numb.  (D) Corresponding changes in Numb expression is seen by whole liver RT-PCR (n=4 
each group; mean 0.078 vs. 1 and 1.44 vs. 1 for DDC and CDE vs. control respectively; p values 
denote Mann Whitney tests).  (E) Reduced Numb gene expression in HPC isolated from 
macrophage depleted vs.  macrophage replete livers following 12 days of CDE diet (pooled 
samples from n=5; mean relative Numb gene 0.097 vs.  1).  (F) Elevated Numb expression in in 
vitro HPC cultures following addition of recombinant Wnt3a vs.  DMSO vehicle control (n=4 
each group, relative gene expression 1.78 vs.  control, p value denotes Mann Whitney test).  





5.5 Macrophage derived Wnt as the potential mechanism for 
influencing cell fate 
 
The previous observations that (1) a central difference between the CDE and DDC 
diets is the loss of Numb expression during the DDC‟s ductular HPC activation, and (2) 
that a conversion of the HPC phenotype from infiltrative to ductular when macrophages 
are depleted in the CDE diet together with a loss of HPC Numb expression links the 
presence of macrophages and Numb expression.  This therefore led to the hypothesis 
that paracrine signalling by macrophages directly influences HPC Numb expression and 
subsequently HPC cell fate choice.   
 
As discussed previously the Wnt family of secreted signalling molecules have been 
reported to exert control over Numb expression (Chapter 1).  Therefore, to examine a 
mechanism whereby macrophages directly influence Numb expression by HPCs, the 
role of paracrine Wnt signalling was investigated in this system.  Firstly, when HPCs 
were cultured in the presence of Wnt3a their expression of Numb increases (Figure 
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5.4F).  This data supports the hypothesis that macrophages promote Numb gene 
expression in HPCs in the CDE dietary model.  This therefore implicated Numb as a part 
of a functional pathway by which macrophages promote an infiltrative morphology in 
the CDE diet.   
 
Having demonstrated that HPC Numb expression may be increased by soluble Wnt we 
then asked whether macrophages make Wnts in the context of HPC activation.  To 
examine this directly in an in vivo context, livers from CDE and DDC treated animals 
were digested and the hepatic macrophages isolated by FACS based on F4/80 
expression.  These isolated and purified ex vivo macrophages were subsequently 
analysed by RT-PCR for Wnt3a gene expression (Figure 5.5A).  No significant changes 
were observed in hepatic macrophage Wnt3a gene expression.  However a non-
significant trend towards increased Wnt3a expression was observed in the CDE diet 
versus control.   
 
Axin2 is an established marker of Wnt reception.  Using an alternative approach to 
assess Wnt signal reception by HPCs in vivo, Axin2 gene expression by HPCs in vivo 
was examined in the CDE dietary model following macrophage depletion.  Markedly 
reduced Axin2 gene expression is observed in purified HPCs isolated from the livers of 
liposomal clodronate treated mice undergoing the CDE diet versus CDE diet alone 
control (Figure 5.5B).  In the same samples the effects of macrophage depletion upon 
HPC fate choice was assessed by examining the gene expression of hepatocytic 
(HNF4) and biliary (HNF1β and HNF6) lineage markers (Figure 5.5C).  A shift in 
expression of hepatocytic lineage markers to biliary lineage markers is observed in 
response to macrophage depletion (Figure 5.5C) in keeping with the changes from an 
infiltrative to a ductular HPC phenotype (Figure 5.4A).  Similarly when the effects of 
Wnt are examined on HPC culture an increase in hepatocyte lineage HNF4 is observed 
(Figure 5.5D) together with no change in the biliary lineage marker HNF1β (Figure 
5.5E).   
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Given the evidence for Wnt modulation of Numb as a mechanism by which HPC 
behaviour may be influenced by macrophages, I went onto investigate the role of Wnt in 
the CDE and DDC dietary models and whether correlating changes to HPCs occur 
during macrophage depletion in the CDE diet and macrophage replete DDC and CDE 
diets.  Firstly whole liver changes in Wnt signal pathway were analysed at the 
transcription level and revealed upregulation of Wnt targets including cyclin D1, Jun, 
and c-myc consistent with a state of Wnt pathway activation in both the CDE and DDC 
models (Figure 5.6).  Furthermore significant differences were observed in Wnt gene 
expression in each diet versus respective control, implying different hepatic Wnt 
expression signatures exist in the CDE and the DDC diets (Figure 5.6A).  It is noted that 
whole liver gene expression of Wnt3a shows different trends to those observed for 
isolated hepatic macrophages (Figure 5.5A).   
 
Many other alterations in Wnt related gene expression were observed in this study (see 
Appendix).  Notable changes were observed in the expression of soluble Wnt inhibitors 
WIF and sFz (Figure 5.6C and D).  To investigate the specific reception of Wnt by 
HPCs in the CDE diet I employed the use of the BATgal reporter mouse (Maretto et al., 
2003), which were a kind gift from Peter Hohenstein (MRC HGU Unit, Edinburgh).  
BATgal
+
 mice (Figure 5.7A) were fed either the CDE or control diet for up to 2 weeks 
to induce HPCs (Figure 5.7B).  Their livers were then examined for the presence of β-
galactosidase reporter expression by X-gal staining.  No cells in the livers of either CDE 
diet treated or control BATgal
+
 mice were demonstrated (Figure 5.7C).  Positive control 
liver used the constitutive expression of β-galactosidase in ROSA-26 mice and 
confirmed the staining assay performed correctly (Figure 5.7C).  Failure of β-
galactosidase expression in the adult BATgal mice was confirmed with an absence of 
expression of reporter β-galactosidase observed in the intestinal crypts of any of the 
BATgal
+
 mice (Figure 5.7C).   
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Macrophages purified by FACS after 12 days from livers of mice treated with CDE and DDC or 
respective control diets were analysed by RT-PCR for Wnt3a gene expression.  A trend to 
reduction is observed in the DDC diet with a significant increase in macrophage Wnt3a gene 
expression is observed in the CDE diet (n=4 each group vs.  control; 0.32 vs.  1 and 4.4 vs.  1 
respectively; p values denote Mann Whitney test).  (B) Analysis of purified HPCs from livers of 
liposomal clodronate vs.  PBS control animals following 12 days of CDE diet (see Figure 5.3A) 
reveals markedly reduced Axin2 gene expression (pooled HPCs from n=5 each group; relative 
Axin2 expression in purified HPCs from livers <0.001 vs.  PBS control).  (C) Isolated HPCs 
from macrophage deplete CDE treated liver additionally show lower expression of HNF4 
(0.11), but higher expression of HNF1β (1359) and HNF6 (1.90) relative to control CDE treated 
livers.  (D) Elevated HNF4 but not HNF1β (E) gene expression is observed in in vitro HPC 
cultures following addition of recombinant Wnt3a vs.  DMSO vehicle control (n=4 each group, 
relative gene expression 33.4 and 1.21 vs.  control respectively, p values denote Mann Whitney 
test).  Work performed in collaboration with Luke Boulter. 
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Given the failure of the transgenic reporter system in my hands, alternative strategies 
were employed to examine Wnt signal reception in HPCs.  Firstly β-catenin, particularly 
its nuclear localisation, was examined by immunohistochemistry as a marker of active 
Wnt signal reception.  This study revealed that high levels of β-catenin as observed in 
cells with HPC morphology in the CDE diet (Figure 5.7D).  Lower levels were observed 
in the DDC diet and when the CDE diet was treated with liposomal clodronate.  Sox-9 is 
an additional marker of active Wnt signal reception (Blache et al., 2004).  Changes in 
Sox-9 were also observed and again were consistent with increased Wnt signal reception 
by HPCs in the macrophage replete CDE diet than both the macrophage deplete CDE 
diet and macrophage replete DDC diet models (Figure 5.7).   
 
The possibility of differentiated HPCs or hepatocytes being influenced by increased 





; see Chapter 6).  Previously, highly efficient knockout of APC has 
been shown in this model (Reed et al., 2008).  When HPC activation is examined in the 
same mice, no evidence of HPC activation or altered HPC phenotype was observed in 
the context of active β-catenin signalling targeted to hepatocytes (Figure 5.7 E and F).   
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Figure 5.6 Wnt pathway activity in models of different HPC activation 
 
Whole liver was examined for Wnt related gene expression from C57Bl6 or S129 mice treated 
with 12 days of CDE or DDC diet respectively were compared to strain matched controls (n=3 
each group).  (A) Wnt gene expression varies between CDE and DDC diet and respectively 
control and Wnt target genes (B) Cyclin D1 (ccdn1), c-Jun (Jun) and c-Myc (Myc) are 
significantly increased in both the CDE and DDC diets vs.  respective controls.  Variations are 
also seen in expression of secreted Frizzled (sFz) and Wnt inhibitory factor (WIF) gene 
expression (C and D respectively) in the CDE and DDC diets vs.  respective controls.  
Additional data in Appendix.  (*p<0.05, **p<0.01, ***p<0.001).  Performed with n=3 each 
group. 
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Figure 5.7 Wnt activity in CDE diet and failure of BATgal reporter system 
(A) The BATgal reporter construct used to test Wnt signal reception in vivo by activated HPCs 
during the CDE diet (B).  (C) Xgal staining of liver and intestine in the BATgal reporter mice 
reveal no expression of β-galactosidase as compared to ROSA26 control.  (D) 
Immunohistochemical staining for β-catenin and Sox-9 in HPC model identifies cells Wnt 
signalling in cells with HPC morphology; staining performed by Dr Alicia Cole.  (E) 4 days 









 control with no alteration in morphology or expansion (F) in HPCs 
identified (n=3 each group).  All scale bars denote 50μm. 
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5.6 Niche engraftment by macrophages is sufficient for HPC activation 
in the absence of injury 
5.61 Background to experimental methods 
 
Macrophages have been described to play a role in stem cell niches in other organs in 
the context of injury.  In published models, macrophages are described to increase the 
numbers of stem cells and promote wound healing.  My results suggest that in the liver, 
macrophages play a role in specifying progenitor cell fate in the context of injury.  
While no effect on HPC expansion as measured by cell number was observed, it is 
possible that macrophages may also play a role in HPC expansion.  We therefore sought 
to ask the question of whether macrophages are capable of stimulating HPCs in the liver.  
To address this question using the numbers and proliferation of HPCs as a readout we 
utilised the known propensity of BM derived cells to engraft in multiple tissues even in 
the absence of injury.  We elected to utilise an approach of delivering macrophages and 
whole BM via peripheral vein.  This offers the advantage of being minimally invasive 
which is of benefit with regards to simplification of the model, in addition to mimicking 
what is frequently used in BM transplantation studies and human therapy.   
 
Multiple studies in the field of BM transplantation have tracked the efficiency of BM 
engraftment in organs following infusion via a peripheral vein.  The liver, BM and lung 
are the principle sites of engraftment in an un-irradiated mouse recipient of whole BM 
with each organ experiencing approximately the same proportion of donor cell 
engraftment (Cui et al., 1999).  Importantly each tissue appears to show different 
dynamics of cellular engraftment with variability in engraftment seen both over time in 
organs and between different organs. 
 
Recently, several studies have suggested beneficial effects in human patients with liver 
injury following the intravenous delivery of BMCs.  These effects have included 
endpoints such as liver function and regeneration (Houlihan and Newsome, 2008).  
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Therapy using BMC is clinically attractive from a variety of perspectives.  The BM is 
readily available under minimal invasive techniques, and provides an autologous source 
with consequent immunological advantages.  Furthermore donor BMCs may be purified, 
expanded and manipulated to enrich for beneficial effects or populations.  Previously 
reports that BMCs themselves may adopt an epithelial phenotype in the liver are now 
thought to be unfounded or to occur at an insignificant magnitude (Chapter 1).  None-
the-less the effects of BMCs in humans and murine studies along with their known 
trafficking into the liver, may suggest that following engraftment their effects upon 
resident liver cell populations may be elicited by paracrine signalling.  Such a paracrine 
signalling mechanism is yet to be described in the literature.  Furthermore the effects I 
have observed previously of trafficking of macrophages into the HPC niche where they 
can influence HPC behaviour may provide a mechanism by which BMC therapy results 
in the beneficial effects described to date.   
 
5.62 Transfer of syngeneic BMCs to healthy mice results in HPC activation 
in healthy recipient mice 
 
I therefore sought to utilise the propensity of BMCs to engraft within the liver to 
investigate whether macrophages may play a role in HPC activation.  My experimental 
model used healthy un-irradiated mice which received unfractionated BMC from in-bred 
littermates.  Using male to female BMC transfer tracking of donor derived BMC is 
possible using the presence of the Y-Chromosome as a marker as previously described 
(Chapter 4).   
 
Initial observations were made in female mice which received a single transfer of 10
7
 
unfractionated BMCs from male donors (to allow cell tracking via the Y chromosome).  
These animals showed a consistent, periportal expansion of panCK, Dlk1 and EpCAM 
positive HPCs, from day 7 post transfer onward which lasted for up to 6 weeks (Figure 
5.8).  This effect was observed in both recipient of sex-mismatched and sex-matched 
BMC.  Irradiation of BMCs prior to infusion rendered them incapable of inducing HPC 
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activation (Figure 5.8), In both instances HPC activation is observed to occur in earnest 
between 1 and 6 weeks following BMC transfer.  Examination of proliferation using 
BrdU at early time points demonstrates that as early as 1 day following BMC transfer 
proliferation is seen within the HPC compartment (Figure 5.8).  The HPC expansion 
seen histologically is mirrored by an increase in HPC RNA expression with significant 
increase in CK19 gene expression along with consistent trends to increased expression 
in EpCAM, and Fn14 gene observed also (Figure 5.8).   
 
Further examination of mice receiving BMC transfer revealed a number of other 
striking effects.  Firstly following a period of initial reduction in liver size, a consistent 
and significant increase in size of livers is observed in mice following BMC transfer 
returning to normal size over a period of 2-6 months (Figure 5.9).  This increased liver 
size occurred between 3 and 6 weeks following BMC transfer, and therefore is 
associated with the expansion of HPCs.  In the longer term this relative hepatomegaly 
normalises with no difference in liver size 100 days post BMC transfer.   
 
Serum analysis performed following BMC transfer reveals a relative reduction in 
serum albumin immediately following HPC transfer.  This occurs along with an increase 
in whole liver albumin gene expression (Figure 5.9). 
 
In all previous models of HPC induction described to date, a significant hepatocellular 
injury is observed and is believed to drive resultant HPC activation.  Histological 
analysis of specimens following BMC transfer however revealed no evidence of 
significant hepatocellular injury at any time point (Figure 5.8).  Therefore I sought to 
investigate whether any detectable evidence of liver inflammation or hepatocyte injury 
occurred using a number of different methods.  Despite the administration of BMC 
containing a large leukocyte population no prominent CD45
+
 infiltrate was observed in 
the liver by immunohistochemistry (Figure 5.10A).  Furthermore there was no elevation 
of serum transaminases in mice treated with BMC transfer (Figure 5.10B and C).   
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Figure 5.8 Whole BM transfer results in HPC activation in healthy liver 
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(A) Absence of injury with simultaneous expansion of HPCs in female mouse liver 42 days 
following tail vein injection of 10
7
 BMCs from inbred male donors.  Male BMC transfer 
experiments were repeated 4 times, each with n=5 animals per group.  (B) Quantification of 
HPCs over time following after transfer of 10
7
 male BMCs (n=5 each group, except n=2 at day 
3,7 and 21).  Data is presented as mean number of cells per field±SEM.  (C) Quantification of 
HPCs over time following after transfer of 10
7
 syngeneic BMCs from inbred female donors (n=5 
each group).  Data is presented as relative change in cells per x200 magnification field 
(experimental mean/time matched control mean)±SEM.  (D) PanCK
+
 HPCs in inbred female 
recipients of syngeneic BMC transfer with corresponding HPC quantification.  (E) Proliferation 
of HPCs is seen as early as 1 Day following cell transfer (BrdU 2 hours prior to tissue harvest), 





Figure 5.9 Functional consequences of whole bone marrow transfer 
 
(A-C) HPC marker gene expression is raised in whole liver following syngeneic BMC transfer 
(CK19, Fn14 and EpCAM respectively).  Values represent fold change versus 24 hours post 
PBS transfer, mean±SEM.  (D) Liver size assessed by relative liver weight (liver weight/body 
weight)/(control liver weight/control body weight) following syngeneic BMC transfer (n4 each 
group).  p values denote t-test result vs.  control.  (E) Initial reduction in serum albumin is 
followed by increases in serum albumin and occurs following increases in whole liver Albumin 
gene expression (F).   
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HPC activation is strongly associated with carcinogenesis in both human disease and 
rodent HPC models.  I therefore wished to examine whether the transient induction of 
HPCs in the BMC transfer model resulted in long term side effects.  Examining mice 
(n=5) for 400 days following BMC transfer no adverse effects were seen.  Specifically 
careful examination of livers at harvesting revealed no macroscopic or microscopic 
evidence of liver tumours.  Histologically the livers appeared normal and while relative 
increases in HPCs were seen compared to young mice, no changes were seen against 
aged matched controls (Figure 5.11).  Additionally no biochemical abnormality was 
observed in mice 400 days following BMC transfer (Bilirubin 83.12, ALT 277.19, 
AST 299211, Albumin 350.63; MeanSEM; n=5). 
 
5.63 Bone marrow transfer results in transient liver engraftment by donor-derived 
macrophages  
 
To examine the biology of donor cells within the recipient liver, two independent cell-
tracking strategies were employed.  Firstly Y chromosome detection from the sex-
mismatched BMC transfer group was performed.  In addition, a separate series of GFP 
mismatched BMC transfer experiments were performed whereby GFP
+
 donor BMCs 
were delivered to WT littermates.  Examination of both series of experiments 
demonstrated rapid, albeit transient, engraftment of the recipient liver with donor–
derived cells, with no evidence of detectable transdifferentiation of donor BMCs into 
HPCs or hepatocytes (Figure 5.12).  Whilst after one day following transfer, donor cells 
were seen throughout all three zones of the hepatic lobule with no specific localisation 
(Figure 5.12A), from 3 days following transfer, donor-derived cells were found directly 
adjacent to bile ductules and HPCs, and frequently made direct physical contact with the 
panCK
+
 progenitors (Figure 5.12B and C).  By seven days following BMC transfer the 
numbers of engrafted cells was considerably lower than at either of the previous time 
points examined.  Again cells were seen in direct contact with panCK
+ 
HPCs.  After 21 
days following BMC transfer no convincing donor derived cells were seen in the 
recipient livers. 
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Figure 5.10 Absence of injury or inflammation following BMC transfer 
(A) Immunohistochemical analysis of liver for CD45 expression shows no evidence of leukocyte 
infiltration following BMC transfer compared to PBS control at any time following syngeneic or 
sex-mismatched BMC injection.  All scale bars denote 50μm.  No changes in serum Alt (B) AST 
(C) or Alk Phos (D) are observed 21 days following BMC transfer (all p>0.05 by T test, n=5 
each group).   
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Figure 5.11 Absence of long term side effects following BMC transfer 
 
Microscopic examination of livers 400 days following peripheral vein infusion with 10
7
 BMCs 
from an inbred male donor reveals no evidence of injury or carcinogenesis.  Additionally no 
expansion of panCK
+





In order to quantify the numbers of donor cells within the liver two independent 
strategies were performed.  Firstly whole liver gDNA was assessed by qPCR for the 
presence of the Y chromosome in the sex-mismatched model.  Additionally, as no 
evidence of transdifferentiation to hepatocytes was observed from donor BMCs, the 
non-parenchymal cell fraction was assessed for GFP
+
 expression in the GFP mismatched 
model.  Interestingly both methods revealed similar dynamics of loss of engrafted cells 
within the liver over time.  Donor derived cells were consistently undetectable in 
recipient livers by 42 days post injection (Figure 5.13).   
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Figure 5.12 Localised engraftment to the HPC niche following BMC transfer 
In the sex-mismatched BMC transfer model engrafted cells within perfused liver were assessed 
following immunohistochemical and FISH analysis by confocal microscopy.  No hepatocytes or 
panCK
+
 HPCs were identified as donor derived.  One day following BMC transfer small donor 
derived cells were scattered throughout the parenchyma, however by 3 and 7 days a significant 
proportion of donor derived cells were in direct contact with panCK
+
 HPCs.  Male control 
demonstrates all cell populations contain Y chromosome
+
 cells; insert antibody isotype control.  
All scale bars denote 50μm. 
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Figure 5.13 Transient cellular engraftment following BMC transfer 
Following BMC infusion, cellular engraftment was assessed in perfused liver by two 
independent methods.  Firstly NPCs were isolated by density centrifugation at multiple time 
points following GFP-mismatched BMC transfer.  NPC were then assessed by FACS for GFP 
expression along-side CD45.  (A) Representative FACS plots shown for examination at days 3 
and 42 following BMC transfer.  In addition qPCR for Y chromosome gDNA was performed on 
whole liver following sex-mismatched BMC transfer.  (B) Data for each method of 
quantification is presented (green-GFP mismatched FACS, blue-sex-mismatch qPCR).   
 
 
To characterise the phenotype of engrafted, donor-derived cells FACS selection of GFP
+
 cells 
in wild type liver was performed 3 days post BMC delivery.  The resultant cell isolate was 
exclusively CD45
+
 (Figure 5.13A), and the majority (81%) were F4/80
+
 macrophages (Figure 
5.14A).  The identity of engrafted BMCs as macrophages was then confirmed by in situ co-
staining of Y chromosome and F4/80 in liver sections (Figure 5.14B).   
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Figure 5.14 Macrophages from whole BMC engraft following transfer 
 (A) Examination of extracted GFP
+





 BMC by F4/80 immunocytochemistry reveals 81% of cells engrafted donor derived cells 
are macrophages.  Contemporaneous staining control for F4/80 using BM.  (B) 
Immunohistochemistry for F4/80 reveals engraftment of macrophages within the liver 3 days 






5.64 Macrophages are themselves capable of activating an HPC response 
 
The experiments described above suggest a central role for macrophages in the 
activation of HPCs following BMC transfer.  Thus, I hypothesised that in vitro matured 
macrophages would stimulate an HPC response to a similar or greater magnitude than 





macrophages to healthy mice, livers and serum were analysed.  Macrophage specific cell 
transfer once again resulted in absence of hepatic inflammation (Figure 5.15A and B).  
Nonetheless increased serum albumin was observed (Figure 5.15D), together with a 
robust activation of HPC proliferation (Figure 5.15F and G).  These effects are 
analogous to the response seen with BMCs as hypothesised.  In keeping with the 
activation of HPCs serum Alkaline Phosphatase was significantly elevated in 
macrophage treated mice (Figure 5.15C).   
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Figure 5.15 Macrophage transfer recapitulates whole BMC transfer 
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 macrophages given via tail 
vein injection shows no change in ALT (A), or AST (B) compared to control.  (C) Alkaline 
Phosphatase show significant rise in macrophage treated animals (186 vs.  182 vs.  152U/l in 
Mac vs.  BMC vs.  PBS treated mice, n=5 each).  (D) Serum Albumin shows significant rise vs.  
PBS control (38.6 vs.  38.2 vs.  36.0g/l in Mac vs.  BMC vs.  PBS treated mice, n=5 each).  (E) 
No significant change in liver weight : body weight following cell therapy at 21 days 0.054, 
0.052, 0.053, 0.052 in mice given Macs alone, irradiated Macs, BMC, and PBS control 
respectively (n=5 each group).  (F) Quantification of panCK
+
 HPCs 21 days following cell 
therapy, with corresponding immunohistochemical analysis (G).  All scale bars denote 50μm, 





5.7 HPC activation following BMC transfer is dependent on TWEAK-
Fn14 signalling 
 
To determine the mechanism by which engrafted BM-derived macrophages stimulate 
the HPC response, I screened whole liver RNA for the presence of growth factors known 
to be associated with HPC proliferation, including: HGF, IFN, TNF, IL6, LT, LTβ, 
OSM, and TWEAK.  Expression of LT, LTβ and OSM were not reliably detected in 
liver unlike in positive control (E15 liver/spleen/thymus).  No significant changes in 
hepatic expression of IL6, TNF or IFN were observed following BMC transfer (Figure 
5.17A-C).  In contrast TWEAK mRNA levels were strongly induced during the first 
week following BMC transfer and returned to normal (Figure 5.17D) as engrafted cells 
were lost from the liver (Figure 5.13).  Hepatic HGF showed a non-significant trend 
towards increased gene expression also (Figure 5.17E).   
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Figure 5.16 Fate of HPCs following macrophage transfer 
Immunohistochemical analysis of liver using PanCK (green), BrdU (red) and DAPI (blue) 
following transfer of 10
7
 macrophages.  BrdU (50mg/kg) is administered 21 following cell 
transfer and tissue analysed either 2 hours later (day 21) or 4 days later (day 25).  (A) Early 
analysis following BrdU pulse reveals panCK
+
 cells with uptake of BrdU label.  Non-
parenchymal cells also infrequently take up BrdU (A) as do hepatocytes (B).  Later analysis 4 
days following BrdU reveals clusters of BrdU
+





cells are observed (C) in addition to clusters of BrdU
+
 cells 
containing both hepatocytes and panCK
+
 HPCs (D).  Clusters of BrdU
+
 hepatocytes are also 
observed in the periportal areas in direct juxtaposition to panCK
+
 HPCs (E).  All scale bars 
denote 50μm. 
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Figure 5.17 Screening cytokines reveals TWEAK as a potential signal for HPC 
activation 
 
Analysis of whole liver mRNA expression by qRT-PCR was performed 1-42 days following 
infusion of 10
7
 syngeneic BMC into healthy female C57/Bl6 mice (n=5 each group) and 
compared to PBS treated control.  P values denote T test value vs.  PBS treated control.   
 
 
Having observed that TWEAK expression in whole liver follows a pattern similar to 
the engraftment of macrophages within the liver, I therefore sought to investigate if the 
increased expression of TWEAK following syngeneic BMC therapy originated from the 
donor derived macrophages.  Initially I assessed whether TWEAK expression was a 
characteristic of mature macrophages in the absence of infusion.  In vitro differentiated 
pure populations of F4/80
+
 macrophages express high levels of TWEAK mRNA 
compared to undifferentiated and purified BMCs (Figure 5.18B).  Then, aiming to assess 
if engrafted donor-derived cells were the source of TWEAK signalling post BMC 




 donor-derived cells were sorted from perfused wild-type recipient livers 
and examined for TWEAK expression 3 days following GFP-mismatched BMC transfer.  
Relative to whole BM, TWEAK mRNA levels were 2.8-fold elevated in the GFP
+
 
pullout fraction (Figure 5.18B) consistent with TWEAK production in-situ by donor 
derived macrophages following BMC transfer.   
 
To test the hypothesis that TWEAK signalling mediates HPC expansion following 
BMC transfer, I used recipient mice lacking the Fn14 TWEAK receptor (Fn14
-/-
) and 
compared the extent of HPC response invoked by transfer of wild-type BMCs between 
these and WT recipient controls.  In the absence of Fn14, HPC expansion was entirely 
abrogated (Figure 5.19).  In Fn14
-
 recipients no evidence of expansion of HPCs 
expressing panCK, Dlk1 or EpCAM is observed 42 days following intravenous BMC 
transfer in contrast to when BMC is given to healthy wild type recipients.   
 
 
Figure 5.18 Engrafted macrophages produce TWEAK within the liver 
Analysis of TWEAK gene expression by qRT-PCR performed on in vitro differentiated 
macrophages revealed 20.8±0.96 (mean±SEM) times increased expression of TWEAK in 
enriched macrophages vs.  whole BMC control (A).  3 days following GFP-mismatched BMC 
transfer donor derived GFP+ cells were sorted by FACS from the pooled NPC fraction from the 
whole livers of 3 mice.  TWEAK gene expression in this cell population was 2.83±0.60 
(mean±SEM) times higher assessed vs.  whole BMC control.  P values denote T test result vs.  
control, n=3-5 each group.   
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Figure 5.19 BMC mediated HPC activation is dependent on TWEAK signalling  
(A) Transfer of murine 10
7
 BMC was performed into healthy Fn14 knockout (Fn14
-/-
) and Wild 
type female mice recipients.  The HPC response was assessed by panCK+ HPC expansion (A) 
together with immunohistochemical analysis for panCK, Dlk1 and EpCAM (B).  All groups 
n=5.  p values given for T test.  All scale bars denote 50μm. 
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A series of changes are described to occur with age in the behaviour of stem and 
progenitor cells in the BM (Mayack et al., 2010; Warren and Rossi, 2009).  Described 
changes include an increased propensity of haematopoietic stem cells to differentiate 
towards myeloid rather than lymphoid lineages (Gazit et al., 2008).  I therefore asked 
whether aged BMC were capable of induction of HPC activation in a similar fashion to 
BMC isolated from young mice examined previously.  Identical changes in HPC 
activation were observed when BMCs from old donors (18 months old) were given to 
young female mice compared to when BMCs from young donors (6 weeks) are used 
(Figure 5.20).   
 
Changes in the haematopoietic potential of the old and young donor BM used in the 
experiment described previously was performed along with that from age matched mice 
injured with the CDE diet.  Haematopoietic potential was assessed in vitro from freshly 
isolated BM using colony forming assays.  A variety of colony phenotypes can be 
distinguished from this assay.  Each phenotype represents the different potential of 
colony forming cells from varying stages of the leukocyte/erythrocyte lineage.  The 
relative frequency of each colony forming unit from each group of mice was as 
predicted.  No changes were observed with aging upon the frequency of committed 
haematopoietic progenitors (Figure 5.20C).  However, a significant loss of multipotent 
colony forming stem cells was observed in the aged mouse upon exposure to the CDE 
diet (Figure 5.20D).   
 
Chapter 5-Macrophages as functional cells within the HPC niche 
 187 
Figure 5.20 Effect of aged BMC on HPC expansion 
(A) 42 days following i.v. injection of 10
7
 male BMC from either 6 week (young) or 18 month 
(old) mice, recipient mouse liver was assessed for HPC expansion by panCK 
immunohistochemistry and panCK
+
 HPCs quantified (B).  Scale bars denote 50μm.  BMCs were 
extracted from healthy young and old mice in addition to old mice exposed to 12 days of CDE 
diet, and colony forming assay performed in methocult media.  Data is presented as number of 
colonies per 1000 BMCs.  Data is presented for total colonies, total granulocyte/monocyte/mixed 
granulocyte and monocyte (GM total), mixed granulocyte/monocyte (GM), granulocyte (G), 
monocyte (M), erythriod (E) and granulocyte/monocyte/erythroid/monocyte/megakaryocyte 
(GEMM) colonies (C).  Numerical data represents mean for each group (n=4 each).  GEMM 
colonies data is presented separately (D).  p values denote Mann Whitney test.   




The question of what role macrophages play in the regenerative process in the liver 
from HPCs has been raised by earlier work in this thesis and many other studies (Yin et 
al., 1999; Paku et al., 2001; Pull et al., 2005; Gyorki et al., 2009; Lorenzini et al., 2010).  
The work presented here demonstrates macrophages play a central functional role in 
controlling HPC activation and modulating the HPC regenerative response to injury.  
Following successful depletion of hepatic macrophages I demonstrate a role for 
macrophages in shaping the phenotype of bipotential HPCs, driving a hepatocytic 
differentiation and thereby promoting hepatocellular regeneration in response to the 
CDE diet.  This mechanism for this influence appears to be via paracrine Wnt signalling, 
which inturn modulates HPC Numb expression leading to inhibition of Notch mediated 
cholangiocyte differentiation.  Furthermore, work performed by the adoptive transfer of 
macrophage demonstrates that, even in the absence of local hepatocellular injury, 
macrophages promote the expansion of otherwise unstimulated HPCs.  This 
phenomenon appears to be via an alternative paracrine signalling pathway utilising the 
TNF related TWEAK signal which acts on Fn14 receptors of the HPCs themselves.   
 
5.81 Macrophage depletion during the CDE diet 
 
As demonstrated in this work the Liposomal Clodronate is an exceptionally efficient 
method for depleting hepatic macrophages.  Cellular depletion of F4/80
+
 macrophages 
using liposomal clodronate in my hands is consistent with previous reports of F4/80 
depletion both in the liver and spleen of mice 3 days following a repeated dosing 
strategy (Nishioka et al., 2007) with return seen 5 days following injection (Yamamoto 
et al., 1996).  Here liposomal clodronate treatment a rebound in peripheral blood 
monocytes has been reported from 1-5 days post treatment.  This increase in circulating 
monocytes is postulated to result from compensatory increased production of fresh BM 
derived monocytes during the tissue macrophage repopulation phase, following 
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macrophage depletion (Yamamoto et al., 1996).  Interestingly, in the model system used 
in this work, I have observed large numbers of F4/80
+
 macrophages adherent to the 
hepatic vasculature following hepatic injury and repeated intrahepatic macrophage 
depletion (Figure 5.3C).  I propose that this observation is a result of active macrophage 
repopulation following depletion and subsequent intravascular repletion.  This itself 
offers as an elegant model for the studying the kinetics and biology of macrophage 
recruitment to the liver.   
 
Effective macrophage depletion in the healthy liver using the DTR deletion system in 
transgenic mice was not achieved in my hands.  This is clearly in contrast to other 
studies (Cailhier et al., 2005; Duffield et al., 2005).  In previous studies, efficient and 
significant depletion of peritoneal macrophages was seen between 8hr and 4 days 
following i.p. DT injection at up to 25ng/g (Cailhier et al., 2005). Alternatively 
depletion of hepatic macrophages has been dsecribed 24 hours after repeated doses of 
10-25ng/g DT via either i.p. or i.v. injection (Duffield et al., 2005).  The discrepancy 
between the published findings and my results in this work probably lies in the differing 
time between DT delivery and tissue analysis in these different studies.  None-the-less 
my findings support what is apparent from the previous studies that intrahepatic 
macrophage depletion by liposomal clodronate is significantly more effective than in the 
CD11b-DTR transgenic system.  In the work presented here liposomal clodronate was 
chosen not only for its improved rapidity of hepatic macrophage depletion and the 
improved specificity of action regarding other leukocyte subsets.   
 
In contrast to the CD11b-DTR system, Liposomal clodronate is described to play a 
specific macrophage depletion role without off target effects, including neutrophils 
(Kitamoto et al., 2009; Monkkonen et al., 1994; Van Rooijen, 1989).  An elevation in 
numbers of peripheral neutrophil numbers have however been described following 
liposomal clodronate but are believed to be secondary to reduced monocyte mediated 
neutrophil clearance (Yamamoto et al., 1996).   
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Consistent changes in serum biochemistry are seen following liposomal clodronate 
administration during the CDE diet in this study.  Transaminases in particular are 
strikingly increased following liposomal clodronate treatment.  This may reflect 
increased cellular injury but is more likely to be explained by a failure of phagocytosis 
of apoptotic hepatocytes which are then able to liberate transaminases directly.  This 
would be consistent with the relatively mild rise in transaminases seen following 
apoptosis, however if large scale hepatocyte apoptosis is induced, e.g. by ectopic FAS 
expression, then dramatic changes in serum transaminases are observed consistent with a 
saturation of hepatocyte phagocytosis by macrophages (Feldmann et al., 1998).   
 
Considering the above and the demonstration from Chapters 3 and 4 that macrophages 
are actively recruited into the HPC niche during HPC activation it was surprising that 
HPC number did not change following the complete depletion of hepatic macrophages.  
This result may imply that macrophages play little or no role in modulating the 
expansion of HPCs.  Alternatively it is possible that the effects of macrophages upon 
HPCs are more subtle than merely influencing overall numbers of HPCs and may 
instead affect HPC generation, death and/or differentiation rate.  HPCs are understood to 
be bipotential cells capable of either hepatocyte or biliary specification.  It appears that 
in different injury models different phenotypes of HPCs are observed.  It is assumed that 
these differences in observed HPC morphology are a feature of the models and related to 
the principle site of injury and therefore regenerative requirement.  In other words 
models in which biliary injury predominates stimulate a biliary phenotype of HPCs due 
to a preponderance of HPC differentiation into freshly formed cholangiocytes.  Whether 
HPC phenotype within a single injury model can be influenced by factors excluding the 
method of injury is a question which to my knowledge has not been answered 
previously.  However in this work I clearly demonstrate that macrophages play a central 
role in the determination of HPC behaviour.   
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5.81A HPC quantification as a method for assessing HPC activation 
 
Measuring HPC number, as a marker of HPC activation, is a widely used and 
appropriate method for the assessment of HPC activation.  It is, however, naturally a 
function both of HPC production and loss.  HPC production is dependent on their 
formation, almost certainly in the main from HPCs themselves.  Certainly all models 
studied in this work and other related published work provides compelling evidence that 
HPCs are capable of proliferation both in vivo and in vitro.  Any reduction in HPC 
number is most simply a function of a combination of their death, or loss by 
differentiation into other cell populations, outweighing any production from precursor 
sources.  It is probable that HPC death, most likely via apoptosis is also a means by 
which the number of observed HPCs may be influenced.  None-the-less, although these 
features were not specifically quantified in this study, as HPC number remains entirely 
stable it is likely that both the generation and loss of panCK
+
 HPCs are not dramatically 
altered during macrophage deficiency. 
 
To study HPC biology the choice of marker used to identify this population is crucial.  
For historical reasons the majority of this work has used panCK as a marker for HPCs.  
As discussed previously in Chapter 1, panCK is a validated HPC marker.  It is clear, 
however, that there is heterogeneity within HPCs.  EpCAM is now a well validated HPC 
marker with, in my opinion, more supporting evidence for it use as a marker currently, 
than panCK.  EpCAM therefore, may be of more relevance to study HPC biology.  
None-the-less my work demonstrates that the two markers appear to colocalise very 
closely frequently and whilst not always doing so, both panCK and EpCAM appear to 
mark the same population in most instances (Figure 5.4B).  This demonstration of Dlk1, 
EpCAM and panCK made in this work is the first such description within HPCs.   
 
5.81B Mechanism of action of macrophage influence upon HPC cell fate 
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The observation that HPC morphology can be altered by the presence/absence of 
macrophages in the CDE dietary model is a core observation of this work.  The switch 
from an infiltrative, single file HPC response in the CDE diet to a non-infiltrative 
ductular HPC response with macrophage depletion suggests that macrophages are 
responsible for the former phenotype.  In this work I have utilised a variety of markers 
of lineage commitment, including HNF4α, HNF1β, and HNF6, which are well 
established in this field as markers of lineage commitment for hepatic progenitor cells 
(Rountree et al., 2007; Zaret, 2002).  HNF1β, and HNF6 are described as inhibited by 
the action of the pro-hepatocytic CEBPα during development (Yamasaki et al., 2006; 
Hunter et al., 2007; Tanimizu et al., 2004).  These factors are viewed as specific for 
cholangiocyte (biliary) differentiation, while HNF4α is widely regarded as a marker of 
hepatocellular lineage commitment.  An important extension of this thesis in the future 
will be to further characterise cell fate choice using differentiation into functional 
hepatocytes and cholangiocytes.   
 
With respect to the factors controlling cell fate choice the most striking feature in this 
work is the marked alteration in the morphology of HPCs in the CDE diet upon the 
depletion of macrophages using liposomal clodronate (Figure 5.4A).  The identification 
of Numb as a central difference between the phenotypes of infiltrating and ductular 
HPCs was originally made by Luke Boulter.  This observation correlates with 
downstream changes in Notch pathway activation in the different models as assessed by 
Hes gene expression (personal communication by Luke Boulter).  Given the role of 
Notch pathway signalling in the formation of the intrahepatic biliary tree (see Chapter 1) 
the novel identification of Numb, a known inhibitor of Notch signalling, provides a 
mechanism by which fate choice in HPCs may be regulated.  Therefore these two central 
observations associate macrophage function and Notch signalling control over HPC fate 
choice. 
 
The question then arising is how Numb itself is controlled during HPC activation? It is 
clear from this work that Numb is expressed by the biliary tree in the uninjured liver but 
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upon activation in a ductular proliferation model, Numb is lost in DDC whilst its is 
maintained during the infiltrative HPC response in CDE diet (Figure 5.4C and D).  It is 
also apparent that the addition of Wnt to HPC culture results in upregulation of Numb 
(Figure 5.4E), and that depletion of macrophages results in a reduction in Numb 
expression by HPCs in vivo.  Numb has been described as a direct target of Wnt.  In 
contrast to work in embryology where Wnt3a has been described to modulate Numb at 
the post transcriptional level (Katoh, 2006a), in this work we demonstrate that Wnt3a is 
able to effect Numb at the gene transcriptional level.  This observation is in keeping with 
other previous reports of control at the level of gene transcription (Holowacz et al., 
2006), and furthermore, is in keeping with the observation that mammalian Numb gene 
lies in close proximity to TCF/LEF binding sites which in primates and humans even lie 
within the Numb promoter (Katoh, 2006b).  These observations all support a role for the 
modulation of Numb gene expression by the Wnt signalling pathway. 
 
The results presented in this work demonstrate a trend towards increased Wnt3a 
production by macrophages following CDE diet treatment.  Clearly other Wnts may 
additionally be produced by macrophages in the context of the two dietary models.  
Macrophages have been described to produce Wnts in a variety of settings, typically in 
response to a hostile or injured environment (Staal et al., 2008; Blumenthal et al., 2006; 
Pereira et al., 2009).  Given the description of Wnt3a's role in modulating Numb 
behaviour (Katoh, 2006a) and the role for recombinant Wnt3a in stimulating hepatocyte 
differentiation both in the adult and development (Figure 5.5D and Hay et al., 2008; 
Ober et al., 2006) it is a clear candidate for the signalling mechanism from macrophages 
to HPCs.  Additionally Wnt3a is the paradigm of canonical Wnt signalling, a feature 
suggested to occur in HPCs by their elevation in nuclear β-catenin (Figure 5.6H).  Here I 
show detectable and active Wnt3a gene transcription in isolated and purified hepatic 
macrophages, an observation not previously reported.   
 
A recent study using Wnt1 knockdown in the rat PH/AAF model supports a role for 
Wnt1 in the differentiation of HPCs into hepatocytes (Williams et al., 2010).  Although 
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no changes in whole liver Wnt1 expression were observed in my work it is possible that 
local periportal expression of Wnt1, particularly as this is observed by Williams et al., 
may exist.  Further elucidation of the regional and cellular expression of the Wnts in the 
regenerating liver will undoubtedly broaden our understanding of this family of proteins 
in regulating stem/progenitor cell behaviour in the future.  Macrophage expression of 
other Wnts, including Wnt2, has been described previously in the mouse.  In the liver 
expression of a number of Wnts by macrophages has been suggested also (Zeng et al., 
2007).  Wnt2 signal predominantly via the canonical (β-catenin) dependent pathway 
(Lobov et al., 2005).  It is interesting to note that whole liver Wnt2a is increased in the 
CDE diet but reduced in the DDC diet (Figure 5.6A) and that based on Ct values is the 
second most highly expressed Wnt mRNA in the liver during CDE or DDC diet behind 
Wnt 5a (see Appendix).  In the first instance however, I elected to examine the effect of 
Wnt3a on HPCs in culture as this is a commercially available recombinant protein and is 
the archetypical example of a canonical Wnt signal.  Further investigations of the effects 
of other Wnts including Wnt 5a upon HPCs are warranted in addition to those of Wnt 3 
reported here in the future.   
 
In contrast to the previous report of Wnt4 expression in a mixed population of stellate 
and Kupffer cells in mouse liver (Zeng et al., 2007) I did not detect Wnt4 transcript in 
isolated hepatic macrophages.  These results therefore imply that Wnt4 is expressed by 
hepatic stellate cells, a result not specifically confirmed in this work.  This further 
highlights the likelihood that Wnt expression is almost certainly highly complex, 
delivered from multiple cellular sources, and comes under additional control by a variety 
of other regulatory proteins such as WIF, sFz which are also modulated during HPC 
activation (Appendix 1) and are well described to play central regulatory role in the Wnt 
signalling pathway (Bi et al., 2009).   
 
A previous study performed using FVB mice has reported changes following 3 weeks 
of the DDC diet on the gene expression of a number of selected Wnts (Hu et al., 2007).  
In comparison to my work many similarities and differences are observed.  I did not 
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observe the large increases in Wnts 1, 5b, 7b and 11 previously reported.  My 
observations regarding the changes observed between Wnt 6 and particularly the large 
increase in Wnt 7a were however consistent with that of Hu et al.  (Hu et al., 2007).  In 
the normal whole liver my observations were broadly in keeping with the previous 
descriptions of comparatively high expression of Wnts 1, 2, 2b, 4, 5a, 5b and 11 (Zeng et 
al., 2007) .  In contrast to the published report which was performed in older C57Bl6 
mice I additionally observed consistent expression of Wnts 3a, 6, 7a and 16 in the 
healthy liver.  Whether these inconsistencies between these data reported in this study 
and previous publications are due to the changes in length of diet exposure, mouse age 
or strain are not clear, however a combination of these factors seem likely to explain 
these discrepancies. 
 
From the observations that macrophages produce Wnts in situ (Figure 5.5A) and that 
HPCs show reduced response to Wnt when macrophages are depleted (Figure 5.5B), I 
propose that the functional effects of macrophage depletion during HPC activation are 
mediated through a loss of Wnt expression.  This loss of Wnt reception by HPCs leads to 
a subsequent reduction in their Numb expression, with downstream effects on the Notch 
signalling pathway resulting in alteration in progenitor cell fate choice.  While this has 
not been formally tested in this work, we are planning to do this as part of ongoing study 
into HPC biology.  The role of Numb may also be directly assessed by knockdown using 
siRNA in the BMOL HPC line.  Additionally using HPC/macrophage co-culture the 
effects of paracrine signalling by macrophages to HPCs may be dissected.  When used in 
conjunction with interference with Wnt signalling by the use of recombinant Wnt 
inhibitors such as WIF and sFz we will be able to address the role of macrophage 
derived Wnt on cell fate choices by HPCs.   
 
As briefly introduced previously, it is interesting to note that there is no apparent 
alteration in the localisation of macrophages and HPC in either the DDC or CDE dietary 
models.  It appears that alterations in macrophage function between the two models 
account for the changes in Numb and secondarily HPC morphology.  To address this 
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question directly the HPC phenotype could be monitored following adoptive transfer of 
macrophages from the CDE diet treated liver to a DDC treated mouse and vice versa.  I 
would predict that in this instance Wnt-producing macrophages form the CDE treated 
liver would have a dominant effect, promoting a switch to an infiltrative HPC phenotype 
in this model.  Similarly, it would also be fascinating to examine the effects of switching 
the CDE diet to DDC diet and vice versa to examine whether one HPC phenotype 
(infiltrative or ductular) is dominant.  Should such experiments further support a role for 
macrophages in the establishment of HPC phenotype during regeneration then a central 
question remains why they should behave differently in the CDE and DDC models? I 
would propose that this is a function imposed upon them by their local environment and 
most likely in response to the local requirements for regeneration in the two model 
systems. 
 
A further implication of the work presented here is that the recruitment of 
macrophages to influence cell fate may explain other observations in liver regeneration 
made previously by other groups.  For example T3 is reported to influence macrophage 
migration and/or phenotype and separately described to improve the hepatocellular 
differentiation of HPCs.  Raised T3 promotes the accumulation of younger recently 
immigrated macrophages (Gomes et al., 2004).  It is therefore possible that the effects of 
T3 seen on improving hepatocyte differentiation of HPCs in the rat model (Laszlo et al., 
2008) may be explained by secondary effects upon HPC differentiation mediated by an 
accumulated macrophage population.   
 
5.81C Failure of the BATgal transgenic reporter system in the adult liver  
 
The use of Wnt reporter mice is a widely used and accepted practice for studying Wnt 
signalling.  A variety of such reporter strains are in wide use.  In general TCF/LEF 
elements or Axin2 promoters are used to drive a detectable protein such as GFP or β-
galactosidase (Barolo, 2006).  BATgal mice were one of the first such reporter mice to 
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be developed by Stephano Piccolo et al..  I opted to use these mice to study Wnt signal 
reception by HPCs at an early stage in this work prior to the publications by other 
groups using alternative transgenic reporter systems (Hu et al., 2007).  Unfortunately in 
none of the adult BATgal
+
 animals in my work was β-galactosidase detected.  
Interestingly this failure of β-galactosidase expression was also observed in the intestine, 
where Wnt reception has been repeated shown by other groups (Clarke, 2006).  Failure 
of β-galactosidase expression in the BATgal mice was not due to its technical failure of 
detection as it was reliably and consistently detected in contemporaneous ROSA26 
positive controls (Figure 5.6).  BATgal mice have been used repeatedly and successfully 
only in neonatal studies (Liebner et al., 2004; Maretto et al., 2003).  No reports exist to 
date of successful BATgal reporting in the adult.  It therefore appears that for epigenetic 
reasons, silencing of the BATgal reporter construct appears to occur in the adult mice.   
 
5.82 The role of macrophages in stimulating HPC expansion in the 
absence of injury 
 
An urgent need exists to develop therapies for liver disease.  The potential for 
manipulating the endogenous HPC population is both a feasible and attractive option.  
Genetic modification has shown the potential to influence HPC activity (Jakubowski et 
al., 2005; Knight et al., 2000) as has indirect (Spahr et al., 2008) and direct 
pharmaceutical targeting of HPC function (Knight et al., 2008).  The findings reported 
in this work highlight another therapeutic avenue by which host HPCs can be modulated 
exogenously.  I propose that the pathway of macrophage recruitment and TWEAK 
mediated HPC stimulation as a mechanism by which autologous BMC therapy may be 
beneficial in human liver disease.  Animal models of BMC therapy for liver disease and 
clinical autologous BMC therapy studies are already underway with encouraging 
preliminary results (Gaia et al., 2006; Houlihan and Newsome, 2008; Terai et al., 2005; 
Yannaki et al., 2006).  However until now there has been little or no mechanistic insight 
into how such “Bone Marrow Therapy” may be having its beneficial effect.   
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The novel observation reported here that a single infusion of either unfractionated 
BMCs or purified macrophages results in activation of an HPC response provides an 
explanation for how BM based therapy may be beneficial in chronic liver disease.  
Following whole BMC transfer, donor-derived macrophages engraft in recipient liver 
and stimulate HPC activation through a proposed paracrine mechanism involving the 
known HPC mitogen, TWEAK.  The beneficial effects of BMC transfer on recipient 
liver is exemplified by the observed changes in liver growth and enhanced hepatic 
function which, I propose is due to increased parenchymal mass resulting from 
differentiation of HPCs.   
 
In other organs and in the context of injury, previously published reports imply that 
macrophages can modulate stem cell behaviour.  These observations suggest a role for 
macrophages in linking the response to injury to the commencement of regeneration 
(Pull et al., 2005; Seno et al., 2009).  My observations both support, and extend these 
observations.  I demonstrate that macrophages are able to modulate stem/progenitor cell 
behaviour, even in the absence of injury.  Furthermore, my data supports the importance 
of the stem cell niche in this function, as donor-derived macrophages localise 
specifically to periportal liver regions where HPC expansion is known to originate from.   
 
Using BMC transfer I have observed a consistent and reproducible HPC expansion in 
the livers of healthy uninjured and un-irradiated mice.  Mice are described to show 
immunogenicity to sex-mismatched grafts in transplantation studies.  None-the-less the 
observation that this effect occurs either when sex-matched or sex-mismatched BMC are 
used argues strongly against the response being due to a minor histocompatability 
reaction in the sex-mismatched BMC groups.  The loss of HPC activation upon 
irradiation of the donor BMC further supports the requirement for functionality of 
BMCs and strongly argues against the involvement of either a bystander reaction to 
debris, or immunogenic antigens via a minor histocompatability reaction.   
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Interestingly when differentiated macrophages are delivered instead of whole BMC, 
the HPC response is only partially reversible by irradiation of the donor cells.  
Irradiation is believed to principally damage proliferating cells, with other quiescent cell 
populations such as fibroblasts being relatively resistant to even lethal irradiation (von 
Holzen et al., 2007).  Therefore, this implies that precursors in the BMC are responsible 
for the HPC activation while more mature cells in the differentiated macrophage 
population are capable of HPC activation in the absence of further proliferation.  
Certainly, the data examining the effects of differentiation on TWEAK expression in 
macrophages shows highly increased TWEAK production following macrophage 
differentiation (Figure 5.18A).  This then suggests that upon differentiation macrophages 
are already in a state where they may induce HPC activation without further 
differentiation.  The previous report showing that TWEAK production in the healthy 
liver in a transgenic mouse model is sufficient to induce HPC activation is therefore in 
keeping with these observations (Jakubowski et al., 2005).  Additionally the increase in 
TWEAK expression upon macrophage maturity suggests that TWEAK production is a 
function of macrophage maturity, although this remains to be conclusively tested.  
Additionally whether alterations in macrophage homing and engraftment in a healthy 
liver occur in immature versus mature macrophages is worthy of further investigation.   
 
The demonstration that HPC activation, in response to BMC transfer, is lost in 
constitutive Fn14
-/-
 mice is strong evidence for the TWEAK/Fn14 signalling pathway in 
HPC activation.  TWEAK ligand and the Fn14 receptor are believed to be monogamous 
with regard to signal transduction (Winkles, 2008).  None-the-less, TWEAK is also 
described to bind the scavenger receptor CD163 which is likely to add a further layer of 
control to TWEAK paracrine signalling (Bover et al., 2007).  As previously discussed, 
CD163 (also known as ED2) is a marker for mature tissue resident macrophages (Bilzer 
et al., 2006).  The data presented in this thesis suggests that even following engraftment, 
macrophages continue to produce TWEAK.  Whether they continue to do so following 
longer term engraftment, is not directly addressed and is an interesting question which in 
the future may be addressed by adaptation of the methodologies used here.  It is however 
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possible that in their immature and recently recruited state, macrophages are rich 
producers of TWEAK, but that with increasing CD163 expression mature tissue resident 
macrophages inhibit TWEAK/Fn14 signalling.  Furthermore, CD163 expression by 
resident macrophages is not static, being induced by IL-10 and IL-6 while pro-
inflammatory mediators like lipopolysaccharide, IFN- and TNF-, suppress CD163 
expression (Buechler et al., 2000).  This may then imply that freshly recruited 
macrophages provide more of a regenerative stimulus while more mature macrophages 
persistent in injured tissue are less pro-regenerative and perhaps more profibrotic.  
Additionally this process may be a further mechanism by which TWEAK mediated 
regeneration may be targeted therapeutically.  It will be important to observe the 
changes in TWEAK signalling which result from manipulation of these cytokines.   
 
The changes in liver structure and function which occur following either BMC or 
macrophage transfer appear to be temporality associated with the expansion of HPCs.  
The relative increase in liver size occurs between 3 and 6 weeks following BMC transfer 
and therefore is associated with, but lags slightly behind, the expansion of HPCs.  This 
relative hepatomegaly occurs following a period of relative reduction in liver size 
immediately following BMC transfer and therefore may represent a compensatory 
hypertrophy.  Interestingly in the longer term when HPC expansion normalises so does 
liver size; once again linking, by association, HPC expansion and liver growth.   
 
The data presented in this work provides strong evidence that macrophages are the 
cells within (or a product of cells within) whole BMC which are responsible for the 
activation of HPCs.  Macrophages recapitulate the HPC activation observed following 
whole BMC transfer.  Donor derived macrophages are identified in the right place at the 
right time, specifically in juxtaposition to HPCs as the HPC expansion begins.  
Additionally macrophages are the overwhelmingly dominant donor derived population 
within the recipient liver at this time.  Finally, engrafted macrophages are producing 
TWEAK signal in situ. TWEAK is not only known to be mitogenic to HPCs 
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(Jakubowski et al., 2005; Tirnitz-Parker et al., 2010) but additionally I demonstrate that 
HPC activation is reliant upon TWEAK signalling in this model.   
 
The failure of macrophage infusion to produce a more marked activation of HPC than 
BMC is striking.  Given that only a minor proportion of BMCs are (or may become) of 
monocyte lineage, a significantly larger number of macrophages are infused when a pure 
population of 10
7
 macrophages are infused compared to 10
7
 unfractioned BMCs.  The 
apparently high levels of TWEAK expression by in vitro differentiated macrophages 
were predicted at the time to lead to heightened HPC activation.  The reason for the 
failure of macrophages to produce a greater HPC activation compared to BMC is not 
currently clear.  It is conceivable that the pathway of HPC activation in this scenario is 
saturated upon delivery of 10
7
 cells in both instances.  Further planned dose response 
studies are likely to directly address this question.   
 
The work presented here does not exclude the possibility that other populations within 
whole BMC are capable of HPC activation.  I plan to address this question with future 
work using purified leukocyte and mesenchymal cell populations in transfer 
experiments.  Additionally experiments with the CD11b-DTR mouse system will permit 
the conditional ablation of CD11b
+
 macrophages from whole BMC derived from a DTR 
donor, within a wild type recipient.  It is not inconceivable that other cell populations 
may be able to active HPCs.  Lymphocytes, themselves described to activate HPCs 
(Strick-Marchand et al., 2008), are known to be recruited to the liver by activated 
myofibroblasts (Holt et al., 2009).  Lymphocytes, in similarity to macrophages, express 
a host of cytokines which are known to be mitogenic for HPCs when delivered by 
paracrine signalling (see Chapter 1).  Be this the case or not, the implications of the 
work presented here highlight the potential for the use of macrophages from a readily 
available autologous source as a means to therapeutically manipulate liver regeneration.  
Whether other leukocyte populations may show the same potential remains to be 
examined.   
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Previous reports support the proposal that macrophages may influence progenitor cell 
behaviour in vivo (see Chapter 1).  Recruitment of haematopoietic stem cells via CCR2 
to the sites of injury has been observed to promote tissue repair and regeneration (Si et 
al., 2010).  M-CSF deficient op/op mice are well described to have regenerative 
deficiencies in the liver in addition to other adult organs (Amemiya et al., 2009).  It is 
possible that the influx of leukocytes which typically occurs following liver injury is an 
integral mechanism by which regeneration is stimulated.  Therefore the artificial influx 
of macrophages following adoptive transfer into a healthy organ which I describe in this 
study may stimulate this regenerative response even in the absence of injury.   
 
My work to date has not addressed the mechanism by which macrophages given by 
peripheral vein infusion migrate to the liver.  As introduced in Chapter 1, this 
observation is well established although the specific engraftment in a selected few 
organs would suggest a targeting recruitment of leukocytes.  Macrophages are known to 
express CXCR4.  I would propose that our findings mirror the SDF1/CXCR4 axis 
previously described by Kollet et al.  where expression of SDF by bile ducts results in 




 progenitor cells following tail vein injection (Kollet 
et al., 2003).  Recruitment of lymphocytes has also been described to the liver via a host 
of chemokines, and in analogous fashion it is likely that macrophage recruitment to the 
HPC niche is promoted by a similarly complex cocktail of chemokines (Holt et al., 
2009).  Additional studies are being performed in the Fn14
-/-
 mice to investigate the 
possibility that the failure of HPC activation in this model is not due to a failure of 
engraftment of donor derived BMC/macrophages.  Additionally, this axis is being 
investigated using TWEAK knockout mice as donors in BMC and macrophage transfer 
studies and furthermore by using TWEAK neutralising antibody in wild type to wild 
type cell transfers.   
 
5.83 The use of macrophages as therapy for liver disease 
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The CCl4 model used to assess the effect of macrophage therapy on HPC expansion is 
a widely used and well validated method of induction of injury and fibrosis (Friedman, 
2008; Henderson and Iredale, 2007; Russo et al., 2006; Duffield et al., 2005).  Using 12 
weeks treatment reproducably induces significant fibrosis which falls short of cirrhosis 
histologically.  Mice in this CCl4 model were originally established to investigate the 
effect of macrophage therapy upon fibrosis remodeling and resolution.  Ongoing work 
using such fibrosis models will be a crucial next step in the validation of macrophage 
mediated HPC expansion as a therapeutically useful strategy for human chronic liver 
disease.  Preliminary work in this area by myself and others in the Forbes laboratory has 
shown consistent but often non-significant trends to increased HPC activation following 
macrophage infusion during CCl4 mediated hepatic fibrosis.  Further work to address 
this issue both in rodents and potentially also in human studies will be vital if such a 
therapy is developed in the future and may be performed in additional injury models.   
 
Changes in BM and macrophage function are well recognised with age (Gazit et al., 
2008; Kohut et al., 2004; Lloberas and Celada, 2002).  The burden of liver disease 
particularly in the UK is predominantly in an aged population (Leon and McCambridge, 
2006).  The predominant focus of my work investigating the role of macrophage and 
BMC stimulation on HPC has been performed in young mice (6-8 weeks) receiving cells 
from similarly young mice.  I have also investigated the effects of using aged BMC in 
stimulation of HPCs and found that the effect is reproduced when aged BMC are 
delivered and that there is no attenuation of HPC activation in this instance (Figure 
5.20).  Further studies to confirm whether aged mice will respond in a similar manner to 
cell infusion as young mice are needed.  However the preliminary study presented here 
demonstrates the potential efficacy of such a cell therapy in elderly patients. 
  
The description of a paracrine signalling mechanism between donor macrophages and 
host cells following BMC therapy is, to my knowledge, the first in liver.  Furthermore, 
the strategy of using peripherally applied autologous cells to modulate the regenerative 
response of the HPC compartment is entirely novel.  In contrast to traditional 
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stem/progenitor cell transplantation, this approach relies on the transient survival of 
infused cells, used not as direct precursors for tissue regeneration, but instead to target 
endogenous stem cells and utilise the liver‟s own regenerative capabilities.  This 
approach to regenerative medicine from a therapeutic standpoint offers several key 
advantages over others currently under investigation, including the ready availability of 
donor cells from an autologous source; the feasibility of the approach; and finally, our 
demonstration that the mechanism of action involves simple paracrine signalling 
between donor and host liver cells.  Rigorous characterisation of the stem/progenitor cell 
response invoked in host liver by cell therapy will be crucial to directing this work in a 
safe and efficacious manner.  Regardless, I believe this type of work exemplifies basic 
stem/progenitor cell science that has genuine translational human impact.   
 





 Macrophages influence HPC cell phenotype during in vivo expansion while not 
influencing the magnitude of expansion in response to injury 
 
 
 Macrophages stimulate HPC activation and alteration in liver structure and 
function in the absence of injury 
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Chapter 6: Hepatocyte MDM2 deletion reveals the 




 A transgenic model using inducible hepatocyte specific deletion of MDM2 will 




 To study a conditional model with complete functional repopulation of the liver 
by HPCs. 
 




The use of genetic manipulation is a powerful tool for the examination of genes and 
proteins in biology.  Genetic engineering may be used in an in vivo context where DNA 
that originated from the same (cisgenic) or different (transgenic) species is added or 
altered.  Genes may be manipulated by insertion or by their replacement, resulting in 
permanent expression or loss.  Alternatively regulatory elements may be added in the 
form of promoters which allow gene expression under certain conditions; for example a 
tissue specific or cell population specific context.  Furthermore, some genetic constructs 
allow exogenous control or inducibility.  Such systems include tetracycline or tamoxifen 
inducibility where gene transcription and protein localisation may be controlled by the 
addition of the exogenous substances.  Genetic recombination using either the Cre/Lox 
or Flp/FRT systems allows the site directed recombination of DNA under controlled 
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conditions both in vitro and in vivo.  By combining specific genetic promoters with this 
technology recombination may be once again targeted to specific tissues or cell 
populations.  Furthermore by adding an inducible element of control the recombination 
event may be induced in particular tissues or cells, as and when required.  Using such 
technology the loss or alteration of a gene can be studied in one target organ of interest. 
This is possible even if experimental animals cannot survive the loss of this gene in 
other organs or during development.  Furthermore genetic recombination allows 
examination of manipulation of specific cell populations in an otherwise wild-type 
environment in vivo.   
 
Expression of the site specific DNA recombinase enzyme (Cre recombinase or 
Flippase recombinase) can be used to alter the genetic sequence by recombination at 
predetermined sites containing specific DNA sequences (lox P or Flippase Recognition 
Target [FRT] respectively).  Two of each of these short palindromic sequences 
containing an asymmetric sequence are used to enable such recombination, which occurs 
a result of each double stranded DNA being cut by the recombinase protein.  The broken 
strands are then rejoined with DNA ligase; both quickly and efficiently.  The results of 
recombination depend on the position and orientation of the loxP sites.  For two loxP 
sites on the same chromosome arm, inverted loxP site will cause an inversion, while a 
direct repeat will result in a deletion event together with the production of a short 
circular DNA excision fragment (Mallo, 2006).   
 
The AhCre inducible activation system was originally described as a mechanism of 
targeting Cre recombinase expression in an inducible manner to the gastrointestinal tract 
(Ireland et al., 2004).  This report also described the induction of Cre recombinase 
within the liver in addition to the intestine together with lower expression in gallbladder 
and pancreas.  Here Cre recombinase expression in the liver was shown to occur 
throughout the lobule, with no hepatic zone failing to undergo recombination.  The 
AhCre system utilises the promoter element of the rat cytochrome P4501A1 (CYP1A1, 
also known as aryl hydrocarbon hydroxylase) gene to regulate Cre recombinase 
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expression (Campbell et al., 1996).  This promoter element is normally silent as 
demonstrated by the very low spontaneous recombination of floxed reporter elements.  
The promoter element is however strongly activated upon the cells exposure to defined 
lipophilic xenobiotics such as β-naphthoflavone (βNF).  Such xenobiotics act by binding 
to a cytoplasmic basic helix-loop-helix DNA-binding aryl hydrocarbon receptor (AhR), 
resulting in the dissociation of a Hsp90 dimer bound to the AhR (Matsushita et al., 
1993).  The AhR is then able to bind to an AhR nuclear translocator (Arnt).  This 
AhR/Arnt complex then binds, probably as part of a larger protein complex containing 
other DNA binding factors, to the xenobiotic responsive element of DNA which drives 
the inducible expression of the CYP1A1 gene (Figure 6.1B).  It is thought that this 
induction mechanism has evolved as system by which cells are able to degrade lipophilic 
xenobiotics only when required to do, thereby conserving unnecessary energy through 
the needless constitutive expression of CYP1A1 in the absence of lipophilic xenobiotics 
(Beresford, 1993; Guengerich et al., 1982).  This system is in many ways analogous to 
that of the lac operon used by bacteria to control the expression of β-galactosidase 
(Jacob and Monod, 1961).   
 
The AhCre system may be used to facilitate population specific recombination as 
described by Ireland et al.. Cytochromes are enzymes classically associated with 
hepatocytes, however as described above extrahepatic recombination has additionally 
been observed in other epithelial tissues (Ireland et al., 2004).  Within the liver, 
immunohistochemical analysis of CYP1A1 expression demonstrates a pan-lobular 
expression, and although basal expression is higher in zone 3, this gradient is lost upon 
induction with lipophilic xenobiotics such as βNF (Baron et al., 1982).  In a study 
investigating the spontaneous activation in the R26R reporter (Cre inducible β-
galactosidase) very little spontaneous activation of the reporter was seen in the livers of 
mice in the absence of induction with xenobiotics (Kemp et al., 2004).   
 
Using loxP mediated targeting the AhCre promoter therefore offers a mechanism of 
hepatocyte specific genetic recombination within the liver and consequently is a 
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powerful tool for researchers in the field of hepatic regeneration.  The choice of genetic 
target offers the potential to examine a variety of biological effects of hepatocyte 
manipulation.   
 
From a HPC regenerative standpoint there is a need to develop effective models for 
HPC induction as the mouse models previously described produce a rather limited 
induction of HPCs, particularly in comparison to what may occur in human disease 
(Chapter 1).  Furthermore the models in mice do so via an uncharacterised mechanism, 
hence dissecting the mechanism controlling HPC activation in such models becomes 
particularly challenging.   
 
As previously discussed, the activation of HPCs occurs when the regenerative capacity 
of hepatocytes is overwhelmed leading to activation of the facultative HPCs.  Therefore 
either massive injury is required, which itself brings with it the problem of morbidity 
and mortality, or inhibition of hepatocyte mediated hepatocyte regeneration is required.  
Hepatocyte senescence may be induced to varying degrees by a variety of toxic stimuli 
and does so by a complex process which includes the induction of p21 and p16 (Chapter 
1.31).  The growth arrest proteins, p21 and p16, are downstream of p53 which is seen as 
the master controller of cell fate choice.  p53 itself, stands at the junction of an 
extremely complex network of cellular signalling and assimilates and integrates different 
input signals such as oncogene activation, DNA damage, oxidative stress and mitotic 
impairment (Vousden and Lu, 2002).  As a result of these inputs p53 controls a variety 
of processes.  For example, p53 is known to modulate DNA repair, cell cycle arrest, 
senescence or even apoptosis.  Fine control over these processes is achieved through 
integration of signalling pathways. For example in the case of p53‟s control over 
apoptosis, regulation is achieved not only dependent upon the degree of p53 
phosphorylation but also the length of time phosphorylated p53 exists within the cell.  
Recent evidence suggests that low level and transient p53 activation results in the 
transcription of a programme acting predominantly to block the cell cycle while 
attenuating transcription of pro-apoptotic genes (Das et al., 2007).  When more 
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prolonged or more pronounced p53 activation occurs another set of pro-apoptotic genes, 
such as Bax, Perp, Puma and Noxa, are transcribed   (Aylon and Oren, 2007; Wang et 
al., 2007).  In summary therefore, prolonged activation of p53 has the potential not only 
to induce growth arrest and senescence within a cell, but also its eventual death by 
apoptosis (Aylon and Oren, 2007).   
 
Figure 6.1 Introduction to the AhCre MDM2flox model 
The arylhydrocarbon β-Napthoflavone (βNF) is used to induce the expression of Cre 
Recombinase in the AhCre promoter system (A).  The physiological role of CYP1A1 is to 
metabolise arylhydrocarbons.  (B) Following the exogenous addition of βNF, the 
arylhydrocarbon receptor (AhR) translocates to the hepatocyte nucleus, and upon binding to the 
CYP1A1 promoter induces CYP1A1 gene expression.  (C) The transgenic MDM2 construct 
utilises the insertion of Lox P sites (arrows) between exons 4 and 5, and 6 and 8.  Upon exposure 
to Cre Recombinase the floxed segment containing exons 5 and 6 is removed from gDNA 
resulting in a null MDM2 allele.  Exons are represented by green boxes, adapted from Grier et 
al.  2002.   
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Murine Double Minute 2 (MDM2), a gene found on mouse chromosome 9, is a key 
negative regulator of the p53 tumour suppressor.  Unsurprisingly MDM2 is frequently a 
site of oncogenesis (Momand et al., 1992), being amplified in many tumour types 
(Cahilly-Snyder et al., 1987; Evans et al., 2001).  MDM2 functions both as an E3 
ubiquitin ligase, that recognises p53, and an inhibitor of p53 transcriptional activation.  
MDM2's transcription is itself promoted by p53, and therefore MDM2 acts as an 
important negative feedback loop controlling p53 function.  Many oncogenic mutations 
have been described acting to increase levels of MDM2 expression thereby dampening 
p53 function.  Indeed the demonstration that the generation of cancer in p53 knockout 
mice is not affected by MDM2 or MDM4 knockout suggests that the major anticancer 
role of these proteins is via p53.   
 
Constitutive deletion of MDM2 is embryonic lethal, however rescue of such mice 
occurs in the context of p53 deletion, confirming p53's importance in MDM2 function 
(Jones et al., 1995; Montes de Oca Luna et al., 1995).  More recently a floxed construct 
of the murine MDM2 gene has been produced by placing loxP sequences within introns 
of the MDM2 gene, to conditionally deletion exons 5 and 6 (Grier et al., 2002).  Exons 5 
and 6 of MDM2 constitute the majority of its p53 binding domain (de Oca Luna et al., 
1996).  Homozygous floxed MDM2 mice (MDM2
flox/flox
) display no abnormal 
phenotype in the absence of recombination and yet recapitulate embryonic lethality 
when the floxed exons 5 and 6 are deleted (Grier et al., 2002).   
 
Therefore, I hypothesised that the hepatocyte specific deletion of MDM2 in the liver 
may provide an appropriate environment for HPC induction by the hepatocyte specific 
upregulation of p53.  I hypothesised that this accumulation of p53 would lead to 
impaired entry into cell cycle of hepatocytes; and furthermore may induce hepatocellular 
loss by the induction of apoptosis in recombined hepatocytes.  Therefore, in this 
environment, in which a variable degree of hepatocellular injury may be induced 
together with a widespread failure of hepatocyte mediated hepatocellular replication, one 
would predict that regeneration would occur from an HPC source.   
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To test this hypothesis, mice containing the AhCre construct were crossed with 
MDM2
flox




offspring.  Resultant off-spring were 
born at Mendelian ratios suggesting no embryonic phenotype.  These mice were healthy 
and appeared entirely normal as adults.   
 


























 mice, high levels of nuclear p53 protein are seen in hepatocytes throughout 
the hepatic lobule, including those abutting the limiting plate in zone 1 and central vein 
in zone 3 (Figure 6.2).  To assess the recombination efficiency following a single 
80mg/kg βNF induction, assessment of hepatocytes with raised p53 expression was 
performed in mice 2 days following induction which confirmed highly efficient 
hepatocyte specific genetic recombination of the MDM2 gene (Figure 6.2).   
 
The efficiency of recombination in this model was examined in more detail using a 
gDNA qPCR based approach.  Using two primer sets in parallel to amplify a segment 
within the floxed region of the MDM2 gene construct, along with a reference segment 
out with the floxed segment, the efficiency of deletion of the floxed segment was 
assessed.  Firstly a methodology for highly pure hepatocyte enrichment was developed 
using 3 sequential density gradient centrifugation steps.  All cells, isolated using this 
protocol were large with hepatocyte-like morphology at cytological assessment (Figure 
6.6A).  Cells were assessed for purity by CYP2D6 immunocytochemistry (Figure 6.6B).  
415/415 cells expressing CYP2D6 corresponding to >99% purity (p<0.05). 
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When hepatocytes and non-parenchymal cells were isolated and purified following 




 mice and the efficiency of recombination 
assessed quantitatively by gDNA qPCR only 3.2% of MDM2 genes in hepatocytes 
failed to undergo MDM2 inactivation.  Hepatocytes, but not other non-parenchymal 
cells, underwent recombination in keeping with the known expression of CYP1A1 by 
hepatocytes (Oinonen and Lindros, 1998).  Of the non-parenchymal cell fraction only 
0.8% of MDM2 genes underwent MDM2 gene inactivation. 
 
6.5 Hepatic phenotype following hepatocyte specific MDM2 gene 
deletion  
 
6.51 Induced hepatocyte senescence in the AhCre MDM2flox model 
 




 mice clinically lose weight and 
develop bilirubinuria (as confirmed by urine dipstick), approximately 4 days following 
induction.  Given the increases observed in p53 protein, I then asked whether this over 
expression had functional consequences which may be responsible for these clinical 
signs.  Firstly levels of p21 were seen to rise at both the protein and RNA level (Figure 
6.3A and B).  Other downstream targets of p53 such as p16 also increased following 
induction but over a slower time course (Figure 6.3C).   
 
Increases in p53, p21 and p16 were hypothesised to give rise to senescence in the 
recombined hepatocytes.  This was tested by examining the presence of the senescent 





galactosidase was seen to be widely expressed by hepatocytes following the induction 
with βNF (Figure 6.3B).  
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Figure 6.2 Highly efficient recombination following βNF induction 
(A) 2 days following induction with 80mg/kg i.p. βNF mouse liver analysed with p53 














 mice.  (B) Using an optimised method of isolating pure 
populations of primary hepatocyte, a >99% pure population of hepatocytes was obtained as 
assessed by CYP2D6 expression.  (C) Hepatocytes isolated 2 days following induction using 








 were assessed 
for p53 expression the overwhelming majority of these hepatocytes are p53
hi
.  (D) Combination 
of qPCR primers sets directed at regions outside (reference sequence) and inside the floxed 
segment of the MDM2 gene were used for detection of gDNA from purified isolated hepatocytes 









 control mice 2 days following βNF (; n=3 each group). 
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Figure 6.3 Hepatocyte specific MDM2 deletion results in hepatocyte senescence 
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(A) 2 days following induction with 80mg/kg i.p. βNF mouse liver analysed with p21 









controls consistent with elevation at the RNA 
transcript level over time (B).  p16, a downstream prosenescent target of p53, is also elevated 
over time following MDM2 inactivation (C).  (D) Senescence associated β-galactosidase 
expression 4 days following βNF induction.  Using a mitogen cocktail of HGF and T3 










 mice 3 days following 80mg/kg βNF.  (E) Representative 




proliferation are shown for dual immunohistochemistry 
for CYP2D6 (red) and BrdU (green).  (F) Proliferation, 24 hours later, was assessed by 
immunohistochemistry for BrdU in CYP2D6
+
 hepatocytes (n3 each group).  (G) Analysis of 




 hepatocytes following mitogen and control treatment with 
representative immunohistochemical analysis (H) performed using p53 (red), BrdU (green) and 
CYP2D6 (blue).  No proliferation of p53
hi
 hepatocytes is seen in WT controls while only a 
single cell was p53
hi







mice.  In contrast, frequent p53
hi






 mice.  All scale bars denote 50m. 
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Hepatocyte senescence was also tested functionally by assessing whether recombined 
hepatocytes are able to respond to a combination of known mitogens (T3 and HGF), by 
entering cell cycle.  When this mitogen cocktail is administered in vivo, significant entry 
into S-phase is observed within the hepatocyte population in control mice.  This effect 




 mice after 
hepatocyte specific MDM2 deletion (Figure 6.3E and F).  Therefore, a combination of 
senescence associated markers and failure to respond to normally mitogenic stimuli 
indicates a state of senescence is achieved in hepatocytes following induction in the 
AhCre MDM2
flox
 model.   
 
Induced hepatocyte senescence is p21 dependent 
 
To test whether the senescence phenotype induced in hepatocytes following MDM2 




mice were bred onto a 
p21
null
 background.  When the same in vivo mitogen stimuli used previously were 
applied to these mice hepatocytes did respond to the mitogen cocktail and enter cell 
cycle even after induction using βNF.  This was in contrast to their p21
wt
 controls which 
did not respond to the mitogen cocktail (Figure 6.3F).  This therefore demonstrates that 
p21 plays a central role in the induction of senescence following MDM2 loss.  Further 
detailed examination of the characteristics of the proliferating cells in this model 
revealed that the increased proliferation in the p21
null
 mice, versus p21
wt
 mice, occurred 
in p53
hi
 hepatocytes (Figure 6.3G and H).   
 
6.52 Induced hepatocellular injury in the AhCre MDMflox model 
 




 mice, dramatic rises in ALT, AST, 
bilirubin and alkaline phosphatase are observed (Figure 6.4A-D).  Derangement of liver 
function is observed with increase in Alt from a baseline of 42U/L to a peak of 471U/L 2 
days following induction (Figure 6.4C).  Similarly AST increases from a baseline of 246 
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to 1170U/L (Figure 6.4B).  Associated increases in bilirubin and alkaline Phosphatase 
and a reduction in serum albumin are also witnessed, in keeping with hepatic injury 
(Figures 6.4C-E respectively).  The onset of bilirubinuria, along with associated 
derangement of the liver function tests provides a rudimentary assessment of liver injury 
in these mice.  Liver injury was also assessed histologically, revealing evidence of 
profound hepatocellular death (Figure 6.4F).   
 
Hepatocyte apoptosis was assessed using TUNEL staining demonstrating the 
occurrence of significant and widespread hepatocyte apoptosis (Figure 6.4G).  
Furthermore, a p53 dependent pro-apoptotic program consisting of Bax 1 and PUMA is 
activated following βNF induction (Figure 6.4H and I).  Highest expression of both Bax 
1 and PUMA occurs 2 days following induction with 11.7 and 2.72 times expression of 
induced control mice observed respectively.  Together, these results show that the loss of 
MDM2 function and consequent elevation of p53 results in injury, together with the 
previously observed senescence. 
 
6.53 Induced massive HPC activation in the AhCre MDM2flox model 
 
Given the induction of both hepatocyte senescence and hepatocellular injury following 




 model, I hypothesised that HPC activation 
would also occur in response to this regenerative stimulus.  Using a variety of HPC 
markers, including panCK, Dlk1 and EpCAM, a progressive and massive HPC 




model (Figure 6.5).  In similarity to the 
phenotype of HPC activation in the murine CDE diet or rat PH/AAF model, HPC 
activation in this instance occurs in an infiltrating phenotype.  Here HPCs extend as 
cords rather than ducts and infiltrate into the hepatic parenchyma (Figure 6.5A).  
Consistent with the histological evidence of significant HPC activation an elevation of 
HPC markers at the RNA level is observed in whole liver following βNF induction 
(Figure 6.5E-G). 
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Figure 6.4 Hepatocyte specific MDM2 deletion results in hepatocellular injury 
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controls: (A) ALT (B) AST (C) Bilirubin (D) Alkaline Phosphatase and (E) Albumin.  (F) 









respectively), but widespread parenchymal injury is observed on H&E staining 8 days following 




 mice.  (G) TUNEL staining 
(Alexa 488 detection; green and DAPI; blue) reveals widespread parenchymal apoptosis 5 and 8 




 controls given 80mg/kg i.p. βNF (a 
rare apoptotic cells in day 5 control mice is shown while representative field shown for day 8 
control).  Whole liver analysis by qRT-PCR for apoptosis associated gene Bax 1(H) and PUMA 




data points, control data for days 2 and 5 n=3, and n=2 for 




The HPC activation which occurs following induction in the AhCre MDM2
flox
 model 
is striking, with large numbers of HPCs observed as early as 8 days following induction 
of genetic recombination.  This response is much more rapid than the HPC expansion 
observed with the CDE diet (Chapter 3). Furthermore, the magnitude of the HPC 




model is significantly greater than the CDE diet (243 
vs.  61 HPCs per field respectively; Figure 6.5).   
 





, morbidity with hunching piloerection and social withdrawal and even 
occasional mortality occurred.  Together with the changes described above, this implied 
that these clinical consequences were related to liver injury.  I therefore asked whether 
these side effects were associated with the degree of induction in hepatocytes?  Using 
identical induction doses of βNF in aged matched female mice, induction of widespread 
p53 over-expression is noted in the liver 2 days following induction (Figure 6.6A).  
However while widespread, the p53 upregulation in female mice, it was induced at 
obviously reduced efficiency in comparison to male mice receiving the same induction 
regime.   
Using qPCR (as previously described in Figure 6.2) to assess recombination in this 
population 19% of MDM2 genes retained the floxed segment of the gene corresponding 
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to 81% recombination at the chromosome level (Figure 6.6C).  While not as efficient as 




 model (see Section 6.41), this 
remains a highly efficient induction system.  When induced, with this resultant lower 
efficiency, female mice did not display the severity or frequency of clinical side effects 
observed in their, more efficiently induced, male counterparts. 
 
6.6 Characterisation of hepatic phenotype in alternative models of 
transgenic MDM2 deletion in AhCre MDM2
flox
 models  
 
The effect of the lower proportion of hepatocyte recombination on the resultant HPC 




 mice.  In this model, an 
attenuated expansion of panCK
+
 HPCs is observed peaking again at approximately 6-8 
days following induction (Figure 6.6B).  Here no animal mortality was observed, with 
all mice surviving to at least 45 days without significant morbidity.  This is in significant 
contrast to universal  requirement for humane euthanasia by day 9 following induction in 
male mice given the identical induction regime.   
 




 mice, using lower 
induction doses (40mg/kg βNF), results again in lower efficiency of p53 induction and 
minimal expansion of HPCs (Figure 6.6D).  Once again this induction is associated with 
no significant mouse morbidity or mortality that observed with the previous higher dose 
(80mg/kg βNF) in male mice.  These results are, once again, in keeping with a dose 
dependent induction of recombination. Similarly higher induction doses (3x80mg/kg 




 mice results once again in mortality.   
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Figure 6.5 Progressive activation of HPC following induction in the AhCre MDM2 
model 
(A) Following induction with 80mg/kg i.p. βNF a progressive and dramatic expansion of 
panCK
+
 HPCs is observed within the liver.  (B) Quantification of HPCs over time (n3 each 







 (hom) mice at time of maximum HPC expansion (day 19 
and 8 respectively) vs.  maximal HPC expansion in CDE diet (Day 12).  (D) HPCs express Dlk1.  
Corresponding changes in mRNA expression of HPC markers CK19, Dlk1 and EpCAM (E-G 
respectively)are observed vs.  control in the AhCre MDM2
flox
 model (all MDM2 time points 
n=3, all controls n3).  *p<0.05, **p<0.01, ***p<0.001 by Mann Whitney test, all scale bars 
denote 50m. 
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 Figure 6.6 Reduced recombination and HPC activation in female mice  
 




mice leads to widespread but 
incomplete p53 upregulation in hepatocytes 2 days following induction, while no p53 over 




 controls following βNF (A).  Expansion of 
panCK
+






 controls (B).  qPCR 




 over time reveals 
reduced efficiency of recombination with only 81% of MDM2 genes being inactivated 2 days 





mice survive beyond 19 days without HPC expansion when induced with 
the lower 40mg/kg i.p. βNF induction regime (D). 
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Figure 6.7 Efficient recombination but delayed hepatic injury in AhCre MDM2-/flox 
mice 





exceptionally efficient hepatocyte specific p53 upregulation is observed by 





 HPC expansion over 3 weeks (B). 
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6.61 Hepatic parenchymal repopulation in the AhCre+ MDM2flox/- model 
 
In an alternative model of MDM2 inactivation, congenitally heterozygous MDM2 
deficient mice (which show no overt phenotype mice), were crossed onto an MDM2
flox
 




mice.  Following MDM2
flox
 inactivation by 
administration of 80mg/kg βNF highly efficient recombination was once again observed 
by hepatocyte specific p53 upregulation (Figure 6.7A). This effect is comparable to that 




male mice (section 6.2). Once again in this 




 HPCs is observed (Figure 6.7B, see 














 mice remain healthy over the period of the first two weeks, with a minority 
of mice developing clinical signs of liver injury between 14 and 21 days.  These signs 




 mice at approximately 
1 week post-induction.  Most heterozygote mice however survived without the need for 
humane euthanasia.  The development of clinical signs is once again consistent with the 
contemporaneous development of dramatic HPC activation.  Analysis of liver injury 
both histologically and by TUNEL assay reveals marked hepatocellular injury and 
apoptosis over this period (Figure 6.8A and B).  Serum analysis also confirms the 
presence of liver injury with raised transaminases and bilirubin (Figure 6.8C and D).   
 
In summary therefore, differing levels of hepatocyte recombination may be achieved 
together with different levels of resultant liver injury occurring over defined but variable 
time courses by using different induction regimes. Differing induction regimes used here 
took the form of dose adjustments of βNF, altering the mouse sex, and/or genotype. 
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Figure 6.8 Hepatocellular injury and apoptosis in the AhCre+ MDM2flox/- model 
 




 mice, apoptosis was 
assessed by TUNEL assay (A) together with liver injury by H&E (B).  Apoptotic cells (brown) 
can be seen as early as 2 days following induction with increased numbers 19 days post 
induction.  Corresponding serum analysis for AST (C) and Bilirubin (D); n5 each group (AST 
P<0.0001; T test). 
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In each of the models described above both the number and proportion of p53
hi
 
hepatocytes in livers reduced over time after induction.  This implies a gradual loss of 
p53
hi
 recombined hepatocytes.  As widespread hepatocyte apoptosis occurs following 
recombination, the reduction in overall p53
hi
 hepatocyte number might be expected.  
Therefore the change in proportion of p53
hi
 hepatocytes was not necessarily unexpected, 
however it was also clear that liver function and architecture returned to normal over a 
period of time (Figure 6.9A). This was also accompanied resolution of HPC activation.   
 
With the hypothesis that HPCs were the precursor source for hepatocyte regeneration 
in this model, I asked whether there was evidence of HPC mediated regeneration in the 
AhCre MDM2
flox
 model.  To do so, I utilised the observation that all hepatocytes could 
be induced to undergo recombination to lineage trace hepatocyte versus non-hepatocyte 
mediated regeneration of freshly derived hepatocytes in this model.   
 
As previously described, hepatocyte proliferation (assessed by BrdU incorporation) 
following recombination was extremely rare (Figure 6.3), implying a limited role of 
hepatocyte mediated hepatocyte regeneration.  Furthermore the rare hepatocytes 
identified in cell cycle 4 days following recombination were overwhelmingly p53
low
, and 
therefore likely themselves to be from a non-recombined precursor source.  The 
permanent genetic recombination in the hepatocyte population following induction 
affords an ability to separate regeneration from a recombined (e.g. hepatocyte source) 
from a non-recombined (e.g. progenitor cell source).  In support of an HPC mediated 
regenerative response in this model I observed a reducing proportion of p53
hi 
hepatocytes over time, even in the highly efficient recombination models (Figure 6.9C).   
 
Therefore, in this novel model, an unrecombined and undifferentiated source of 
hepatocytes is responsible for the replenishment of freshly derived hepatocytes.  I 
therefore assessed whether HPCs may be the source of these freshly regenerated 
hepatocytes in this model.  As previously described a large expansion of HPCs is 
observed following induction (Figures 6.5 and 6.7).  
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Figure 6.9 Regeneration of hepatocytes from a precursor source  




mice 6 months following 
induction with 80mg/kg i.p. βNF by H&E (A) and panCK immunohistochemistry (B) reveals 
resolution of injury an associated loss of HPC activation over time.  Assessment of proportion of 
recombined hepatocytes over time using detection of CYP2D6 (red) and p53 (green) in the same 
groups of mice (C) with quantification of recombined hepatocytes expressed % total hepatocytes 




 control mice at each time 
point).  All scale bars denote 50m. 
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In order for panCK
+
 HPCs to be a potential source of regeneration of hepatocytes in 
this model they must themselves not undergo genetic recombination of the MDM2 locus 
in response to βNF induction.  Once again using p53 upregulation as a marker of MDM2 
gene deletion, there was no evidence of recombination in the panCK
+
 HPC compartment 
(Figure 6.10).  Additionally in the portal areas p53
low
 hepatocytes were observed and 










To investigate the potential for HPCs derived from the MDM2 model to differentiate 
into hepatocytes in vitro, HPCs were extracted and subsequently cultured under 
differentiation conditions.  HPCs were isolated at the time of peak HPC activation (eight 
days following induction), and purified and then cultured in vitro.  These cells retained 
small, HPC like morphology until cultured under differentiation conditions, following 
which they developed a hepatocyte like morphology.  Analysis of expression patterns of 
the hepatocyte marker HNF4α demonstrated that HPCs in vitro may differentiate into 
hepatocyte-like cells under differentiation conditions (Figure 6.11A and B).   
 
RNA expression analysis of these populations revealed a reduction in HPC markers 
without the consistent development of a differentiated hepatocellular-like phenotype 
(Figure 6.11C).  While Dlk expression fell under differentiation conditions, Fn14 gene 
expression was increased and no significant changes were identified in CK19, EpCAM, 
HNF3β, HNF4, and HNF1β (Figure 6.12).  Albumin gene expression fell significantly 
during differentiation conditions but was strikingly lower than hepatocyte control in both 
undifferentiated and differentiated HPCs.  Asialoglycoprotein gene expression was not 
detected consistently in either HPC population (sensitivity 4000x less than hepatocyte 
control).   
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Figure 6.10 HPCs are not phenotypically affected by induction in the AhCre 
MDM2flox model  
Confocal analysis following immunohistochemical identification of p53 status of panCK
+
 HPCs 




 mice.  p53
hi
 
hepatocytes are observed within the parenchyma (arrows).  panCK
+
 HPCs are not p53
hi
 (hollow 
arrowheads).  Additionally p53
lo
 hepatocytes are observed in the portal tract often in direct 
contact with panCK
+
 HPCs (solid arrowheads).  Scale bar denotes 50m. 
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Figure 6.11 In vitro evidence for HPC mediated regeneration 
(A) 




mice 8 days after βNF induction 
(1x80mg/kg; n=3).  NPCs were cultured for 14 days in low serum HPC media to remove 
contaminating endothelia at which point no cells (n=308 from 4 independent experiments) 
expressed HNF4 (E).  Following HPC differentiation HNF4 expression was noted on 12.6% 
of cells (n=1145 from 4 independent experiments).  No significant changes in HNF4 (C), 
HNF3β were seen on a population basis following 5 days in differentiation media.  RNA 
analysis performed in triplicates from n=4 samples in each group. 
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Figure 6.12 Gene analysis following in vitro differentiation of HPCs 
RNA analysis of HPC and hepatocytic gene expression on a population basis from in vitro 
cultures HPCs as shown previously in Figure 6.11.  Gene expression of HNF3β (A), CK19 (B) 
and FP (C) did not change upon differentiation of HPCs in vitro while Dlk gene expression fell 
(D) during this time while Fn14 (E) EpCAM (F) and Albumin (G) gene expression increased.  
Asialoglycoprotein expression was not detected in either HPC population (H) RNA analysis 
performed in triplicates from n=4 samples in each group.   
 
 





In order to examine the differentiation capacity of panCK
+
 HPCs in vivo a BrdU pulse-
chase strategy was used.  Following initial trials of BrdU delivered at either 2,4,5, or 8 
days following induction it was noted that if BrdU was delivered 2 days following 
induction a high proportion of BrdU labelled cells were panCK
+
 (Figure 6.13A).  This 
time point represented the period with the largest proportional BrdU labeling of panCK
+
 
HPCs, none-the-less BrdU label expression was not isolated to the panCK
+
 population 
even at this optimal time point.  When BrdU was administered at day 2 and liver 
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analysis performed 2 days later, limited BrdU expression was observed in control 
animals, whilst in experimental animals a dramatic periportal BrdU labelling was 




 model (Figure 6.13A).  BrdU labelled cells in the 
periportal area included cells with hepatocyte like phenotypes (Figure 6.13B) and cells 
with enlarged nuclei but with intermediate expression of panCK, analogous to small 
hepatocyte like cells (Figure 6.13C).  Additionally when female mice were given BrdU 4 
days following induction were assessed at day 8 clustered of periportal BrdU
+
 cells were 




 cells and BrdU
+
 hepatocytes (Figure 6.13D).   
 
Examination between the relationship of HPCs and liver regeneration in the 
repopulating AhCre MDM2
flox/- 
model was performed by assessing the identity of 
proliferating cells during the period of hepatocyte repopulation.  At this time large 
numbers of proliferating (Ki-67
+
) hepatocytes are observed (Figure 6.14).   
 
6.9 Absence of long term sequelae following complete hepatic 
parenchymal regeneration in the AhCre MDM2
flox/-
 model  
 





significant morbidity and mortality ensues.  Therefore, in this model it is not possible to 
ask the question: what are the functional consequences of regeneration of hepatocytes 
from HPCs? I therefore sought to examine whether this question could be addressed 
using an alternative model in which large scale hepatocyte repopulation was once again 
observed but in which the clinical consequences were not as severe.  Working under the 





 mice was due to the partial compensation of chronically reduced MDM2 
expression in p53 regulation, I examined hepatic repopulation in these mice.  Once again 
using p53 as a marker for MDM2 recombination, following full induction long term 
restoration of hepatocytes was observed in these mice (Figure 6.19).  I then sought to 
address whether any long term sequelae were observed following complete hepatocyte 
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repopulation alongside dramatic HPC induction.  No hepatocellular carcinomas were 
observed in this cohort (n=6) and detailed analysis by H&E (Figure 6.9A) and by Pico 
Sirius Red staining revealed a normalisation of liver architecture in the absence of 
fibrosis (Figure 6.15).   
 
Figure 6.13 Product precursor relationship from HPCs to hepatocytes in vivo 
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treated with BrdU.  (A) When BrdU is administered 2 days following induction with 1x80mg/kg 




 mice, analysis 2 hours following BrdU reveals frequent BrdU 
labelling in panCK
+
 HPCs.  When mice are then analysed a further 2 days after BrdU, BrdU is 
observed in large numbers of panCK
-





given the same regime of βNF and BrdU show only very limited BrdU label in the portal areas 2 




2 days following 
BrdU reveals BrdU
+
 hepatocyte-like cells in the portal areas some which do not (B) and some 
which do possess weak panCK
+





are induced with 1x80mg/kg βNF, given BrdU 4 days later, and liver analysis 
performed after a further 4 days, periportal clusters of BrdU
+
 cells are observed containing both 
panCK
+
 HPCs and hepatocytes.  Scale bar denotes 50m. 
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Figure 6.14 Generation of proliferating hepatocytes from HPCs 





mice.  HPCs are assessed by panCK and proliferation by Ki-67.  
When the relationship between cords of Ki-67 positive hepatocytes to HPCs is assessed each 
stream of proliferating hepatocytes can be observed to lie in direct opposition to the distal tip of 





6.10 Manipulation of HPC results in altered regeneration in the AhCre 
MDM2
flox
 model  
 
Having previously demonstrated a role for TWEAK in the activation of HPCs 
following macrophage infusion I hypothesised that TWEAK would also be mitogenic 
stimulus in HPC mediated regeneration in the AhCre MDM2
flox
 model.  To test this and 
observe the functional consequences of impaired TWEAK signalling in HPC mediated 
regeneration this pathway was manipulated both by impaired and augmented TWEAK 





 mice were bred with Fn14
-/-







 mice.  Augmentation of TWEAK signaled was achieved by 
delivery of an Fn14 receptor agonist antibody (Fn14Ab). 
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Figure 6.15 Absence of fibrosis following complete hepatic repopulation by HPCs 
Analysis of fibrosis over time in the AhCre MDM2
flox/- 
model using picosirius red histochemistry 
reveals normal baseline appearances of the liver and no fibrosis 2 days following induction with 
1x80mg/kg βNF (A).  Localised minor increases in picosirius red staining are seen in periportal 
regions 19 days following induction (inset).  Near complete resolution of periportal fibrosis is 
observed 6 months following induction at the time of complete hepatic reconstitution.  
Comparison is made to the fibrosis observed in a 12 week CCl4 model (courtesy of Jules Thorn 
Group).  (B) Quantification of fibrosis using image analysis reveals no significant change in 









 controls.  P values denote T test results.   
 
 
When examined 4 days following induction under these conditions effect on the 
number of HPCs were clearly visible with TWEAK signalling manipulation. A reduced 
HPC response was observed in the context of Fn14 deficiency, whilst an augmented 
HPC activation was seen in mice given the stimulatory TWEAK antibody (Figure 6.16A 
and B).  As previously described, this model would be expected to lead to moderate 






 however, exhibited 
severe clinical side effects as early as day 3 which lead to the requirement for humane 
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euthanasia 4 days following induction in all mice tested.  These clinical signs were 
indistinguishable from those described in their Fn14 competent counterpart but occurred 
with greater severity and at an earlier time point.   
 
 
Figure 6.16 TWEAK dependent regeneration in the AhCre MDM2flox model  





mice were induced with 1x80mg/kg βNF and the HPC response 









receiving Fn14 stimulating antibody given 1 day prior to 
and 1,2, and 3 days following induction.  When HPC activation was assessed by quantification 
of panCK
+









) background.  HPC 




 are treated with Fn14 stimulating 
antibody (Fn14Ab) at day 2 and 4 following induction with 80mg/kg βNF.  Control mice 
received IgG2a control antibody.  Values are presented as meanSEM for MDM2, Fn14
ko
 and 
Fn14Ab (20.531.1, 5.180.6, 34.5524.6 respectively).   




6.11A Efficiency of transgenic induction in AhCre MDM2flox model 
 
The use of transgenic technology has provided an exceptionally powerful tool in the 
study of cellular biology and has offered great insights into stem cells.  The use of 
inducible transgene activation/deactivation permits the detailed examination of the 
effects of a specific abnormality generated in an otherwise normal in vivo system.  It is 
however, highly dependent upon the efficient and specific targeting of transgene 
alteration.  In addition to facilitating examination the effects of genetic manipulation 
within this population, the AhCre inducible promoter system offers other utilities.  
Whilst the identity of the hepatic stem cell remains elusive the opportunity to utilise an 
inducible hepatocyte specific promoter is particularly appealing, as it permits the 
separation of a differentiated hepatocyte population from that of hepatocyte precursors.  
By observing the fate of genetically altered populations, the fate of hepatocytes may be 
observed, and additionally all hepatocytes which arise from progenitors may be 
differentiated from this originally labeled population.   
 
The elegance of the AhCre MDM2
flox
 model in the liver is that it induces changes in 
the hepatocyte population specifically and extremely efficiently.  This specificity has 
previously been implied but not examined specifically (Ireland et al., 2004).  The 
inducibility of cytochromes is a key feature of differentiated hepatocytes (Hay et al., 
2008) and therefore the demonstration in this work that within the liver only hepatocytes 
undergo genetic recombination in response to βNF induction is not surprising.  What is 
particularly impressive in this system is the efficiency with which recombination can be 
achieved (Figure 6.2).  Assessing this efficiency either by examining downstream 
changes in cell gene expression, for examples p53 or p21 (Figures 6.2 and 6.3), or 
examination directly the efficiency of deletion of the MDM2 gene of the gene (Figure 
6.6) reveals recombination up to the limits of detection in the most efficient 
Chapter 6-Hepatocyte MDM2 deletion reveals the potential of HPC mediated regeneration 
 240 
recombination models.  The limits of detection, in this setting using quantification of 
p53/CYP2D6 dual immunohistochemistry, relies on the accurate assignment of 
hepatocyte identity and assessment of p53 status, each of which is made independently 
by the methodology employed.  Therefore potential false negatives may arise by the 





 phenotype to a p53
intermediate
 cell.   
 




 control mice reveals that a single 





 confirmed that p53 up-regulation does not result from the loss of a 
single functional MDM2 allele in a mouse with two previously functioning MDM2 





mice results from the deletion of the floxed segment 





 mice is a reflection of the recombination of the floxed 
MDM2 allele and not an indirect effect of βNF upon the liver itself.  Therefore it follows 
that recovery of hepatocytes with a floxed segment must therefore occur from cells 
which contain at least one floxed allele which at no point underwent recombination.   
 
The efficiency of the AhCre construct for induction of hepatocyte specific 
recombination also lends itself to labelling the hepatocyte population for lineage tracing 
studies.  Whilst the AhCre MDM2
flox
 model allows lineage tracing of the hepatocyte 
population, a key feature of this model is that an altered phenotype is synchronously 
imposed upon the labelled hepatocytes by the dis-inhibition of p53.  Using the AhCre 
inducer with a purely labelling construct such as Lox-Stop-Lox EYFP (Srinivas et al., 
2001; Wang et al., 2009) would in theory permit the analysis of the hepatocyte 
population in an otherwise healthy liver.  Furthermore, in addition to lineage tracing or 
the induction of deleterious effects upon hepatocytes, positive or pro-survival genes 
could be induced using a similar methodology.   
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6.11B Induced hepatocyte senescence in the AhCre MDM2flox model 
 
Over expression of p53 in other environments is strongly associated with the 
development of a senescent phenotype (Xue et al., 2007; Brooks and Gu, 2006).  I 
therefore hypothesised that increased hepatocyte p53 following disabling MDM2 
function may result in cell cycle arrest.  To test this hypothesis senescence associated β-
galactosidase was examined revealing widespread expression in contrast to control mice.   
 
β-galactosidase expression is associated with a senescent phenotype in the liver 
amongst other organs (Paradis et al., 2001).  None-the-less, I wished to test directly 
whether these cells were senescent by delivering a stimulus which is capable of inducing 
proliferation in wild type hepatocytes.  The combination of HGF and T3 used here 
induced significant elevation in BrdU incorporation by hepatocytes in keeping with their 
effects in the rat (Forbes et al., 2000).  When applied to AhCre MDM2
flox
 mice 
following induction this mitogen cocktail failed to induce hepatocyte proliferation 
(Figure 6.3).  Increased non-parenchymal cell proliferation was however observed 
(Figure 6.3E).  Analysis was performed to exclude the detection of such non-
parenchymal assessment using colocalisation of nuclear BrdU in CYP2D6
+
 hepatocytes.  
As such any effects of the mitogen cocktail on the proliferation of other non-
parenchymal cell populations including HPCs which are described to be sensitive to the 




 mice, a relative failure to proliferate upon exposure to 
exogenous mitogenic stimulus is observed, however hepatocyte proliferation is not 
entirely impaired when examined 4 days following βNF induction.  Interestingly while 
exceptionally efficient p53 induction is seen at day 2 following induction, when analysis 
was performed for the p53 status of proliferating hepatocytes in the AhCre MDM2
flox
 
model virtually all proliferating hepatocytes were p53
normal 
(only a single p53
hi
 
hepatocyte contained nuclear BrdU in the examination of entire sections from 6 
recombined animals).  The observation that p53
normal
 status at day 4 only occurs in a 
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small minority of hepatocytes implies these cells represent freshly derived hepatocytes 
from a non-recombined source, which in the presence of exceptionally efficient 
hepatocyte recombination two days previously may point to a hepatocyte precursor cell 
as the source of these freshly derived hepatocytes.   
 
As a downstream target of p53, p21 is thought to be key in the induction of senescence 
by p53 (Aylon and Oren, 2007; Wiebusch and Hagemeier, 2010).  Indeed elevation of 
p21 is observed both at the transcript and protein level following upregulation of p53 in 
hepatocytes following MDM2 loss of function.  Further evidence of the function of the 
high levels of p53 observed is that elevation of p16 transcripts also (Figure 6.3).  Given 
the suspected involvement of p21 in p53 induced senescence, I therefore sought to 
examine the effects of p21 deficiency on hepatocyte senescence in the AhCre MDM2
flox 
model.  Using hepatocyte specific p53 upregulation in constitutively deficient p21 mice 
the ability of hepatocytes to proliferate was once again tested.  This revealed that both in 
the presence and absence of exogenous mitogenic stimulation increased hepatocyte 
proliferation was observed in p21
null
 mice, demonstrating that p21 deficiency at least 
partially resolves the failure to proliferate in p53
hi
 hepatocytes.  Further investigation of 
the p53 status of proliferating hepatocytes in this model revealed that large numbers, 
approximately 4% (vs. <0.05% in p21
wt
), of all proliferating hepatocytes were p53
hi
 
confirming that p21 deficiency allows hepatocytes to escape p53 induced senescence.  It 
is likely that the failure of mitogen to significantly affect the rate of hepatocyte 
proliferation in the p21
null 
model is reflective of the endogenous regenerative stimulus in 
the model supplied as a result of the significant hepatocellular injury observed.   
 
6.11C Liver injury and associated HPC activation in the AhCre MDM2flox model  
 




 model induces 
hepatocyte senescence and hepatocellular injury with a resultant HPC activation.  As 
hypothesised, there is dramatic induction of apoptosis as assessed by TUNEL staining 
throughout the liver lobule (Figure 6.4G) together with hepatocyte death observed 
Chapter 6-Hepatocyte MDM2 deletion reveals the potential of HPC mediated regeneration 
 243 
histologically (Figure 6.4F).  In keeping with these observations elevations of serum 














(Figures 6.4A and B).   
 
The demonstration of large scale HPC activation in the AhCre MDM2
flox
 model 
associated with widespread liver injury, is once again in keeping with the apparent 
requirement for liver injury in order to observe HPC activation (Bird et al., 2008; 
Santoni-Rugiu et al., 2005).  Interestingly the only previous report of HPC activation 
without documented liver injury is in the hepatic specific expression of TWEAK 
(Jakubowski et al., 2005).  In this study while no increased hepatocyte apoptosis was 
observed at the time of HPC activation other markers of liver injury, crucially serum 
transaminases, were not examined in this study.  The previous observations reported in 
this work  that BMC or macrophage infusion results in HPC activation via a TWEAK 
dependent mechanism in the absence of liver injury (Chapter 5), are nonetheless 
consistent with the report by Jakubowski et al.   
 
A key limitation in the study of the mechanism of HPC activation to date, is the lack of 
an understanding of the mechanism by which the established mouse dietary models 
(namely the CDE and DDC diets) lead to injury and hence HPC activation.  Liver injury 
in these model is now well described in these models, both in this work Chapter 3) and 
that previously (Akhurst et al., 2001; Preisegger et al., 1999).  It has been assumed that 
this liver injury is responsible for the stimulation of HPC mediated expansion.  None-
the-less, study of whether HPC activation is directly linked to concurrent injury has been 
impossible, as the mechanism by which dietary manipulation results in hepatocellular 
injury is unknown, in either diet.  This development of a characterised mechanism of 
hepatocellular injury induction together with synchronous HPC activation may permit 
the relationship and mechanistic pathway between liver injury and HPC activation to be 
examined.   
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In the AhCre MDM2
flox
 model, examination using specific HPC markers, either at the 
protein or mRNA level, shows a progressive and marked expansion of HPCs following 
induction with βNF.  This expansion is significantly more dramatic than existing models 
of HPC activation such as the CDE diet (>3 times HPC numbers).  The AhCre 
MDM2
flox
 model, therefore, offers a valuable tool with which to study both HPC biology 
and hepatocellular senescence in the future.  The features of the exceptionally dramatic 
HPC expansion, coupled with a defined molecular signal initiating the response may 
permit a powerful and detailed interrogation of the molecular pathway by which injury 
stimulates HPCs in the future.   
 
The varying phenotypes in the different AhCre MDM2
flox
 models examined in this 
work, provide a useful method for examining HPC activation under varying conditions.  





 recombination and in mice of either sex (Figure 
6.3).  The reduced efficiency of recombination in female mice appears intimately linked 
to the less severe clinical phenotype observed compared to male mice.  I propose that the 
mechanism by which this occurs results both as a from the eventual death of a smaller 
hepatocyte population and also the presence of a larger unrecombined and therefore non-
senescent hepatocyte population.  This non-senescent hepatocyte population may then 
able to proliferate actively during liver injury and result in maintained liver function and 
heightened hepatocellular regeneration.  Accordingly HPC activation would be expected 
to be reduced in this context. Indeed this is what is observed experimentally in these 
animals (Figure 6.7). 
 
Examination of mice in which a dramatic HPC expansion was noted often revealed 




mice are used instead of  
MDM2
flox/flox 
mice, recombination was equally efficient, and yet mortality was higher in 
the MDM2
flox/flox
 than their MDM2
flox/- 
counterparts.  The necessity for the deletion of 
both MDM2 alleles for observed p53 elevation and consequent functional downstream 
effects has been previously discussed.  The complete loss of MDM2 function in 






 mice might be expected to lead to an identical phenotype 
but is not in practice.  In the MDM2
flox/flox
 liver injury and associated severe clinical 
effects occur over 1 week, while in the MDM2
flox/-
 model the injury is delayed for 
approximately 3 weeks and is less clinically severe (Figures 6.5 and 6.7).  It therefore 
appears that the complete loss of MDM2 gene function from a homozygous state results 
in more rapid entry into a pro-apoptotic programme than the complete loss from a 
heterozygote deficient state.  This may perhaps be explained by a degree of 
compensation in heterozygote MDM2 deficient cells, which could delay the onset of  
apoptosis.  Further investigation of the degree p53 accumulation in these cells and 





 mice would be worthwhile future work in this area.  The clinical 
implications of altered susceptibility of cells to enter apoptosis in the context of similar 
p53 upregulation would potentially provide therapies to prevent apoptotic mediated 
organ failure or induce/promote apoptotic mediated clearance of neoplasia.   
 




 model is particularly intriguing as it permits the 
examination of a full recovery from a state of complete hepatocyte recombination 
following induction.  This therefore affords the examination of reconstitution of the 
hepatic parenchyma from a non-recombined source.  As differentiated parenchymal 
hepatocytes are all labelled by the deletion of the MDM2 gene segment, the non-
recombined source is by definition a hepatocyte precursor population.  At the time of 
induction this precursor cell is in an undifferentiated state and therefore unaffected by 
the addition of βNF.  This precursor is, therefore, an hepatic progenitor cell as it 
demonstrates its potential to form differentiated hepatocytes.  This system does not 
however necessarily ascribe a particular phenotype, such as expression of the classically 
accepted HPC markers such as panCK, Dlk1 or EpCAM, to this progenitor cell 
population.   
 
Following the demonstration of repopulation of the hepatic parenchyma from a 
precursor source I sought to investigate the potential of HPCs (defined by the expression 
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of panCK) to play a role in this regenerative process.  Multiple lines of evidence suggest 
a product precursor relationship between the panCK
+
 HPC population and differentiated 
hepatocytes.  Firstly HPCs expansion is observed over the time course of hepatocyte 
repopulation (Figures 6.5 and 6.7), in keeping other models of liver regeneration.  
Secondly, isolated and enriched HPCs from during this regenerative phase are capable of 
differentiating into hepatocyte like cells in vitro (Figure 6.12).  The clustering of BrdU 
labelled hepatocytes adjacent to HPCs following BrdU pulse-chase labelling provides 
further strong evidence of this product precursor relationship in vivo (Figure 6.13).  This 
is additionally supported by the presence of freshly generated hepatocytes in the areas of 
HPC activity in vivo (Figures 6.10 and 6.13) and furthermore by the observation that the 
HPC population remains unrecombined following βNF recombination (Figure 6.11).  
Additionally, replicating hepatocytes are observed as cords during the regenerative 
phase (Figure 6.14).  The nature of these hepatocytes as cords strongly implies a 
relationship of each of these regenerating hepatocytes to one another.  Crucially each of 
these cords of replicating hepatocytes additionally relates back to the distal tip of an 
HPC cord (Figure 6.14).  Finally direct intervention to manipulated HPC mediated 
activation via both stimulation and blockade of TWEAK-Fn14 mediated signalling 
affects the clinical outcome, mechanistically linking HPC mediated regeneration to liver 
function itself (Figure 6.16).  This observation of reduced HPC expansion coupled with 
a syndrome consistent with failed liver regeneration implies that Fn14 signalling is 
functionally necessary for adequate HPC activation in this model.   
 
This description that liver regeneration is exceptionally effective and efficient is not 
the first.  Interrogation of regeneration in partial hepatectomy models have shown for 
many years that large scale hepatocyte replacement may occur rapidly and efficiently 
(Fausto et al., 2006), and the addition of AAF to this model strongly supports the 
proposal that such regeneration may occur from a precursor source if so required 
(Alison, 1998). In these models, in which an impressive form of compensatory 
hyperplasia occurs, what is not clear is to what extent the liver parenchyma may be 
regenerated from such cells.   
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Additional elegant transplantation studies using HPCs have demonstrated the rescue of 
metabolic deficiency in transgenic animals using wild type donor derived cells (Wang et 
al., 2003a).  Furthermore these studies have done much to clarify the identity of the 
repopulating cell.  Whilst they have provided evidence that small clusters of donor 
derived cells may form within the liver, they have not yet shown large scale 
repopulation.  This may be a feature of the requirement of only a small mass of 
metabolically competent cells to rescue this disease model.  However, to date the 
potential of HPCs to repopulate the hepatic parenchyma on a larger scale has not been 




 model, therefore, adds significantly to the field of liver 
regeneration.  This novel model has allowed the extensive repopulation potential of the 
HPC precursor compartment to be examined.  This model, described here, has shown the 
entire repopulation of the hepatic parenchyma in the short term from a repopulating 
progenitor population.   
 
6.11D Examination of the product precursor relationship between HPCs and 
hepatocytes in the AhCre MDM2flox model  
 
Utilising the lineage tracing function of this model I show the regeneration of the 
entire hepatocyte population from a non-hepatocyte precursors.  Direct lineage tracing of 
the precursor population (as defined by a specific marker) is not performed, however by 
a number of methods I demonstrate that HPCs can and do form hepatocytes in this 
model.  Firstly, following extraction and purification, HPCs are capable of 
hepatocellular differentiation (Figure 6.11).  This observation, while relevant for this 
novel model, is not in itself surprising.  HPCs defined by a number of markers have been 
described as capable of hepatocyte differentiation (Rountree et al., 2007; Okabe et al., 
2009; Lorenzini et al., 2010; Conigliaro et al., 2008; Lazaro et al., 1998).  Furthermore, 
spatial association of CK19
+
 HPCs and regenerative nodules has been observed in 
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human liver disease (Lin et al., 2010) by utilising a system of clonal analysis discussed 
previously (Fellous et al., 2009)  
 
It is also unsurprising that results of RNA analysis do not at least superficially 
correlate with data from immunohistochemical analysis of HNF4.  HNF4 acts as a 
transcription factor promoting transcription any genes including HNF1, itself a 
transcription factor which regulates -1-antitrypsin, and transthyretin genes.  Active 
HNF4 is therefore located in the nucleus and this is regarded as a marker of committed 
hepatocytes (Hay et al., 2008).  HNF4 is understood to be strongly regulated at both 
the post transcriptional levels, and therefore whilst no change is noted in HNF4 RNA 
upon HPC differentiation in culture this is not incompatible with the observation that a 
minority of these cells expression high levels of nuclear HNF4 protein.   
 
What is clear from the RNA analysis between undifferentiated and differentiated 
hepatocytes is that whilst there is evidence of loss of primitive HPC markers e.g. Dlk1, 
there is little change in differentiated hepatocyte gene marker expression, particularly 
with reference to hepatocyte controls.  Most of the genes remain exceptionally low (10-
100 000 times lower) than in purified hepatocyte populations.  Whilst cells in the in vitro 
culture system at this time develop hepatocyte-like morphology at the time of analysis it 
is probable that a full genetic hepatocyte programme is not activated at this relatively 
early stage of development.  Clearly further analysis of this in vitro differentiating 
population is desirable, together with optimising the differentiation conditions.   
 
None-the-less, importantly I go onto show using pulse-chase labeling periportal 
clusters of hepatocytes often containing HPCs (Figure 6.13).  The absence of hepatocyte 
labeling during the pulse period implies that these periportal hepatocytes have indeed 
been regenerated from a precursor source.  Furthermore, their spatial localisation 
together with their association within clusters containing HPCs, implies a clonal origin 
from a periportal cell.  This is in keeping with the uptake of BrdU by periportal panCK
+
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HPCs during the pulse phase 2 days previously.  So these HPCs, which are capable of 
forming hepatocytes, actually do so in this in vivo model.  This interpretation is in 
keeping with the in vitro data where differentiation of an enriched and hepatocyte free 
(as defined by absence of HNF4) HPC culture occurs producing hepatocytes (as 
defined by presence of nuclear HNF4).   
 
Crucially, given that HPCs do form hepatocytes in vivo, this model goes onto address 
the question of to what extent they do so.  Using wash out of label retention (loss of 
recombined MDM2) in the hepatocyte population, it is demonstrated that hepatocytes 
may, to all intents and purposes (>95%), be completely restored from a precursor pool.  
With this work, I do not exclude the potential contribution of other precursor 
populations.  I can however see no evidence, either spatially or by pulse-chase labeling, 
of a significant contribution by any other precursor population to hepatocyte 
regeneration.   
 
Together with the observation of significant HPC differentiation into hepatocytes, this 
is strong evidence for repopulation of the liver by this precursor source. By extension it 
seems likely that this repopulation occurs from an even more primitive stem cell 
derived, population. 
  
The application of lineage tracing 
 
The gold standard for demonstration of in-situ product-precursor relationships 
currently in vivo is the use of transgenic controlled activation of markers genes which 
display no active phenotype aside from permitted identification of labelled cells.  The 
AhCre MDM2
flox
 system described in this work clearly differs significantly from this 
strategy.  Instead of aiming to label the stem/progenitor cell population and watch over 
time, for the passage of label into the differentiated parenchyma, I have adopted a 
strategy to completely label the parenchyma and observe washout of this label from an 
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un-modified precursor population.  While providing information regarding the quantity 
of generation of the parenchyma, this strategy provides no information regarding the 
phenotype of the precursor population aside from these cells did not undergo 
recombination at the time of βNF induction.  Further specific analysis investigating the 
product precursor relationship of panCK
+
 HPC to hepatocytes is described above but 
falls short of the definitive clarification of this relationship using transgenic labelling of 
the precursor population.   
 
Published reports in the liver of lineage tracing experiments in the mouse have 
provided some information regarding the potential nature of hepatocyte precursors 
during liver regeneration.  Using a constitutively active Foxl1-Cre mouse a small 
number of hepatocytes (0.5% max) were seen following biliary injury.  Interestingly 
whilst this occurred in an injury model, the proportion of hepatocytes derived from 
Foxl1
+
 precursors during development and physiological liver homeostasis was 
extremely low suggesting that while Foxl1
+
 cells may have the potential to become 
hepatocytes, in reality ( and even during injury) their propensity to support liver function 
is very low indeed (Sackett et al., 2009).  Another constitutively active lineage tracing 
system, this time under the control of a GFAP promoter has also been used to track 
precursors of hepatocytes (Yang et al., 2008).  In this model larger numbers of labelled 
hepatocytes are seen following exposure to a dietary injury model.  None-the-less, again 
the low level of labelled hepatocytes prior to dietary initiation calls into question how 
relevant GFAP
+
 precursors are during development and adult homeostasis. Additionally 
it is apparent that while GFAP is classically a marker of hepatic stellate cells, it is also a 
marker of HPCs and cholangiocytes (Yang et al., 2008).  Therefore the question of the 
role of hepatic stellate cells in the formation of hepatocytes remains in doubt.  It seems 
more plausible that these finding represent the differentiation of HPCs which transiently 
at least express GFAP, into hepatocytes.  Whether all HPCs express GFAP and at what 
point in their differentiation is a question that requires further investigation.  The 




 cells and the panCK
+
 HPCs studied 
in detail in this thesis are not known.   
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The use of an additional Cre-Lox mediated labelling of the stem/progenitor cell 
population is limited in the AhCre MDM2
flox
 model as induction of Cre-recombinase 
will result in non selective deletion of MDM2 and activation of a lineage marker in 
hepatocytes and progenitor cells respectively.  Alternative combinations of transgenic 





may permit this question to be directly 
addressed.  The choice of progenitor cell marker promoter used to drive Flp in such a 
system will be central to its success or failure.  While panCK has proved to be a useful 
antibody for identifying the HPC population in this study, this antibody is believed to 
recognise a number of cytokeratins over and above CK19, as discussed previously.  A 
CK19 promoter would appear a rational choice but will not limit expression to the HPC 
population as it is also actively expressed in the cholangiocyte population along with 
other HPC markers including EpCAM and Dlk1.  Members of the LGR family and 
CD133 show promise as potential targets for stem cell lineage markers in the future.   
  
6.11E Implications and future directions 
 
The implications of this work are profound and wide-ranging.  From the hepatic 
perspective these findings place HPCs at the heart of the process of liver regeneration.  
This therefore exposes them as a highly attractive target for regenerative therapy.  
Therapeutic manipulation of HPCs has been achieved to date on many levels.  Genetic 
manipulation has shown the potential to influence HPC activity is a variety of systems 
(Jakubowski et al., 2005; Knight et al., 2000).  Small molecule manipulation of HPC 
mediated activation has also been observed in humans (Spahr et al., 2008) via indirect 
methods.  Additionally direct pharmaceutical manipulation of HPCs has been observed 
in mice, as a proof of concept (Knight et al., 2008).  Given the repopulation potential of 
HPCs, the ability to influence HPC behaviour in vivo may prove to have profound 
potential in the development of regenerative therapies for liver disease.   
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The fundamental potential of HPCs in liver regeneration also draws attention to the 
role of hepatocyte mediated liver regeneration and whether there is any particular 
relationship between the freshly generated hepatocytes from precursors and ongoing 
liver regeneration.  As previously discussed in Chapter 1, whilst evidence exist for the 
potential of nearly the entire population of hepatocytes to display the potential for 
regeneration, intriguing work recently published examining clonality of liver patches in 
the human liver has demonstrated the relationship of proliferating hepatocytes to the 
portal tract (Fellous et al., 2009).  It is conceivable therefore that all hepatocytes are not 
equal from a regenerative standpoint, and that regeneration from hepatocytes may 
preferentially occur from those hepatocytes arising more recently from precursors.   
 
From the stem cell perspective the observation of entire hepatic parenchymal 
repopulation from a precursor source is the first demonstration of solid organ 
regeneration from a stem cell in vivo.  Whilst it is widely accepted that other organ 
systems with typically high cellular turnover (for example skin, intestine and blood) may 
be repopulated from stem cells, to date only complete repopulation of the BM from stem 
cell populations have been experimentally demonstrated.  Regeneration of single organ 
units in the skin and intestine has been shown from individual stem cell populations 
(Barker et al., 2010; Fuchs and Nowak, 2008).  The observation that the liver, an organ 
with a vastly reduced cell turnover, may be similarly repopulated by precursors 
highlights the possibility that other solid organs for example kidney, pancreas, heart, 
lung or even brain may be similarly capable of large scale regeneration from 
progenitors.  Similar systems of selective targeting of MDM2 deletion in the 
differentiated parenchyma of these other organs could conceivably be employed to 
address this question.   
 
A number of further questions therefore arise from the observations reported in this 
work.  Can I more definitively identify the characteristics and phenotype of the hepatic 
stem cell population? If HPCs can regenerate a liver once, can they do it repeatedly? 
What are the implications for the liver when regeneration occurs from HPCs versus that 
Chapter 6-Hepatocyte MDM2 deletion reveals the potential of HPC mediated regeneration 
 253 
which occurs from differentiated hepatocytes?  Do liver cancers come from 
differentiated hepatocytes and/or from HPCs?  Many of these questions are directly 
addressable using the AhCre model described in this work.  For example provisional 
work examining the functional effects of regeneration from HPCs has shown that the 
liver is functionally normal and that no significant associated fibrosis is observed 
following complete hepatocytic parenchymal regeneration from HPCs (Figures 6.9 and 
6.14).  Additional study examining the effect of re-induction of the regenerated liver 
with further doses of βNF following complete regeneration can be used to examine the 






 model described here is a novel model of HPC activation and 
is the first in the mouse to utilise transgenic technology to activate HPCs via a 
characterised mechanism.  Moreover the activation of HPCs in this model may be 
dramatic and occurs to a much larger extent than other murine models (Jelnes et al., 
2007; Santoni-Rugiu et al., 2005), and may be induced to varying degrees depending on 
mouse sex and induction regime.  I therefore believe that it represents a highly useful 
tool for the study of HPC biology in the future. 
 
It is of significant interest to note that in the context of large scale organ regeneration 
from HPCs, there are no long term side effects, albeit in a small cohort of mice.  
Specifically no mice developed cancers and upon further detailed examination there was 
no evidence of significant residual fibrosis in spite of the dramatic injury and HPC 
activation which has occurred.  There have been significant concerned raised about the 
potential side effects of HPC activity both in terms of fibrosis and HCC (Knight et al., 
2005b).   
 
A number of significant questions remain.  Firstly and crucially what is/are the identity 
of the stem cells within the liver from which HPCs arise? A number of key technologies 
are required to answer this question.  Development of a suitable lineage tracing system 
using a marker analogous to that of LGR5 in the intestine is undoubtedly a keystone in 
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our understanding.  In addition, the development of a suitable transplantation model for 
HPCs and precursors will provide crucial validation of any putative hepatic stem cells.  
The FAH
-/-
 murine system described by Grompe et al.  may be used in such a fashion 
(Wang et al., 2003a).  I believe also that the lethality of MDM2 deletion when 
performed on an Fn14
-/-
 background may provide the opportunity for a model of stem 
cell/HPC transplantation due to the combination of regenerative stimulus and the relative 
selective advantage an Fn14
wt
 HPC would be expected to enjoy in such a context.   
 
 








 model provides a new and novel approach to 
study HPC biology, as well as the biology of hepatocyte senescence in vivo.  
Interrogation of this model to date has demonstrated massive HPC expansion and the 
likely mechanistic drive for such an expansion.  Utilising the hepatocyte lineage tracing 
capability of the model I have been able to demonstrate large scale parenchymal 
repopulation within an adult solid organ in vivo from a progenitor cell source.   
 
Furthermore, I go onto to characterise this activation of HPCs and demonstrated not 
only that these cells may form hepatocytes but that they do so to a large extent 




In summary the work presented in this thesis provides a description of the environment 
surrounding HPCs, the functional effects of the macrophage component of the niche and 
the potential of HPCs to regenerate the liver parenchyma.  This HPC niche is 
stereotypical in nature and is comprised of macrophages and myofibroblasts together 
with a laminin rich basement membrane and these associations are conserved across a 
wide variety of models and species  (Chapter 3). 
 
Upon injury to the liver, the niche expands by the proliferation of cells.  Macrophages 
are actively recruited into the expanding niche from the bone marrow while other niche 
populations proliferate in situ (Chapter 4).  Macrophages within the niche provide a 
functional role in stimulating the shaping the phenotype of expanding HPCs.  They do 
this by the secretion of a variety of signals including Wnt and TWEAK (Chapter 5).   
 
Macrophages delivered intravenously engraft transiently within the liver and home to 
the HPC niche.  Upon doing so, and even in the absence of injury, macrophages may 
stimulate HPC activation resulting in changes in both liver structure and function.  This 
process is dependent upon the paracrine delivery of TWEAK from macrophages to 
endogenous HPCs (Chapter 5).  Such a mechanism provides the potential for targeting 
therapy to stimulate HPC mediated regeneration during liver disease. 
 
Finally I go onto to describe the potential for HPC mediated regeneration of 
hepatocytes.  I show that the hepatic parenchyma may be completely and rapidly 
reconstituted precursor HPCs, and that this regeneration may occur without the 
development of side effects such as fibrosis and carcinogenesis.  Regeneration from 
HPCs may be inhibited by interference with TWEAK signalling and doing so prevents 
HPC activation and may result in liver failure in this model of liver injury (Chapter 6).  
The demonstration of hepatic regeneration by HPC is the first demonstration of 
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Control 95% CI P Value
C57Bl control/ 






Control 95% CI P Value
Aes Amino-terminal enhancer of split
2.34 2.03 0.81 (0.64, 0.98) 0.112722  0.93 (0.74, 1.12) 3.34 2.14 0.43 (0.38, 0.48) 0.000462  
Apc Adenomatosis polyposis coli
4.03 3.74 0.82 (0.65, 0.99) 0.124535  0.86 (0.77, 0.95) 4.17 3.96 0.86 (0.79, 0.93) 0.020845  
Axin1 Axin 1
6.39 6.38 1 (0.69, 1.31) 0.907623  1.75 (0.90, 2.60) 6.68 5.57 0.46 (0.28, 0.64) 0.038327  
Bcl9 B-cell CLL/lymphoma 9
9.02 8.74 0.82 (0.67, 0.97) 0.088077  1.64 (1.02, 2.26) 7.94 8.03 1.06 (0.63, 1.49) 0.864282  
Btrc Beta-transducin repeat containing protein
7.22 6.98 0.85 (0.70, 1.00) 0.167281  2.52 (2.02, 3.02) 6.57 5.65 0.53 (0.46, 0.60) 0.001117  
Ctnnbip1 Catenin beta interacting protein 1
6.21 6.31 1.07 (0.81, 1.33) 0.542976  1.35 (1.21, 1.49) 7.15 5.88 0.42 (0.30, 0.54) 0.000956  
Ccnd1 Cyclin D1
2.31 3.81 2.82 (1.24, 4.40) 0.017252  0.36 (0.15, 0.57) 1.49 5.28 13.85 (8.91, 18.79) 0.000809  
Ccnd2 Cyclin D2
4.54 4.79 1.19 (0.88, 1.50) 0.278204  1.16 (0.66, 1.66) 4.39 4.58 1.14 (0.66, 1.62) 0.617147  
Ccnd3 Cyclin D3
4.41 4.14 0.83 (0.69, 0.97) 0.119461  1.16 (0.82, 1.50) 4.8 3.93 0.55 (0.37, 0.73) 0.024087  
Csnk1a1 Casein kinase 1, alpha 1
2.51 2.27 0.85 (0.77, 0.93) 0.034352  0.79 (0.69, 0.89) 2.66 2.6 0.96 (0.82, 1.10) 0.622054  
Csnk1d Casein kinase 1, delta
3.15 2.88 0.83 (0.72, 0.94) 0.052220  1.13 (1.01, 1.25) 3.28 2.7 0.67 (0.57, 0.77) 0.002496  
Csnk2a1 Casein kinase 2, alpha 1 polypeptide
1.69 1.11 0.67 (0.62, 0.72) 0.000459  0.99 (0.89, 1.09) 2.26 1.13 0.46 (0.41, 0.51) 0.000412  
Ctbp1 C-terminal binding protein 1
5.4 5.51 1.08 (0.98, 1.18) 0.192623  1.63 (1.17, 2.09) 5.5 4.8 0.62 (0.44, 0.80) 0.045162  
Ctbp2 C-terminal binding protein 2
6.11 6 0.93 (0.60, 1.26) 0.760007  1.06 (0.88, 1.24) 5.33 5.91 1.5 (1.05, 1.95) 0.068561  
Ctnnb1 Catenin (cadherin associated protein), beta 1
2.41 2.51 1.07 (0.93, 1.21) 0.331378  1.33 (1.17, 1.49) 2.32 2.1 0.86 (0.76, 0.96) 0.064442  
Daam1 Dishevelled associated activator of 
morphogenesis 1 2.87 2.51 0.78 (0.63, 0.93) 0.062387  0.82 (0.62, 1.02) 3.42 2.8 0.65 (0.50, 0.80) 0.034486  
Dixdc1 DIX domain containing 1
7.35 5.63 0.3 (0.15, 0.45) 0.001214  0.81 (0.57, 1.05) 6.72 5.94 0.58 (0.28, 0.88) 0.101937  
Dkk1 Dickkopf homolog 1 (Xenopus laevis)
15.61 14.75 0.55 (0.37, 0.73) 0.050572  1.25 (0.80, 1.70) 15.79 14.43 0.39 (0.30, 0.48) 0.003817  
AVG ΔCt Fold Change
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Control 95% CI P Value
Dvl1 Dishevelled, dsh homolog 1 (Drosophila)
5.53 5.1 0.74 (0.65, 0.83) 0.012325  2.29 (1.64, 2.94) 4.6 3.91 0.62 (0.44, 0.80) 0.041396  
Dvl2 Dishevelled 2, dsh homolog (Drosophila)
9.19 8.95 0.85 (0.52, 1.18) 0.375331  1.64 (0.91, 2.37) 8.58 8.24 0.79 (0.46, 1.12) 0.347301  
Ep300 E1A binding protein p300
5.19 5.07 0.92 (0.66, 1.18) 0.534600  1.03 (0.72, 1.34) 5.59 5.03 0.68 (0.24, 1.12) 0.272692  
Fbxw11 F-box and WD-40 domain protein 11
4.32 4.37 1.04 (0.84, 1.24) 0.714881  0.85 (0.63, 1.07) 3.92 4.61 1.61 (0.63, 2.59) 0.237300  
Fbxw2 F-box and WD-40 domain protein 2
3.26 3.04 0.86 (0.77, 0.95) 0.044806  0.99 (0.83, 1.15) 3.68 3.05 0.65 (0.53, 0.77) 0.014219  
Fbxw4 F-box and WD-40 domain protein 4
7.85 7.6 0.84 (0.45, 1.23) 0.452855  1.26 (0.69, 1.83) 7.81 7.27 0.69 (0.53, 0.85) 0.023534  
Fgf4 Fibroblast growth factor 4
15.03 14.71 0.8 (0.48, 1.12) 0.346761  1.71 (0.40, 3.02) 15 13.94 0.48 (0.05, 0.91) 0.244313  
Fosl1 Fos-like antigen 1
10.29 11.07 1.71 (0.52, 2.90) 0.219832  0.76 (0.13, 1.39) 8.86 11.47 6.09 (1.00, 11.18) 0.002054  
Foxn1 Forkhead box N1
14.3 14.75 1.37 (0.32, 2.42) 0.404344  1.25 (0.80, 1.70) 13.34 14.43 2.13 (1.34, 2.92) 0.029182  
Frat1 Frequently rearranged in advanced T-cell 
lymphomas 9.57 9.28 0.82 (0.37, 1.27) 0.435996  1.5 (0.33, 2.67) 9.41 8.7 0.61 (0.20, 1.02) 0.192832  
Frzb Frizzled-related protein
6.34 6.86 1.44 (0.65, 2.23) 0.319453  0.32 (0.15, 0.49) 5.76 8.52 6.78 (3.08, 10.48) 0.031135  
Fshb Follicle stimulating hormone beta
14.71 14.75 1.03 (0.25, 1.81) 0.748968  2.5
(0.00001, 
5.53) 14.23 13.43 0.58
(0.00001, 
1.27) 0.388381  
Fzd1 Frizzled homolog 1 (Drosophila)
6.94 6.13 0.57 (0.44, 0.70) 0.008243  0.96 (0.53, 1.39) 6.18 6.19 1.01 (0.42, 1.60) 0.985177  
Fzd2 Frizzled homolog 2 (Drosophila)
11.61 11.76 1.11 (0.60, 1.62) 0.748321  0.45 (0.23, 0.67) 11.79 12.93 2.19 (1.53, 2.85) 0.004694  
Fzd3 Frizzled homolog 3 (Drosophila)
11.66 11.78 1.08 (0.29, 1.87) 0.946706  1.85 (0.62, 3.08) 10.18 10.89 1.64 (0.59, 2.69) 0.228337  
Fzd4 Frizzled homolog 4 (Drosophila)
4.14 3.85 0.81 (0.56, 1.06) 0.240311  0.47 (0.32, 0.62) 4.76 4.93 1.13 (0.92, 1.34) 0.273184  
Fzd5 Frizzled homolog 5 (Drosophila)
6.14 5.39 0.59 (0.42, 0.76) 0.019782  1.36 (1.16, 1.56) 5.83 4.95 0.54 (0.42, 0.66) 0.002364  
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C57Bl control/ 






Control 95% CI P Value
Fzd6 Frizzled homolog 6 (Drosophila)
7.61 7.33 0.83 (0.58, 1.08) 0.295008  0.14 (0.06, 0.22) 9.46 10.22 1.69 (0.85, 2.53) 0.061504  
Fzd7 Frizzled homolog 7 (Drosophila)
10.02 10.21 1.14 (0.53, 1.75) 0.811514  2.54 (1.13, 3.95) 10.73 8.86 0.27 (0.13, 0.41) 0.004520  
Fzd8 Frizzled homolog 8 (Drosophila)
11.55 11.14 0.76 (0.47, 1.05) 0.200206  2.15 (1.61, 2.69) 11.51 10.04 0.36 (0.19, 0.53) 0.006669  
Gsk3b Glycogen synthase kinase 3 beta
6.64 7.44 1.75 (1.43, 2.07) 0.001829  0.93 (0.67, 1.19) 7.44 7.55 1.08 (0.85, 1.31) 0.542355  
Jun Jun oncogene
4.4 5.77 2.59 (2.16, 3.02) 0.000440  0.88 (0.50, 1.26) 3.55 5.95 5.26 (2.91, 7.61) 0.001263  
Kremen1 Kringle containing transmembrane protein 1
6.18 5.62 0.68 (0.54, 0.82) 0.023501  1.1 (0.80, 1.40) 6.08 5.48 0.66 (0.46, 0.86) 0.070231  
Lef1 Lymphoid enhancer binding factor 1
14.15 14.19 1.03 (0.21, 1.85) 0.900015  2.67 (0.69, 4.65) 13.11 12.77 0.79 (0.29, 1.29) 0.435241  
Lrp5 Low density lipoprotein receptor-related protein 
5 5.35 5.15 0.87 (0.57, 1.17) 0.431998  3.2 (1.78, 4.62) 4.77 3.47 0.41 (0.27, 0.55) 0.019623  
Lrp6 Low density lipoprotein receptor-related protein 




8.64) 0.071275  1.01
(0.00001, 
2.85) 4.12 5.58 2.77
(0.00001, 
7.10) 0.541898  
Nkd1 Naked cuticle 1 homolog (Drosophila)
7.17 7.04 0.92 (0.70, 1.14) 0.491942  1.39 (0.59, 2.19) 7.05 6.57 0.72 (0.29, 1.15) 0.290880  
Nlk Nemo like kinase
6.11 6.13 1.01 (0.83, 1.19) 0.905628  1.48 (1.16, 1.80) 6.01 5.56 0.73 (0.61, 0.85) 0.029672  
Pitx2 Paired-like homeodomain transcription factor 2
14.41 14.28 0.92 (0.04, 1.80) 0.906068  1.13 (0.50, 1.76) 14.95 14.11 0.56 (0.05, 1.07) 0.379364  
Porcn Porcupine homolog (Drosophila)
9.89 8.55 0.39 (0.29, 0.49) 0.003220  1.6 (0.97, 2.23) 9.53 7.87 0.32 (0.16, 0.48) 0.025190  
Ppp2ca Protein phosphatase 2 (formerly 2A), catalytic 
subunit, alpha isoform 0.58 0.48 0.93 (0.92, 0.94) 0.000907  1.05 (0.98, 1.12) 0.95 0.41 0.69 (0.59, 0.79) 0.005120  
Ppp2r1a Protein phosphatase 2 (formerly 2A), 
regulatory subunit A (PR 65), alpha isoform 2.61 2.55 0.96 (0.82, 1.10) 0.624666  1.22 (1.04, 1.40) 2.47 2.27 0.87 (0.76, 0.98) 0.096653  
Ppp2r5d Protein phosphatase 2, regulatory subunit B 
(B56), delta isoform 5.41 4.8 0.66 (0.57, 0.75) 0.002312  0 (0.00, 0.00) 15.8 14.43 0.39 (0.30, 0.48) 0.003771  
Pygo1 Pygopus 1
11.28 10.78 0.71 (0.34, 1.08) 0.276176  1.09 (0.52, 1.66) 10.83 10.66 0.89 (0.39, 1.39) 0.874325  
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Control 95% CI P Value
Rhou Ras homolog gene family, member U
3.22 4.04 1.76 (1.53, 1.99) 0.000648  0.98 (0.80, 1.16) 3.52 4.07 1.46 (1.20, 1.72) 0.013238  
Senp2 SUMO/sentrin specific peptidase 2
4.99 4.67 0.8 (0.76, 0.84) 0.001450  0.78 (0.66, 0.90) 5.19 5.04 0.9 (0.73, 1.07) 0.317245  
Sfrp1 Secreted frizzled-related protein 1
11.11 10.92 0.88 (0.34, 1.42) 0.659303  2.8 (1.30, 4.30) 7.16 9.43 4.84 (2.92, 6.76) 0.009988  
Sfrp2 Secreted frizzled-related protein 2
13.84 14.26 1.34 (0.50, 2.18) 0.475493  1.67 (0.21, 3.13) 13.6 13.52 0.95
(0.00001, 
1.92) 0.961245  
Sfrp4 Secreted frizzled-related protein 4
15.47 13.65 0.28 (0.18, 0.38) 0.009177  0.58 (0.37, 0.79) 15.02 14.43 0.66 (0.32, 1.00) 0.159411  
Slc9a3r1 Solute carrier family 9 (sodium/hydrogen 
exchanger), member 3 regulator 1 1.07 0.96 0.92 (0.76, 1.08) 0.460959  0.15 (0.13, 0.17) 3.97 3.73 0.85 (0.72, 0.98) 0.107547  
Sox17 SRY-box containing gene 17
13.28 13.71 1.35 (0.55, 2.15) 0.352527  2.86 (1.77, 3.95) 12.36 12.2 0.89 (0.54, 1.24) 0.639505  
T Brachyury
15.61 14.75 0.55 (0.37, 0.73) 0.050572  1.64 (0.89, 2.39) 14.59 14.04 0.68 (0.32, 1.04) 0.254555  
Tcf3 Transcription factor 3
8.26 8.06 0.87 (0.50, 1.24) 0.490429  1.65 (0.94, 2.36) 7.8 7.34 0.73 (0.51, 0.95) 0.092606  
Tcf7 Transcription factor 7, T-cell specific
6.75 5.64 0.46 (0.33, 0.59) 0.003398  1 (0.82, 1.18) 5.8 5.63 0.89 (0.67, 1.11) 0.406529  
Tle1 Transducin-like enhancer of split 1, homolog of 
Drosophila E(spl) 3.73 3.3 0.74 (0.50, 0.98) 0.152192  1.27 (0.78, 1.76) 4.38 2.95 0.37 (0.28, 0.46) 0.007004  
Tle2 Transducin-like enhancer of split 2, homolog of 
Drosophila E(spl) 13.34 13.28 0.96 (0.23, 1.69) 0.941344  4.66 (1.23, 8.09) 12.68 11.06 0.32 (0.14, 0.50) 0.068097  
Wif1 Wnt inhibitory factor 1
14.15 12.72 0.37 (0.07, 0.67) 0.080500  6.05 (1.79, 10.31) 13.45 10.13 0.1 (0.04, 0.16) 0.012897  
Wisp1 WNT1 inducible signaling pathway protein 1
7.6 7.6 1 (0.57, 1.43) 0.860073  2.1 (1.22, 2.98) 6.71 6.53 0.88 (0.42, 1.34) 0.769791  
Wnt1 Wingless-related MMTV integration site 1
15.01 14.75 0.83 (0.15, 1.51) 0.923943  2.22 (0.13, 4.31) 13.69 13.6 0.94
(0.00001, 
2.21) 0.925625  
Wnt10a Wingless related MMTV integration site 10a
15.46 14.75 0.61 (0.40, 0.82) 0.078898  1.74 (0.72, 2.76) 13.65 13.95 1.23 (0.48, 1.98) 0.533690  
Wnt11 Wingless-related MMTV integration site 11
13.62 11.51 0.23 (0.06, 0.40) 0.067082  0.35 (0.09, 0.61) 9.53 13 11.09 (2.05, 20.13) 0.031816  
Wnt16 Wingless-related MMTV integration site 16
12.33 13.63 2.47
(0.00001, 
5.59) 0.206740  8.82
(0.00001, 
18.03) 10.61 10.49 0.92 (0.49, 1.35) 0.651352  
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Control 95% CI P Value
Wnt2 Wingless-related MMTV integration site 2
8.73 9.57 1.8 (1.36, 2.24) 0.008454  1.79 (0.80, 2.78) 10.45 8.74 0.3 (0.10, 0.50) 0.066085  
Wnt2b Wingless related MMTV integration site 2b
9.32 9.15 0.89 (0.48, 1.30) 0.652071  2.27 (1.07, 3.47) 9.09 7.97 0.46 (0.23, 0.69) 0.053854  
Wnt3 Wingless-related MMTV integration site 3
15.61 14.75 0.55 (0.37, 0.73) 0.050572  1.25 (0.80, 1.70) 15.8 14.43 0.39 (0.30, 0.48) 0.003771  
Wnt3a Wingless-related MMTV integration site 3A
14.54 14.39 0.9 (0.32, 1.48) 0.727133  1.64 (0.75, 2.53) 13.43 13.67 1.18 (0.25, 2.11) 0.506291  
Wnt4 Wingless-related MMTV integration site 4
10.08 10.72 1.56 (1.16, 1.96) 0.023505  1.45 (1.11, 1.79) 9.7 10.19 1.4 (1.00, 1.80) 0.088004  
Wnt5a Wingless-related MMTV integration site 5A
14.1 14.58 1.4
(0.00001, 
3.11) 0.402589  7.65 (4.35, 10.95) 12.51 11.65 0.55 (0.29, 0.81) 0.071018  
Wnt5b Wingless-related MMTV integration site 5B
5.38 4.92 0.73 (0.48, 0.98) 0.160886  0.76 (0.61, 0.91) 5.58 5.31 0.83 (0.77, 0.89) 0.006508  
Wnt6 Wingless-related MMTV integration site 6
14.64 14.27 0.78
(0.00001, 
1.60) 0.926742  1.06 (0.50, 1.62) 13.76 14.19 1.35
(0.00001, 
3.36) 0.332070  
Wnt7a Wingless-related MMTV integration site 7A
15.43 14.75 0.63 (0.43, 0.83) 0.078959  1.82 (0.69, 2.95) 11.01 13.89 7.37 (2.52, 12.22) 0.008132  
Wnt7b Wingless-related MMTV integration site 7B
15.61 14.75 0.55 (0.37, 0.73) 0.050572  1.25 (0.80, 1.70) 14.3 14.43 1.1
(0.00001, 
2.32) 0.510059  
Wnt8a Wingless-related MMTV integration site 8A
15.61 14.75 0.55 (0.37, 0.73) 0.050572  1.25 (0.80, 1.70) 15.8 14.43 0.39 (0.30, 0.48) 0.003771  
Wnt8b Wingless related MMTV integration site 8b
14.83 14.75 0.95 (0.31, 1.59) 0.989827  1.89 (0.66, 3.12) 14.84 13.84 0.5 (0.17, 0.83) 0.110988  
Wnt9a Wingless-type MMTV integration site 9A
13.75 13.64 0.93 (0.39, 1.47) 0.685818  0.88 (0.19, 1.57) 13.3 13.83 1.45 (0.55, 2.35) 0.395735  
Gusb Glucuronidase, beta
3.35 3.43 1.06 (0.91, 1.21) 0.412742  0.79 (0.61, 0.97) 2.67 3.78 2.16 (1.61, 2.71) 0.002801  
Hprt1 Hypoxanthine guanine phosphoribosyl 
transferase 1 1.04 0.79 0.84 (0.65, 1.03) 0.207237  0.91 (0.78, 1.04) 1.35 0.92 0.74 (0.68, 0.80) 0.001811  
Hsp90ab1 Heat shock protein 90 alpha (cytosolic), class 
B member 1 -0.78 -0.92 0.91 (0.80, 1.02) 0.204167  1.16 (1.04, 1.28) -0.92 -1.13 0.86 (0.81, 0.91) 0.004713  
Gapdh Glyceraldehyde-3-phosphate dehydrogenase
-1.59 -1.91 0.8 (0.73, 0.87) 0.007116  0.74 (0.65, 0.83) -1.02 -1.47 0.73 (0.62, 0.84) 0.016204  
Actb Actin, beta -2.02 -1.4 1.53 (1.33, 1.73) 0.002420  1.63 (1.36, 1.90) -2.08 -2.1 0.99 (0.83, 1.15) 0.872544  
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